Skin fillers

Dermal fillers made from decellularized plant or fungal tissue address the issues of synthetic fillers by providing non-absorbable, biocompatible solutions for cosmetic and reconstructive uses, ensuring safe and effective tissue integration.

JP7953902B2Active Publication Date: 2026-11-19SPIDERWORT BIOTECHNOLOGIES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022575189
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-06-08
Filing Date
2021-06-08
Publication Date
2026-11-19
Estimated Expiration
2041-06-08

AI Technical Summary

Technical Problem

Existing permanent dermal fillers contain synthetic substances that may cause allergic reactions, granulomas, and foreign body reactions, and there is a need for alternative, improved dermal fillers with better biocompatibility and non-absorbability.

Method used

Dermal fillers comprising decellularized plant or fungal tissue, which are non-absorbable and have controlled particle sizes, are developed, along with methods for preparing such fillers, including sterilization techniques and formulations compatible with carrier fluids and anesthetic agents.

Benefits of technology

The decellularized plant or fungal tissue fillers provide good biocompatibility and are non-absorbable, facilitating cell infiltration and proliferation, while minimizing small particles and ensuring safe, long-lasting cosmetic and reconstructive applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007953902000056
    Figure 0007953902000056
  • Figure 0007953902000057
    Figure 0007953902000057
  • Figure 0007953902000058
    Figure 0007953902000058
Patent Text Reader

Abstract

Provided herein are dermal fillers comprising decellularized plant or fungal tissue, from which cellular material and nucleic acids of such tissue have been removed, as well as methods and uses thereof for cosmetic and / or reconstructive applications. Also provided are methods for preparing such dermal fillers and dermal filler kits.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims the benefits and priority of U.S. Provisional Patent Application No. 63 / 036,126, filed on 8 June 2020, which is incorporated in its entirety by reference.

[0002] The present invention generally relates to skin fillers. More specifically, the present invention relates to skin fillers comprising decellularized plant or fungal tissue. [Background technology]

[0003] Various dermal filler products for subcutaneous injection have been developed primarily for cosmetic purposes. The injection site may vary depending on the specific cosmetic application; superficial wrinkles are treated with intradermal injections, while volume augmentation procedures often involve injections into the deeper dermis. In general, injections into the subcutaneous fat are typically avoided.

[0004] Dermatological filler products are generally divided into two distinct categories: temporary and permanent. Temporary fillers are often composed of hydrogels, such as collagen or hyaluronic acid, and are slowly absorbed into the body over time. In contrast, the only permanent dermatological filler currently approved by the FDA is BellaFill®. BellaFill® consists of 80% (v / v) 3.5% bovine collagen I (w / v) and 20% (v / v) 30-40 μm poly(methyl methacrylate) (PMMA) microspheres. These microspheres are rigid, non-absorbable particles composed of petrochemical polymers. The purpose of these microspheres is to fill physical spaces within tissues, provide a permanent support structure for cells to proliferate on, and deposit natural extracellular matrix proteins that are gradually replaced by absorbable bovine collagen. BellaFill® is a long-lasting and popular choice for patients because it typically requires only one or two treatments with little to no follow-up.

[0005] Unfortunately, permanent dermal fillers in this field often contain synthetic substances that may remain permanently in the body, and may be associated with certain specific risks, such as potential allergic reactions, the possibility of granulomas, and / or foreign body reactions.

[0006] Alternative, additional, and / or improved dermal fillers, methods and uses thereof, as well as methods for the production thereof are desirable. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM

[0007] Provided herein are dermal fillers comprising decellularized plant or fungal tissue, wherein cellular material and nucleic acids of the tissue have been removed; as well as methods and uses thereof for cosmetic and / or reconstructive applications. Also provided are methods for preparing such dermal fillers, and dermal filler kits.

[0008] As described herein, the present inventors have now developed a dermal filler product comprising decellularized plant or fungal tissue. The data provided herein demonstrate that the dermal fillers had good biocompatibility and were substantially non-absorbable. Methods for preparing such dermal filler products are described, which enable a variety of other beneficial properties, including size control and avoidance of small undesirable particles with a size of less than 20 μm. Formulations with good needle passability / injectability through small gauge needles, as well as formulations compatible with a carrier fluid, for example a hydrogel, and compatible with anesthetic agents, have been developed. Sterilization techniques and sterilized products are also described. Particles for dermal filler products having desirable shapes and surface area / volume / loading properties that facilitate cell infiltration / proliferation and / or provide a favorable ratio of native tissue to dermal filler in a subject are described.

[0009] In one embodiment, provided herein is a non-absorbable skin filler comprising a decellularized plant or fungal tissue, wherein cellular material and nucleic acids of the tissue are removed.

[0010] In another embodiment of the above skin filler, the decellularized plant or fungal tissue may be chitin-based, chitosan-based, lignocellulose-based, or cellulose-based.

[0011] In a further embodiment of any one of the one or more skin fillers described above, the decellularized plant or fungal tissue may be derived from a foliar structure, root, pulp, receptacle cup, or pulp structure of a plant.

[0012] In still another embodiment of any one of the one or more skin fillers described above, the decellularized plant or fungal tissue may be derived from lettuce, carrot, apple or pear, or any combination thereof.

[0013] In another embodiment of any one of the one or more skin fillers described above, the decellularized plant or fungal tissue may be homogenized.

[0014] In a further embodiment of any one of the one or more skin fillers described above, the decellularized plant or fungal tissue may be dried, subjected to grinding, and optionally reconstituted or rehydrated.

[0015] In still another embodiment of any one of the one or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles the size of a single structural cell or smaller.

[0016] In another embodiment of any one of the one or more skin fillers described above, the skin filler may further comprise a hydrogel, matrix, or dispersion medium for the decellularized plant or fungal tissue.

[0017] In yet another embodiment of any one or more of the above-described skin fillers, the hydrogel, matrix, or dispersion medium may include PBS, saline solution, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, prulonic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof.

[0018] In any further embodiment of the one or more skin fillers described above, the skin filler may be dried or hydrated.

[0019] In any other embodiment of the one or more skin fillers described above, the skin filler may contain lidocaine or other anesthetics.

[0020] In yet another embodiment of any of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure.

[0021] In any further embodiment of the one or two or more skin fillers described above, the flake-like structure may have a thickness of about 0.01 μm to about 100 μm, for example, about 0.1 μm.

[0022] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles large enough not to be phagocytosed by one or more cells; preferably, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or minimum ferret diameter of at least about 20 μm.

[0023] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 1000 μm.

[0024] In yet another embodiment of any of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or maximum ferret diameter of less than about 200 μm.

[0025] In any further embodiment of one or more of the above skin fillers, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or ferret diameter distribution in the range of about 20 μm to about 200 μm.

[0026] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having a particle size, diameter, or ferret diameter distribution with a peak between approximately 30 μm and approximately 100 μm.

[0027] In yet another embodiment of any of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having an average particle size, diameter, or ferret diameter in the range of about 30 μm to about 100 μm.

[0028] In yet another embodiment of any of the one or more skin fillers described above, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or maximum ferret diameter of less than about 300 μm.

[0029] In yet another embodiment of any one or more of the above skin fillers, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or ferret diameter distribution in the range of about 100 μm to about 300 μm.

[0030] In yet another embodiment of any one or more of the above skin fillers, the decellularized plant or fungal tissue may be broken down into particles having a particle size, diameter, or ferret diameter distribution with a peak within about 100 μm to about 300 μm.

[0031] In yet another embodiment of any one or more of the above skin fillers, the decellularized plant or fungal tissue may be broken down into particles having an average particle size, diameter, or ferret diameter in the range of about 100 μm to about 300 μm.

[0032] In any further embodiment of one or more of the above skin fillers, the decellularized plant or fungal tissue is approximately 200 to 3000 μm in size. 2 Within that range, or approximately 200 to 300 μm 2 The particles may be broken down into particles having an average projected particle area within the range of; decellularized plant or fungal tissues have a surface area-to-volume ratio of 0.1 to 100 μm². -1 It is broken down into particles; the decellularized plant or fungal tissue consists of particles approximately 4 × 10 5 pieces / mL~particles approx. 7×10 9 It is broken down into particles having a packing density of 1 / mL; or any combination thereof.

[0033] In any other embodiment of the one or more skin fillers described above, one or more skin fillers may have a viscosity of less than about 500,000 cp.

[0034] In any other embodiment of the one or two or more skin fillers described above, one or more skin fillers may have a viscosity in the range of about 100,000 cp to about 200,000 cp.

[0035] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be sterilized.

[0036] In yet another embodiment of any one or more of the above-described skin fillers, the skin filler may be sterilized.

[0037] In any other embodiment of the one or two or more skin fillers described above, sterilization may be performed by gamma ray sterilization.

[0038] In any other embodiment of the one or two or more skin fillers described above, sterilization may be performed by autoclaving.

[0039] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be marceled.

[0040] In any further embodiment of one or more of the above-described skin fillers, the mercerization process may be carried out by heating with sodium hydroxide and hydrogen peroxide.

[0041] In any other embodiment of the one or more dermal fillers described above, the dermal filler may be formulated for subdermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof.

[0042] In yet another embodiment of any one or more of the above-described skin fillers, the skin filler may be provided in a syringe or injection device.

[0043] In another embodiment, the use of any one of the one or more skin fillers described herein as a soft tissue filler, or for reconstructive surgery, or both, is provided herein.

[0044] In another embodiment, the use of any one of the one or more skin fillers described herein for improving the cosmetic appearance of an object requiring improvement in cosmetic appearance is provided herein.

[0045] In yet another embodiment, the use of any one of the one or more skin fillers described herein in an object requiring it for increasing tissue volume, smoothing out wrinkles, or both is provided herein.

[0046] In another embodiment, a method in an object requiring it for the purpose of improving cosmetic appearance, increasing tissue volume, smoothing wrinkles, or any combination thereof, A step of administering or injecting one or more dermal fillers described herein into an area where they are needed; Methods are provided herein that include, and thereby improve the cosmetic appearance of a subject, increase tissue volume, smooth out wrinkles, or any combination thereof.

[0047] In any other embodiment of one or more of the uses or methods described above, the native cells of interest may be infiltrated into the skin filler.

[0048] In any further embodiment of one or more of the uses or methods described above, the skin filler may be non-absorbent to such an extent that the decellularized plant or fungal tissue remains substantially intact within the subject.

[0049] In any further embodiment of one or more of the uses or methods described above, the skin filler may be degradable through the addition of one or more enzymes.

[0050] In any other embodiment of one or more of the above uses or methods, the plant or fungal tissue may be cellulosic, and one or more enzymes include cellulase.

[0051] In any further embodiment of one or more of the above uses or methods, the cellulase may be a cellulase derived from the genus Trichoderma sp.

[0052] In another embodiment, a method for preparing a non-absorbable skin filler is provided. A step of providing plant or fungal tissue; A step of decellularizing and reducing the size of plant or fungal tissue to provide particles from which the cellular material and nucleic acids of the tissue have been removed; and Optional step of sterilizing particles; A method for providing a non-absorbable skin filler, comprising the above, is provided herein.

[0053] In another embodiment of the above method, the decellularized plant or fungal tissue may be chitin-based, chitosan-based, lignocellulose-based, or cellulose-based.

[0054] In yet another embodiment of any one or more of the above methods, the decellularized plant or fungal tissue may be derived from the plant's thallus, roots, pulp, hypanthium, or pulp structure.

[0055] In any further embodiment of one or more of the above methods, the decellularized plant or fungal tissue may be derived from lettuce, carrots, apples, or pears, or any combination thereof.

[0056] In any other embodiment of the one or two or more methods described above, the size reduction may include the step of providing particles by mechanical size reduction, and the mechanical size reduction may be performed on a dried, freeze-dried, or freeze-dried material.

[0057] In yet another embodiment of any one or more of the above methods, mechanical size reduction may include the step of providing particles by grinding, extruding, crushing, grinding, sonicating, electrospinning, chemical dissolution, enzymatic degradation, or shearing the plant or fungal tissue before or after decellularization.

[0058] In any further embodiment of the one or two or more methods described above, the size reduction may include the steps of: drying the plant or fungal tissue before or after decellularization; subjecting the dried plant or fungal tissue to mechanical size reduction to provide particles; and optionally restoring, resuspending, or rehydrating the particles.

[0059] In any other embodiment of the one or two or more methods described above, size reduction may provide particles the size of a single structural cell or smaller.

[0060] In yet another embodiment of any one or more of the above methods, the method may further include the step of formulating particles together with a hydrogel, matrix, or dispersion medium.

[0061] In any further embodiment of one or more of the above methods, the hydrogel, matrix, or dispersion medium may include PBS, physiological saline, hyaluronic acid (crosslinked or uncrosslinked), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof.

[0062] In any other embodiment of the one or two or more methods described above, the skin filler may be provided in a dried or hydrated form.

[0063] In yet another embodiment of any one or more of the methods described above, the method may further include the step of formulating with lidocaine or another anesthetic.

[0064] In any further embodiment of one or more of the above methods, size reduction may provide particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure.

[0065] In any other embodiment of the one or two or more methods described above, the flake-like structure may have a thickness of about 0.01 to about 100 μm, for example, about 0.1 μm.

[0066] In yet another embodiment of any one or more of the above methods, the size reduction may further include the step of obtaining particles having a target size, particles within a target size range, or particles having a target size distribution by extrusion, filtration, centrifugation, or other size separation.

[0067] In yet another embodiment of any one or more of the above methods, size reduction may provide particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 1000 μm.

[0068] In any further embodiment of the one or more methods described above, size reduction may provide particles that are large enough not to be phagocytosed by one or more cells; preferably, size reduction may provide particles having a size, diameter, or minimum ferret diameter of at least about 20 μm.

[0069] In any other embodiment of one or more of the above methods, size reduction may provide particles having a size, diameter, or maximum ferret diameter of less than approximately 200 μm.

[0070] In yet another embodiment of any one or more of the above methods, size reduction may provide particles having a size, diameter, or ferret diameter distribution in the range of about 20 μm to about 200 μm.

[0071] In any further embodiment of one or more of the above methods, size reduction may provide particles having a particle size, diameter, or ferret diameter distribution with a peak between approximately 30 μm and approximately 100 μm.

[0072] In any other embodiment of one or more of the above methods, size reduction may provide particles having an average particle size, diameter, or ferret diameter in the range of about 30 μm to about 100 μm.

[0073] In any other embodiment of one or more of the above methods, size reduction may provide particles having a size, diameter, or maximum ferret diameter of less than approximately 300 μm.

[0074] In any other embodiment of one or more of the above methods, size reduction may provide particles having a size, diameter, or ferret diameter distribution in the range of about 100 μm to about 300 μm.

[0075] In any other embodiment of the one or two or more methods described above, size reduction may provide particles having a particle size, diameter, or ferret diameter distribution with a peak within approximately 100 μm to approximately 300 μm.

[0076] In any other embodiment of one or more of the above methods, size reduction may provide particles having an average particle size, diameter, or ferret diameter in the range of about 100 μm to about 300 μm.

[0077] In yet another embodiment of any one or more of the above methods, the size reduction is approximately 200 to approximately 3000 μm. 2in the range of, or from about 200 to about 300 μm 2 Particles having an average projected particle area within the range of may be provided; wherein the decellularized plant or fungal tissue has a surface area to volume ratio of about 0.1 to 100 μm -1 is broken down into particles; the decellularized plant or fungal tissue is broken down into particles having a packing density of about 4×10 5 particles / mL to about 7×10 9 particles / mL; or any combination thereof

[0078] In yet another embodiment of any one of the one or more methods described above, the size reduction may comprise the step of simultaneously performing grinding and passing the resulting particles through a filter to obtain particles below the upper threshold size

[0079] In another embodiment of any one of the one or more methods described above, the method may further comprise the step of performing filtration, differential centrifugation or equilibrium centrifugation, or sieving to remove particles below the lower threshold size and obtain particles larger than the lower threshold size

[0080] In yet another embodiment of any one of the one or more methods described above, the filtration or sieving may be performed using an automated wet sieve

[0081] In yet another embodiment of any one of the one or more methods described above, the size reduction may comprise the step of performing differential centrifugation or equilibrium centrifugation to obtain particles having a target size, particles within a target size range, or particles having a target size distribution

[0082] In any other embodiment of the one or more methods described above, the method comprises the steps of: loading particles in a fluid, such as water or a buffer (e.g., physiological saline), into a first syringe or vessel; and loading a hydrogel, matrix, or dispersion medium into a second syringe or vessel, thereby compounding the particles together with the hydrogel, matrix, or dispersion medium, wherein the first and second syringes or vessels are under fluid connection; and further comprising the steps of mixing the contents of the syringes or vessels by passing them back and forth between the first and second syringes or vessels.

[0083] In any other embodiment of the one or more methods described above, the method may further include the step of formulating the particles together with the hydrogel, matrix, or dispersion medium by mixing the particles with the hydrogel, matrix, or dispersion medium using a size exclusion mixer.

[0084] In any other embodiment of the one or more methods described above, the size exclusion mixer may be a static mixer.

[0085] In yet another embodiment of any one or more of the above methods, the method may further include a step of sterilizing the plant or fungal tissue before or after decellularization.

[0086] In any other embodiment of one or more of the methods described above, the method may further include a step of sterilizing the skin filler.

[0087] In any other embodiment of the one or two or more methods described above, sterilization may be performed by gamma ray sterilization.

[0088] In yet another embodiment of any one or more of the above methods, sterilization may be performed by autoclaving.

[0089] In yet another embodiment of any one or more of the methods described above, sterilization may include multiple sterilization steps.

[0090] In yet another embodiment of any one or more of the above methods, the first sterilization step may include heat treatment.

[0091] In yet another embodiment of any one or more of the above methods, the method may further include the step of mercing plant or fungal tissue.

[0092] In any other embodiment of the one or two or more methods described above, merceleration may be performed after decellularization.

[0093] In yet another embodiment of any one or more of the above methods, the mercel treatment may include treatment of decellularized plant or fungal tissue with a base and peroxide.

[0094] In any other embodiment of the one or two or more methods described above, the base may be a hydroxide base.

[0095] In yet another embodiment of any one of the 1 or 2 or more methods described above, the peroxide may be hydrogen peroxide.

[0096] In any further embodiment of one or more of the above methods, the mercerization process may include heating the decellularized plant or fungal tissue with an aqueous sodium hydroxide solution and hydrogen peroxide.

[0097] In yet another embodiment of any one or more of the above methods, the decellularized plant or fungal tissue may be treated with an aqueous sodium hydroxide solution for a first period, after which hydrogen peroxide may be added to the reaction.

[0098] In any other embodiment of the one or two or more methods described above, the peroxide may be a pre-prepared solution of 30% to 50% aqueous hydrogen peroxide solution.

[0099] In yet another embodiment of any one of the above one or more methods, the hydrogen peroxide aqueous solution may be used in an amount of at least about 75 mL per 500 g of decellularized plant or fungal tissue.

[0100] In yet another embodiment of any one of the above 1 or more methods, after the addition of the hydrogen peroxide aqueous solution pre-preparation, the concentration of peroxide in the mixture of decellularized plant or fungal tissue, base, and hydrogen peroxide aqueous solution pre-preparation may be about 1% to about 5%.

[0101] In any other embodiment of the one or two or more methods described above, the base may be a 1 M sodium hydroxide solution.

[0102] In yet another embodiment of any one or more of the above methods, a 1 M sodium hydroxide solution may be used in an amount of about 2500 mL per 500 g of decellularized plant or fungal tissue.

[0103] In any other embodiment of the one or more methods described above, the method may further include a step of neutralizing the pH by one or more neutralization treatments.

[0104] In yet another embodiment of any one or more of the above methods, one or more neutralization steps may include treatment with an aqueous HCl solution.

[0105] In yet another embodiment of any one or more of the above methods, the mercerization may be carried out by heating to about 80°C.

[0106] In any other embodiment of one or more of the above methods, the mercerization may be carried out for at least about 30 minutes.

[0107] In yet another embodiment of any one or more of the above methods, the method may further include the step of formulating a skin filler for subdermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof.

[0108] In another embodiment, a skin filler prepared by any one of the one or more methods described herein is provided herein.

[0109] In another embodiment of the above-described skin filler, the skin filler may be any one of the one or more skin fillers described herein.

[0110] In yet another embodiment of any of the one or more skin fillers described above, about 0.1% to about 5% or less of the particles of the skin filler may have a ferret diameter of less than about 20 μm or a minimum ferret diameter.

[0111] In any further embodiment of one or more of the above-described skin fillers, less than 0.5% of the particles of the skin filler may have a ferret diameter of less than 20 μm, or a minimum ferret diameter.

[0112] In yet another embodiment of any of the one or more skin fillers described above, less than 0.1% to less than 5% (e.g., less than 0.5%) of the particles of the skin filler may be small enough to be phagocytosed by one or more target cells.

[0113] In another embodiment, a kit comprising one or more of the following is provided herein: Any one or more dermal fillers described herein; Hydrogels, matrices, or dispersion media; PBS, physiological saline, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof; Lidocaine or other anesthetics; One or more syringes, or another injection device; Luer lock fittings or connectors for two or more syringes; Instructions for performing any of the one or more uses or one or more methods described herein; One or more decellularizing reagents; One or more containers, packages, or vessels; One or more buffer solutions, water, or saline solution for injection; A reagent or enzyme (e.g., cellulase) for dissolving the skin filler in an undesirable area or location; or Any combination of those. [Brief explanation of the drawing]

[0114] These and other features will be further understood in relation to the following drawings. [Figure 1] This figure shows the extruded, decellularized cellulose paste described in Example 1 (left panel), and also shows a 1 mL syringe loaded with the paste using an 18 G needle (right panel); [Figure 2] This figure shows cellulose-based skin filler paste subcutaneously injected at three different sites, as described in Example 1; (A) is a side view, and (B) is a magnified view. At 4 weeks, neovascularization was present around the implant (C), and the implant maintained its shape after excision (D). [Figure 3]This figure shows that cell infiltration and matrix deposition were observed in the animal body after 8 weeks, as described in Example 1. The cellulose filler appeared to be biocompatible and generally maintained its spherical shape over time. The figures show Masson tricolor staining (shown in Figures 3(A) and 3(C)) and hematoxylin-eosin staining (shown in Figures 3(B) and 3(D)) at 8 weeks after subcutaneous injection (scale bar = 2 mm for (A, B); scale bar = 200 μm for (C, D)). [Figure 4] This figure shows the results of manually measuring the implant site from outside the animal using calipers, as described in Example 1. A decrease in implant area was observed throughout the 8-week test period. However, the aspect ratio (ratio of width in the x and y directions) did not change significantly. [Figure 5] As described in Example 1, measurements taken externally of the animals using calipers showed a significant reduction of approximately 75% in implant height over an 8-week trial period. This correlates with the reduction in injection site area observed above; [Figure 6] This figure shows the pulverized dried biomaterial (left) and the rehydrated extruded skin filler (right), as described in Example 2; [Figure 7] This figure shows that the biomaterial was sufficiently sheared by the needle method described in Example 2 to the extent that at least some single, intact structural cells (e.g., isolated cell wall pockets) that appear to be perfectly shaped and undisintegrated were obtained; [Figure 8] As shown in Example 2, this figure illustrates the height of the implant as a function of time. No statistically significant differences were observed between the various formulations. However, a significant difference of approximately 10 times was observed in the concentrations of HA and collagen compared to commercially available products. Consistent with low w / v concentration collagen / HA hydrogels, this result appears to be similar to the behavior of saline-based fillers, which result in approximately a 50% reduction in height. [Figure 9]As described in Example 2, this figure shows the calculated volume of the implant mass measured externally with a caliper as a function of time. The implant volume was calculated using height, x-width, and y-width, assuming a semi-ellipsoid shape. No statistically significant differences were observed between the various formulations, showing a trend consistent with a decrease in height. [Figure 10] This diagram shows PMMA microspheres (indicated by white circles) at a size of 30-50 μm three months after implantation. Although natural tissue is growing around the implant, the volume ratio of PMMA in the tissue is very high. This indicates that the tissue is composed primarily of synthetic materials, rather than natural cells and proteins. [Figure 11] This figure illustrates the sterile sample processing. As described in Example 3, the GLP version of the decellularization process was performed using sterile materials and sterile techniques; [Figure 12] This figure illustrates the freeze-drying process of a decellularized cellulose scaffold derived from apples, as described in Example 3. (A) The decellularized material was collected and placed in a Falcon tube, and the channel was pressurized to allow water vapor to escape by evaporation / sublimation. (B) The material was placed in a freeze-dryer. (C) Freeze-drying was carried out at -46°C, 0.05 mbar for 48 hours. (D) shows the freeze-dried final product; [Figure 13] This figure shows that dried cellulose biomaterial was pulverized into powder at 18,000, 12,000, and 6,000 rpm, as described in Example 3, and simultaneously passed through an 80 μm filter. The collection tray after processing is shown. The fastest RPM setting was used to minimize processing time. No effect of pulverization speed on particle size distribution was observed (data shown in Example 3). [Figure 14]This figure shows the filtration process described in Example 3. (A) shows the powder obtained by grinding the material through an 80 μm filter, and (B) the powder is subjected to wet sieving by passing it through 45 μm and 25 μm sieves (B) to limit the size range of the powder (C). The narrow size range of particles was concentrated by centrifugation (D). Automated wet sieving dramatically improved processing time and efficiency, and is now used; [Figure 15] This figure shows particles stained with Congo Red as described in Example 3. The particles were stained with 0.1% Congo Red and imaged at 2.5x (A, B) and 10x (C, D). (A, C) Unfiltered particles. (B, D) Filtered particles. The images were collected to quantify the particle size distribution. Typically, 10 images at 2.5x magnification yield approximately 1000 particles, which is a statistically significant sample size; [Figure 16] This figure shows the particle size analysis as described in Example 3. The particles were thresholded and segmented using Fiji (ImageJ). (A, B) Filtered particles. (C, D) Unfiltered particles. (A, C) Thresholded images. (B, D) Particle contours by size analysis; [Figure 17] This figure shows the particle size analysis of filtered and unfiltered decellularized apple particles. Ferret diameter was used to quantify particle size. Images (N=15) for each condition were analyzed from fluorescence microscopy images of particles stained with Congo red. N=2292 for unfiltered particles, N=1595 for filtered particles. There was a statistically significant difference in the mean values ​​(P=7.4×10⁻⁵). [Figure 18] As described in Example 3, these figures (A-D) show SEM micrographs of decellularized apple powder, with increasing magnification. [Figure 19] This figure shows the manual image processing required to determine the diameter of the section, as described in Example 3. The section has an irregular shape, and a single length descriptor cannot capture this complexity (Source: Decellularized Apple). [Figure 20]This figure shows the particle size distribution of decellularized apples obtained by SEM, as described in Example 3. From the distribution, a peak at 47.11 ± 1.11 μm (N=133 thin sections) was identified. The distribution obtained from SEM image analysis was much narrower than that obtained by optical methods. However, this method has drawbacks, including a small N-value due to the manual approach of measuring particles one at a time, the influence of particle angle orientation, and the inability to reliably detect edges. For these reasons, this method was undesirable for particle size characterization; [Figure 21] This figure shows the particle size distribution after crushing decellularized apples at various rates, measured before automated wet sieving filtration, as described in Example 3. The particles were generated by crushing at 6000 RPM (black) and 18000 RPM (gray) before sieving. The two distributions were similar. The average particle size was 73.07 ± 0.58 μm at 6000 RPM and 73.50 ± 0.56 μm at 18000 RPM. The values ​​are the mean and standard error of the mean. N=2579 for 6000 RPM and N=2354 for 18000 RPM. There was no significant difference in average particle size (P=0.58). [Figure 22] This figure shows a sample of a particle suspension in a sealed Nalgene bottle for gamma irradiation with a label, as described in Example 3; [Figure 23] This figure shows a sample image obtained from Keyence electron microscopy. The bright red overlay indicates the particles used in the analysis. [Figure 24] As described in Example 3, this figure shows the particle area for particles irradiated with gamma rays (N=3800) and particles that were not irradiated (N=4692); [Figure 25] As described in Example 3, this figure shows the histogram of the maximum particle diameter for particles irradiated with gamma rays (N=3800) and particles that were not irradiated (N=4692); [Figure 26]As described in Example 3, this figure shows the minimum diameter histograms for gamma-ray irradiated particles (N=3800) and unirradiated particles (N=4692); [Figure 27] This figure shows the particle size distribution of apple-derived particles obtained via fractional centrifugation, as described in Example 3. (A) shows the particle size distribution of unfiltered particles after initial removal of larger particle sizes by manual sieving (45 μm), and (B) shows the distribution after five centrifugation cycles of 1 minute each at 1000 rpm. To collect all the material, centrifugation at 5000 rpm for 7 minutes was used; [Figure 28] This figure shows an in vitro cell culture test using AA (apple) particles, as described in Example 3. Blue = 3T3 cell nuclei. In some cases, thin flakes of larger particles may also be visible as a result of Hoechst 33342 staining. Red = particles stained with 0.01% Congo Red, remaining after washing away free particles. Figure 28(A, B) shows the control. Figure 28(C, D) = control and staining. Figure 28(E, F) = filtration: 25-45 μm. Figure 28(G, H) = filtration: 25-45 μm and staining. Figure 28(I, J) = no filtration. Figure 28(K, L) = no filtration and staining. Scale = 250 μm; [Figure 29] This figure shows an injectable skin filler containing alginate, as described in Example 3. The particles accounted for 20% of the volume. Two mixing methods were tested. (A) shows mixing the powder in water and alginate solution. (B) shows mixing the powder first in the water component, followed by the slow addition of the alginate. The first method did not mix well, and the needle clogged. The second method mixed well, but unfiltered particles clogged the needle. When the unfiltered particles were replaced with filtered particles, the mixture could be easily pushed out; [Figure 30]This figure shows the mixing of skin filler components using a syringe Luer lock connector, as described in Example 3. (A) shows the two components loaded into individual syringes. The clear liquid is 1% alginate, and the red liquid is particles suspended in 0.9% saline and lidocaine (final concentration = 0.3%). Congo Red was added for visualization (final concentration 0.1%). (B) shows the Luer lock connector. (C) shows the mixing of the components (a total of 60 back-and-forth movements). (D) shows the Luer lock removed and replaced with an extrusion needle. Note that the solution does not clog the 27G needle; [Figure 31] This figure shows the collagen filler described in Example 3. (A) shows the particle size distribution of PMMA beads in BellaFill. (B) shows Congo red-stained collagen to be used in a dermal filler currently under development, with only minimal secondary nonspecific staining. (C) shows the PMMA beads in BellaFill. (D) shows cellulose particles to be used in a collagen dermal filler currently under development, stained with Congo red. Note: Background staining of collagen is weaker compared to the signal from cellulose particles. Scale = 250 μm; [Figure 32] This figure shows the results of injection of a skin filler, as described in Example 3. (A) shows the contour of the elevation boundary before injection, and (B) shows the contour of the elevation boundary after injection; [Figure 33] This figure shows the excision of a filler based on saline, hyaluronic acid (HA), and collagen, combined with 20% decellularized apple-derived filtered particles and 0.3% lidocaine, as described in Example 3; [Figure 34] This diagram shows the implant sizes, as described in Example 3. The heights of the AAS (blue), AAHA (red), AAC (black), and BellaFill (purple) implants are shown. All implants shrank over time due to reabsorption of the dispersion medium / hydrogel. The AAS formulation was absorbed rapidly; [Figure 35] The implant volumes are shown as described in Example 3. Volumes of AAS (blue), AAHA (red), AAC (black), and BellaFill (purple) implants. All implants shrank over time due to reabsorption of the dispersion medium / hydrogel. The AAS formulation was absorbed rapidly; [Figure 36] As shown in Example 6, the particle size distribution of the obtained apple-derived particles is shown; [Figure 37] As described in Example 7, Figure 37A shows a control micrograph, Figure 37B shows a micrograph of cells from a 20% v / v apple-derived particle solution and C1C12 cells, and Figure 37C shows a micrograph of cells from a 20% filtered particle sample; [Figure 38] As described in Example 7, this figure shows the cell concentration (cells / mm2) of 20% filtered apple-derived particle samples and unfiltered apple-derived particle samples; [Figure 39] As described in Example 7, this figure shows the surface area coverage of cells in the control sample and filtered and unfiltered low-concentration samples. [Figure 40] This figure shows the standard absorbance-concentration curve prepared using the sample from Example 8; [Figure 41] This figure shows the absorbance-concentration curves of the sample described in Example 8 at absorbances of 450 nm, 475 nm, 500 nm, and 525 nm; [Figure 42] This figure shows the wavelength sweep of a 20% pear-derived particle pre-processing solution and a 2M sucrose control solution, as described in Example 8; [Figure 43] This figure shows the absorbance-concentration curve of the sample at 320 nm, as described in Example 8; [Figure 44] This figure shows the force-displacement curve of HyStem HA using an apple-derived particle (HAAA) sample, as described in Example 10; [Figure 45]This figure shows the force-displacement curve of the BellaFill dermal filler, as described in Example 10; [Figure 46] This figure shows the force-displacement curve of the diluted HAAA sample, as described in Example 10; [Figure 47] As described in Example 10, the figures show force-displacement curves for a gelatin (GE; particle-free) sample, with Figure 47A showing the force-displacement curve for GE extrusion through a 27G needle, and Figure 47B showing the force-displacement curve for GE extrusion through a 30G needle; [Figure 48] This figure shows the force-displacement curves of gelatin and apple-derived particle (GEAA) samples, as described in Example 10; [Figure 49] As described in Example 10, the figures show the force-displacement curves of diluted GE samples. Figure 49A shows the force-displacement curve of diluted GE heated before extrusion, and Figure 47B shows the force-displacement curve of diluted GE sample kept at room temperature before extrusion. [Figure 50] This figure shows the force-displacement curve of an alginate (AL; particle-free) sample, as described in Example 10; [Figure 51] This figure shows the dry mass % of a mercerized apple (AA) sample after centrifugation in water or PBS, as described in Example 13; [Figure 52] This figure shows microscopic images of the samples described in Example 14. Figure 52A is a sample with an AA:NaOH ratio of 1:5, Figure 52B is a sample with an AA:NaOH ratio of 1:2, and Figure 52C is a sample with an AA:NaOH ratio of 1:1. [Figure 53] This figure shows the particle size distribution of the sample described in Example 14 and imaged in Figure 52; [Figure 54] As described in Example 15, Figure 54A shows a microscopic image of a mixture of mercerized AA and pear powder (before centrifugation), with Figure 54A showing a microscopic image at the 500 μm scale and Figure 54B showing a microscopic image at the 100 μm scale; [Figure 55] As described in Example 15, Figure 55A shows a microscopic image of the supernatant collected by centrifugation of a mercerized AA and pear powder mixture, with Figure 55B showing a microscopic image at a 500 μm scale; Figure 55A shows a microscopic image at a 100 μm scale. [Figure 56] Figure 56A shows a microscopic image of pellets formed from the marcel-processed AA and pear powder mixture described in Example 15, with Figure 56B showing a microscopic image at the 500 μm scale; Figure 56A shows a microscopic image at the 100 μm scale. [Figure 57] As described in Example 15, Figure 57A shows a microscopic image of the marcel-processed AA and pear powder pellet samples after sieving, with Figure 57B showing a microscopic image at a 500 μm scale; [Figure 58] As described in Example 15, Figure 58A shows a microscopic image of the mercerized AA and pear powder pellet samples after the final centrifugation, with Figure 58B showing a microscopic image at a 500 μm scale; Figure 58B shows a microscopic image at a 100 μm scale. [Figure 59] Figures 54 to 58 show the relative frequencies of each specific particle diameter in microscope images acquired at 2.5x magnification; [Figure 60] Figures 54 to 58 show the particle size distribution of each microscopic image acquired at 2.5x magnification. Figure 60A shows the particle size distribution of the pellet after the final centrifugation, Figure 60B shows the particle size distribution of the sieved pellet, Figure 60C shows the particle size distribution of the pellet after the initial centrifugation, Figure 60D shows the particle size distribution of the supernatant, and Figure 60E shows the particle size distribution of the AA and pear powder mixture that was first mercerized. [Figure 61] Figures 54 to 58 show the relative frequency of each specific particle diameter in microscope images acquired at 10x magnification; [Figure 62]Figures 54 to 58 show the particle size distribution of each microscopic image acquired at 10x magnification. Figure 62A shows the particle size distribution of the pellet after final centrifugation, Figure 62B shows the particle size distribution of the sieved pellet, Figure 62C shows the particle size distribution of the pellet after initial centrifugation, Figure 62D shows the particle size distribution of the supernatant, and Figure 62E shows the particle size distribution of the AA and pear powder mixture that was initially marcel-processed. [Figure 63] This figure shows the particle size distribution of the mercerized AA sample before and after extrusion, as described in Example 16; [Figure 64] As described in Example 17, the figures show the force-displacement curves for extrusion of decellularized AA (Mer20Sal80) formulations diluted with 20% (v / v) water samples and 0.9% physiological saline, and mercel-processed AA (Mer100) formulations. Figure 64A shows the force-displacement curve for the water sample, Figure 64B shows the force-displacement curve for the Mer20Sal80 formulation, and Figure 64C shows the force-displacement curve for the Mer100 formulation. [Figure 65] This figure shows the maximum extrusion force of the force-displacement curve shown in Figure 64; [Figure 66] Figure 64 shows the average (plateau) extrusion force of the force-displacement curve; [Figure 67] This figure shows the force-displacement curves of the Mer100 formulation extruded through 27G and 30G needles, as described in Example 17; [Figure 68] This figure shows the force-displacement curves of the Mer100 formulation extruded through a 27G needle from a standard 1cc syringe and a BellaFill syringe; [Figure 69] Figures 67 and 68 show the maximum extrusion force of the force-displacement curve; [Figure 70] This figure shows the force-extrusion curves of the Mer100 formulation through a 27G needle extruded at crosshead speeds of 1 mm / s, 2.5 mm / s, and 5.0 mm / s, as described in Example 17; [Figure 71]This figure shows the maximum extrusion force of the force-displacement curve shown in Figure 70; [Figure 72] As described in Example 18, the figures show the force-displacement curves of the GE formulation and the mercerized AA formulation, with Figure 72A showing the force-displacement curve of the 5% GE formulation, Figure 72B showing the force-displacement curve of the 2.5% GE formulation, Figure 72C showing the force-displacement curve of the 1% GE formulation, Figure 72D showing the force-displacement curve of the 0.5% GE formulation, and Figure 72E showing the force-displacement curve of the 0.25% GE formulation; [Figure 73] This figure shows the maximum extrusion force of the force-displacement curve shown in Figure 72; [Figure 74] As described in Example 19, Figure 74A shows the stress-strain-time chart of a mercerized AA sample, and Figure 74B shows the stress-strain-time chart of an undiluted mercerized AA sample; [Figure 75] As described in Example 19, Figure 75A shows the storage modulus, loss modulus, and loss coefficient curves of a mercerized AA sample. Figure 75A shows the storage modulus (E') and loss modulus (E”) of an undiluted mercerized AA sample, Figure 75B shows the loss coefficient curve of an undiluted mercerized AA sample, Figure 75C shows the storage modulus (E') and loss modulus (E”) of a diluted mercerized AA sample, and Figure 75D shows the loss coefficient curve of a diluted mercerized AA sample. [Figure 76] Figure 76A shows a microscopic image of a mercerized AA sample stored at 4°C, and Figure 76B shows a microscopic image of a mercerized AA sample maintained in a shaking incubator. [Figure 77] This figure, described in Example 20 and imaged in Figure 76, shows the particle size distribution of the Marcel-processed AA sample; [Figure 78]Figure 78A shows the distribution of circularity and roundness of the particles in the mercerized AA sample, as described in Example 20 and visualized in Figure 76. Figure 78B shows the distribution of circularity of the mercerized AA sample, and Figure 78A shows the distribution of roundness of the mercerized AA sample. [Figure 79] This figure shows the standard absorbance concentration curves at wavelengths of 540 nm and 570 nm for D-glucose produced from enzymatic activity in cellulose-based skin fillers, as described in Example 26; [Figure 80] This figure shows the concentrations of D-glucose produced using enzyme solutions diluted in different buffers at 37°C, as described in Example 26; [Figure 81] This figure shows the concentrations of D-glucose produced using pectinase:cellulase ratios diluted in different buffers at 37°C, as described in Example 26; [Figure 82] This figure shows the concentrations of D-glucose produced at 37°C using various enzyme concentrations, as described in Example 26; [Figure 83] This figure shows microscopic images of cellulose-derived particles after 48 hours of incubation at various enzyme concentrations, as described in Example 26; [Figure 84] This figure shows the concentrations of D-glucose produced at 37°C using various pectinase:cellulase ratios, as described in Example 26; [Figure 85] This figure shows microscopic images of cellulose-derived particles after 48 hours of incubation at various pectinase:cellulase ratios, as described in Example 26; [Figure 86] This figure shows the concentrations of D-glucose produced using fresh enzyme solutions of various concentrations, as described in Example 26; [Figure 87] This figure shows microscopic images of cellulose-derived particles after 48 hours of incubation in various fresh enzyme solutions, as described in Example 26; [Figure 88] This figure shows the concentrations of D-glucose produced using pre-prepared enzyme solutions of various concentrations, as described in Example 26; [Figure 89] As described in Example 27, the figures show photographs of excised tissue taken from rats injected with dermal fillers according to certain embodiments of the present disclosure, with Figure 89B showing an excised tissue from a rat injected with a hyaluronic acid (HA) dermal filler formulation and Figure 89C showing an excised tissue from a rat injected with a collagen dermal filler formulation; [Figure 90] As described in Example 27, the figures show microscopic images of the injected saline solution 12 weeks later. Figure 90A shows a microscopic image of the injected saline solution stained with Masson's tricolor (MT) at a magnification of 1x, Figure 90B shows a microscopic image of the injected saline solution stained with MT at a magnification of 10x, Figure 90C shows a microscopic image of the injected saline solution stained with MT at a magnification of 20x, Figure 90D shows a microscopic image of the injected saline solution stained with hematoxylin and eosin (HE) at a magnification of 1x, Figure 90E shows a microscopic image of the injected saline solution stained with HE at a magnification of 10x, and Figure 90F shows a microscopic image of the injected saline solution stained with HE at a magnification of 20x. [Figure 91] As described in Example 27, the figures show microscopic images of injected HA dermal filler formulations 12 weeks later. Figure 91A shows a microscopic image of the injected HA formulation stained with MT at 1x magnification, Figure 91B shows a microscopic image of the injected HA formulation stained with MT at 10x magnification, Figure 91C shows a microscopic image of the injected HA formulation stained with MT at 20x magnification, Figure 91D shows a microscopic image of the injected HA formulation stained with HE at 1x magnification, Figure 91E shows a microscopic image of the injected HA formulation stained with HE at 10x magnification, and Figure 91F shows a microscopic image of the injected HA formulation stained with HE at 20x magnification; [Figure 92]As described in Example 27, the figures show microscopic images of injected collagen dermal filler formulations 12 weeks later. Figure 92A shows a microscopic image of the injected collagen formulation stained with MT at 1x magnification, Figure 92B shows a microscopic image of the injected collagen formulation stained with MT at 10x magnification, Figure 92C shows a microscopic image of the injected collagen formulation stained with MT at 20x magnification, Figure 92D shows a microscopic image of the injected collagen formulation stained with HE at 1x magnification, Figure 92E shows a microscopic image of the injected collagen formulation stained with HE at 10x magnification, and Figure 92F shows a microscopic image of the injected collagen formulation stained with HE at 20x magnification; [Figure 93] As described in Example 27, the figures show microscopic images of injected skin filler formulations stained with Congo red at 12 weeks, at 10x magnification. Figure 93A shows the injected saline formulation, Figure 93B shows the injected HA formulation, and Figure 93C shows the injected collagen formulation. [Figure 94] This figure shows microscopic images of injected skin filler formulations stained with CD31, CD45, or Verhoeff Van Gienson (Verhoeff) dyes 12 weeks after injection, as described in Example 27; [Figure 95] This figure shows the change over time in the height of the elevation formed by injection of the skin filler formulation described in Example 27; [Figure 96] This figure shows the change over time in the height of the elevation formed by injection of the skin filler formulations described in Examples 27 and 28; and [Figure 97] This figure shows microscopic images of injected skin filler formulations stained with CD31, CD45, or Verhoefff dye 12 weeks after injection, as described in Example 28. [Modes for carrying out the invention]

[0115] Skin fillers, methods and uses thereof for cosmetic and / or reconstructive applications, and methods for preparing such skin fillers and related skin filler kits are described herein. Embodiments and examples are provided for illustrative purposes intended for those skilled in the art and are not intended to limit them in any way.

[0116] Skin fillers comprising decellularized plant or fungal tissue from which the cellular material and nucleic acids of the tissue have been removed; and methods and uses thereof for cosmetic and / or reconstructive applications are provided herein. Methods for preparing such skin fillers and skin filler kits are also provided.

[0117] As described herein, the inventors have now developed a dermal filler product containing decellularized plant or fungal tissue. The data provided herein demonstrate that the dermal filler has good biocompatibility and is substantially non-absorbable, i.e., “permanent”. Methods for preparing such dermal filler products are described, which enable a variety of other beneficial properties, including size control and avoidance of small, undesirable particles smaller than 20 μm in size. Formulations with good needle passability / injectability through small gauge needles, as well as formulations compatible with dispersion media, e.g., hydrogels and anesthetics, have been developed. Sterilization methods and sterile products are also described. Particles for dermal filler products having desirable shape and surface area / volume / filling properties that promote cell infiltration / proliferation and / or provide a good ratio of natural tissue to dermal filler in the subject are described.

[0118] Dermatological fillers are materials commonly used for cosmetic and / or aesthetic applications, such as filling wrinkles, altering appearance, or addressing soft tissue damage caused by disease or injury. In certain embodiments, the dermatological filler products described herein can be considered “permanent” in that they provide long-lasting, natural, and biocompatible solutions for such applications. Many dermatological fillers in this field are temporary. After a certain period of time, conventional dermatological fillers are absorbed by the body. Some use synthetic particles, such as PMMA, to provide longer-lasting solutions. In certain embodiments, the approach described herein may provide cellulosic materials processed to a target size range for dermatological fillers. These may be produced from natural plant polymers and may be permanent because humans do not have the enzymes to break down cellulose. As described in detail herein, such particles have been successfully produced and are within the desired target size range. These particles were used in various dermatological filler formulations and injected into rat models. These particles may have a desirable SA:V ratio, promote angiogenesis, be biocompatible, and provide tissue composed more of the patient's own tissue than synthetic materials.

[0119] In one embodiment, a non-absorbable skin filler is provided herein, comprising decellularized plant or fungal tissue from which the cellular material and nucleic acids of the tissue have been removed.

[0120] As will be understood, a skin filler can be considered non-absorbable if it contains at least one filler or particulate component that is substantially non-absorbable or persistent (e.g., resistant to degradation) after implantation into a subject. For example, in certain embodiments, the skin fillers described herein may contain decellularized plant tissue in the form of cellulosic or cellulose-containing particles, which can be considered substantially non-absorbable because the human body does not have the enzymes to break down cellulose. In certain embodiments, a non-absorbable skin filler may contain one or more fillers or particulate components that are permanent, semi-permanent, or persistent in the body after, for example, injection or implantation.

[0121] It should be understood that, unless otherwise specified, the meanings / definitions of the plant kingdom and fungal kingdom used herein are based on the Cavalier-Smith classification (1998).

[0122] In certain embodiments, the plant or fungal tissue may generally include any suitable plant or fungal tissue or portion that contains a suitable scaffold structure suitable for a particular application.

[0123] In certain embodiments, the plant or fungal tissues include: apple hypanth (Malus pumila) tissue, fern (Monilophytes) tissue, turnip (Brassica rapa) root tissue, ginkgo branch tissue, horsetail (equisetum) tissue, hermocallis hybrid leaf tissue, kale (Brassica oleracea) stem tissue, coniferous Douglas fir (Pseudotsuga menziesii) tissue, cactus fruit (pitaya) pulp tissue, Maculata Vinca tissue, aquatic lotus (Nelumbo nucifera) tissue, and tulip (Tulipa gesneriana). Petal tissue of gesneriana, tissue of plantain (banana (Musa paradisiaca)), stem tissue of broccoli (Brassica oleracea), stem tissue of maple leaf (European maple (Acer psuedoplatanus)), primary root tissue of beet (sugar beet (Beta vulgaris)), tissue of onion (Allium cepa)), tissue of orchid (Orchidaceae)), stem tissue of turnip (Brassica lapa), tissue of chives (Leek (Allium ampeloprasum)), branch tissue of maple (Acer genus)), tissue of celery (Dutch parsley (Apium graveolens)), stem tissue of onion (pine tissue), aloe vera tissue, watermelon (Citrullus lanatus var. lanatus).lanatus tissue, creeping jenny (Lysimachia nummularia) tissue, cactus tissue, Lychnis alpina tissue, rhubarb (Rheum rhabarbarum) tissue, pumpkin flesh (Cucurbita pepo) tissue, dracaena (Asparagaceae) stem tissue, spiderwort (Tradescantia virginiana) stem tissue, asparagus (Asparagus officinalis) stem tissue, mushroom (fungus) tissue, fennel (Foeniculum vulgare) tissue, rose (Rosa) tissue, carrot (Daucus carota) The tissue may include carota (carota) tissue or pear (pomaceous) tissue. Additional examples of plant and fungal tissues are described in Example 18 of International Publication No. 2017 / 136950, “Decellularised Cell Wall Structures from Plants and Fungus and Use Thereof as Scaffold Materials,” which is incorporated herein by reference in its entirety.

[0124] In certain embodiments, the decellularized plant or fungal tissue may be cellulosic, chitinic, chitosanic, ligninic, lignanic, hemicelluloseic, pectinic, or any combination thereof. In certain embodiments, the plant or fungal tissue may be apple hypanthium (Malus sieboldiana) tissue, fern (Fernidae) tissue, turnip (Brassica rapa) root tissue, ginkgo branch tissue, horsetail (Equisetum hyemale) tissue, daylily hybrid leaf tissue, kale (Brassica oleracea) stem tissue, coniferous tree (Douglas fir) tissue, cactus fruit (pitaya) pulp tissue, Maculata vinca tissue, water Lotus (lotus) tissue, tulip (Tulippa guesneriana) petal tissue, plantain (banana) tissue, broccoli (Brassica oleracea) stem tissue, maple leaf (Acer palmatum) stem tissue, beet (sugar beet) primary root tissue, leek (onion) tissue, orchid (Orchidaceae) tissue, turnip (Brassica rapa) stem tissue, chive (leek) tissue, maple (Acer genus) wood branch tissue, celery ( The tissues may include those derived from: Dutch parsley tissue, onion stem tissue, pine tissue, aloe vera tissue, watermelon (Citrus lanatus variety lanatus) tissue, creeping jenny (Solanum nigrum) tissue, cactus tissue, Lychnis alpina tissue, rhubarb (Reum lavallum) tissue, pumpkin flesh (Cucurbita pepo) tissue, Dracaena stem tissue, Tradescantia virginiana stem tissue, asparagus (Asparagus officinalis) stem tissue, mushroom (fungus) tissue, fennel tissue, rose (Rosa) tissue, carrot (Daucus carota) tissue, or pear (Pomegranate) tissue, or genetically modified tissues produced through direct genome modification or selective breeding, or any combination thereof.

[0125] It will also be understood that the cellular material and nucleic acids of plant or fungal tissues may include intracellular contents, e.g., cellular organelles (e.g., chloroplasts, mitochondria), cell nuclei, cellular nucleic acids, and / or cellular proteins. These may be substantially, partially, or completely removed from the plant or fungal tissue and / or from the scaffolding biomaterial. It will be recognized that trace amounts of such components may still be present in the decellularized plant or fungal tissues described herein. It will also be understood that references to decellularized plant or fungal tissues herein are intended to reflect that such cellular material found in the source of the plant or fungal tissue is substantially removed, but this does not rule out the possibility that the decellularized plant or fungal tissue may, in certain embodiments, contain, or may contain, any kind of subsequently introduced or reintroduced cells, cellular material, and / or nucleic acids, e.g., animal or human cells.

[0126] Various methods may be used to produce the decellularized plant or fungal tissues described herein. For example, in certain embodiments, the decellularized plant or fungal tissues may include plant or fungal tissues decellularized by heat shock, treatment with surfactants (e.g., SDS, Triton X, EDA, alkaline treatment, acid, ionic surfactants, nonionic surfactants, and zwitterionic surfactants), osmotic shock, freeze-drying, physical dissolution (e.g., hydrostatic pressure), electrical disruption (e.g., non-thermal irreversible electroporation), or enzymatic digestion, or any combination thereof. In certain embodiments, the biomaterials described herein can be obtained from plants and / or fungi by employing a decellularization process that may include (individually or in combination) any of several approaches, including but not limited to heat shock (e.g., rapid freeze-thaw), chemical treatment (e.g., surfactants), osmotic shock (e.g., distilled water), freeze-drying, physical dissolution (e.g., pressurized treatment), electrical disruption, and / or enzymatic digestion.

[0127] In certain embodiments, the decellularized plant or fungal tissue may include plant or fungal tissue that has been decellularized by treatment with a surfactant or surfactant. Examples of surfactants include, but are not limited to, sodium dodecyl sulfate (SDS), Triton X, EDA, alkaline treatment, acids, ionic surfactants, nonionic surfactants, and zwitterionic surfactants.

[0128] In yet another embodiment, the decellularized plant or fungal tissue may include plant or fungal tissue that has been decellularized by treatment with SDS. In yet another embodiment, residual SDS may be removed from the plant or fungal tissue by washing with a divalent salt aqueous solution. The divalent salt aqueous solution may be used to precipitate / settle the salt residue containing SDS micelles from the solution / scaffold, and the salt residue or SDS micelles may be removed by treatment with dH2O, acetic acid or dimethyl sulfoxide (DMSO), or sonication. In certain embodiments, the divalent salt in the divalent salt aqueous solution may include, for example, MgCl2 or CaCl2.

[0129] In another embodiment, plant or fungal tissue may be decellularized by treatment with an SDS solution containing 0.01–10%, for example, about 0.1%–about 1%, or for example, about 0.1% or about 1% SDS, in a solvent, for example, water, ethanol, or another suitable organic solvent, after which residual SDS may be removed using an aqueous CaCl2 solution of about 100 mM concentration, and then incubated in dH2O. In a particular embodiment, the SDS solution may be at a higher concentration than 0.1% to facilitate decellularization, and may be accompanied by increased washing to remove residual SDS. In a particular embodiment, plant or fungal tissue may be decellularized by treatment with an SDS solution containing about 0.1% SDS in water, after which residual SDS may be removed using an aqueous CaCl2 solution of about 100 mM concentration, and then incubated in dH2O.

[0130] Further examples of decellularization protocols that can be adapted to produce the decellularized plant or fungal tissues described herein can be found in International Publication No. 2017 / 136950, entitled "Decellularised Cell Wall Structures from Plants and Fungus and Use Thereof as Scaffold Materials," which is incorporated herein by reference in its entirety.

[0131] In another embodiment, the decellularized plant or fungal tissue may be chitin-based, chitosan-based, lignocellulose-based, or cellulose-based. In yet another embodiment, the decellularized plant or fungal tissue may be derived from the leaf-like structure, root, pulp, hypanthium, or pulp structure of a plant. In yet another embodiment, the decellularized plant or fungal tissue may be derived from lettuce, carrot, apple, or pear, or any combination thereof.

[0132] In any other embodiment of the 1 or 2 or more skin fillers described above, the decellularized plant or fungal tissue may be homogenized. In yet another embodiment, the decellularized plant or fungal tissue may be dried, pulverized, and optionally restored or rehydrated.

[0133] In yet another embodiment of any one or more of the above skin fillers, the decellularized plant or fungal tissue may be broken down into single structural cell-sized or smaller particles. In certain embodiments, the single structural cell may be derived from an extended 3D structure of the plant or fungal tissue, or it may include isolated structural cells, which typically have a three-dimensional structure similar to a hollow cell or pocket, as shown in Figure 7. It will be understood that such structures typically include lignocellulosic materials, e.g., cellulose and / or lignin-based structures. In certain embodiments, it will be understood that such structures may include other constituent units, e.g., chitin and / or pectin. In certain embodiments, as shown in Figures 18 and 19, the single structural cell may be broken down (e.g., pulverized) into smaller particles, e.g., flakes.

[0134] In any other embodiment of the one or more dermal fillers described above, the dermal filler may further comprise a hydrogel, matrix, or dispersion medium for decellularized plant or fungal tissue. In certain embodiments, the hydrogel, matrix, or dispersion medium may comprise PBS (saline solution), hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof.

[0135] It should be noted that, as used herein, the term “dissolved and regenerated cellulose” refers to cellulose that has been dissolved and subsequently “regenerated” through solvent exchange and mixing with plant or fungal tissue. Any suitable solvent may be used to dissolve the cellulose. For example, in one embodiment, a solution of LiCl and dimethylacetamide (DMAc) may be used to dissolve the cellulose.

[0136] In certain embodiments, such hydrogels, matrices, or dispersion media may be, for example, of biological origin (e.g., natural proteins), synthetic polymers, or synthetic analogs of naturally occurring polymers.

[0137] Further discussions and examples regarding hydrogels, matrices, and / or dispersion media can be found in Nguyen et al. "Cosmetic Medicine: Facial Resurfacing and Injectables", Plast Reconstr Surg. 129, 142e (2012); and Luebberding et al. "Critical Appraisal of the Safety of Dermal Fillers: A Primer for Clinicians", Curr Derm Rep. 2, 150 (2013), which are each incorporated in their entirety by reference.

[0138] In certain embodiments, a hydrogel, matrix, or dispersion medium may be used to resuspend the dermal filler particles for the purpose of obtaining a substantially uniform dispersion and enabling injection, for example, through a small-gauge needle.

[0139] In certain embodiments, the viscosity of the skin filler may be adjusted as desired. In certain embodiments, for example, a lower viscosity makes injection easier, while a higher viscosity maintains a uniform particle arrangement and / or allows the volume to be maintained for a longer period of time. In certain embodiments, the viscosity value may be within a range or vary, for example, in a certain example, a saline carrier yields about 1 cP, while a higher viscosity dispersion medium yields a higher viscosity, e.g., about 3 × 10⁻⁶. 6 cP (as in commercially available products, e.g., Bellafill) or higher may be obtained.

[0140] In further embodiments, the skin filler may have a viscosity of less than about 500,000 cp. In certain embodiments, the skin filler may have a viscosity in the range of about 100,000 cp to about 500,000 cp.

[0141] In any further embodiment of the one or more dermal fillers described above, the dermal filler may be dried or hydrated. In certain embodiments, the dermal filler may be provided in a dried or freeze-dried form, which may be for restoration in water, hydrogel, or other dispersion media before use, for example.

[0142] In any other embodiment of the one or more skin fillers described above, the skin filler may contain lidocaine or other anesthetics.

[0143] In certain embodiments of the skin fillers described herein, the decellularized plant or fungal tissue may be broken down into particles that generally have a flaky structure, which may have any preferred shape, e.g., regular or irregular 3D or 2D shapes, e.g., irregular, square, or circular shapes. A given shape may typically have a minimum and maximum diameter or ferret diameter, but in some cases (such as in the case of a circular structure), these may be equal or approximately equal. Preferably, in certain embodiments, the particles, or at least the majority of the particles, may be large enough in size / shape to avoid or prevent cellular uptake or phagocytosis. Thus, in certain embodiments, distribution of particles with a diameter (whether it is the normal diameter, minimum ferret diameter, and / or maximum ferret diameter) less than 20 μm may be avoided if cellular uptake and / or phagocytosis is undesirable.

[0144] In certain embodiments of the skin fillers described herein, the decellularized plant or fungal tissue may be broken down into particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure. In certain embodiments, the flake-like structure may have a thickness of about 0.01 μm to about 100 μm, for example, about 0.1 μm.

[0145] In some embodiments of the skin fillers described herein, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 500 μm.

[0146] In certain embodiments, the decellularized plant or fungal tissue may be broken down into particles large enough not to be phagocytosed by one or more cells (preferably, the decellularized plant or fungal tissue may be broken down into particles having a size, diameter, or minimum ferret diameter of at least about 20 μm); it may be broken down into particles having a size, diameter, or maximum ferret diameter of less than about 200 μm; it may be broken down into particles having a size, diameter, or ferret diameter distribution in the range of about 20 μm to about 200 μm; it may be broken down into particles having a particle size, diameter, or ferret diameter distribution with a peak between about 30 μm and about 100 μm; it may be broken down into particles having an average particle size, diameter, or ferret diameter in the range of about 30 μm to about 100 μm; or any combination thereof.

[0147] In another embodiment, the decellularized plant or fungal tissue may be decomposed into particles having a size, diameter, or maximum ferret diameter of less than about 300 μm; into particles having a size, diameter, or ferret diameter distribution in the range of about 100 μm to about 300 μm; into particles having a particle size, diameter, or ferret diameter distribution with a peak within the range of about 100 μm to about 300 μm; into particles having an average particle size, diameter, or ferret diameter in the range of about 100 μm to about 300 μm; or any combination thereof.

[0148] In yet another embodiment of the skin filler described herein, the decellularized plant or fungal tissue is approximately 200 to approximately 3000 μm in size. 2 Within that range, or approximately 200 to 300 μm 2 The particles may be broken down into particles having an average projected particle area within the range of; decellularized plant or fungal tissues have a surface area-to-volume ratio of approximately 0.1 to 100 μm². -1 It may be broken down into particles; decellularized plant or fungal tissue consists of particles of approximately 4 × 10 5 pieces / mL~particles approx. 7×10 9 The particles may be broken down into particles having a packing density of 1 / mL; or any combination thereof.

[0149] In any other embodiment of the one or more skin fillers described above, the decellularized plant or fungal tissue may be sterilized. In yet another embodiment of the one or more skin fillers described above, the skin filler may be sterilized. In certain embodiments, sterilization may be performed by irradiation, for example, gamma ray sterilization.

[0150] In another embodiment, plant or fungal tissue may be mercelerated. As will be understood, mercelerating plant or fungal tissue breaks it down into tissue / cellular components (including single structural cells, groups of structural cells, or both). In certain embodiments, alkaline / basic solutions and peroxides may be used for mercelerating. In certain embodiments, two or more treatments or solutions may be used simultaneously or sequentially.

[0151] In certain embodiments, the mercerization process may include at least one treatment with a base solution. It will be understood that the base solution may generally contain any suitable base, e.g., any suitable base capable of performing osmotic shock and / or disruption of hydrogen bonds and / or polymer crystalline structures to extract intact tissue structures. It will be understood that, particularly in skin filler applications, the base may be selected as needed, e.g., physiologically occurring, easily washable, harmless, or a combination thereof. In certain embodiments, the base may include NaOH, KOH, or a combination thereof. In one embodiment, the base may be dissolved / mixed in a suitable solvent to form a base solution. Typically, the solvent may include water, but other solvents or combinations of solvents (e.g., a mixture of water and ethanol) are also conceivable. The base solution may include base concentrations of about 0.1 to 10 M, or any concentration in between (which may be rounded to the nearest 0.1 unit), or any subrange spanning any two of these concentrations. In certain embodiments, the base concentration may be approximately 0.5 M to 3 M, or any value in between (which may be rounded to the nearest 0.1 unit), or any partial range spanning any two of these concentrations. For example, in certain embodiments, the base solution may contain an aqueous NaOH solution at a concentration of approximately 0.5 M to 3 M. As will be understood, the base solution may be adjusted as desired to suit the desired structure to be extracted, the plant or fungal tissue used, as well as the processing conditions (i.e., heating, stirring).

[0152] In a particular embodiment, the base may include a base selected from the group consisting of: Carbonates; nitrates; phosphates; sulfates; ammonia; sodium hydroxide; calcium hydroxide; magnesium hydroxide; potassium hydroxide; lithium hydroxide; zinc hydroxide; sodium carbonate; sodium bicarbonate; butyllithium; sodium azide; sodium amide; sodium hydride; sodium borohydride; or lithium diisopropylamine. Depending on the base, neutralization and / or washing may be performed to remove residual base and other reagents, for example, to prevent undesirable contamination.

[0153] In a preferred embodiment, the mercerization process may include the treatment of plant or fungal tissue (preferably decellularized plant or fungal tissue) using sodium hydroxide and hydrogen peroxide along with heating.

[0154] However, it should be noted that other extraction methods may be used and are assumed. For example, in another embodiment, plant and / or fungal tissues may be macerated. As will be understood, similar to Marcel processing, maceration of plant or fungal tissues breaks down the plant or fungal tissue into tissue / cellular components (including single structural cells, groups of structural cells, or both). However, unlike Marcel processing, maceration generally involves the use of acidic solutions rather than basic solutions. Therefore, maceration may remove certain acid-soluble lignin components rather than base-soluble lignin components, thus providing, for example, structural cells with different lignin content.

[0155] In any other embodiment of the one or more dermal fillers described above, the dermal filler may be formulated for subdermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof. In yet another embodiment, the dermal filler may be provided in or with a syringe or injection device.

[0156] In yet another embodiment, the use of any one of the one or more skin fillers described herein as a soft tissue filler for reconstructive surgery or both; for improving the cosmetic appearance of an object requiring improvement of cosmetic appearance; for increasing tissue volume, smoothing wrinkles, or both in an object requiring such improvement; or any combination thereof.

[0157] In another embodiment, a method in an object requiring it for the purpose of improving cosmetic appearance, increasing tissue volume, smoothing wrinkles, or any combination thereof, The step includes administering or injecting one or more dermal fillers described herein into an area where they are needed; Methods for improving the cosmetic appearance of an object, increasing tissue volume, smoothing wrinkles, or any combination thereof are provided herein.

[0158] In certain embodiments, the target native cells may infiltrate the skin filler after administration / injection / implantation.

[0159] In yet another embodiment, the skin filler may be non-absorbent to such an extent that, for example, the decellularized plant or fungal tissue remains substantially intact within the subject for at least about three months, at least about four months, at least about five months, or at least about six months.

[0160] In another embodiment, the skin filler may be degradable through the addition of one or more enzymes. As described above, the skin fillers of this disclosure may be non-absorbable to such an extent that the decellularized plant or fungal tissue is considered to remain substantially intact, and possibly permanent, within the subject for a period of time. However, it will be understood that in some circumstances it may be desirable to remove the skin filler. Therefore, in such embodiments, the skin filler may be removable by degrading its decellularized plant or fungal tissue using one or more enzymes that are not produced by the subject being administered or injected.

[0161] In certain embodiments, one or more enzymes used to decompose the skin filler may be selected based on the decellularized plant or fungal tissue. For example, as already described herein, the skin filler may contain decellularized plant or fungal tissue that is chitinous, chitosanous, lignocelluloseous, or cellulose-based. Therefore, one or more enzymes can be selected to decompose chitin, chitosan, lignocellulose, or cellulose. As a further example, if the plant or fungal tissue is cellulose-based, one or more enzymes may include cellulase.

[0162] In certain embodiments, one or more enzymes may be the same type of enzyme from different sources. For example, one or more enzymes may include cellulase from Aspergillus niger and cellulase from Trichoderma sp. In certain embodiments, one or more enzymes may include different enzymes. For example, one or more enzymes may include cellulase and pectinase (e.g., from Aspergillus niger). Different types of enzymes may be selected based on the decellularized plant or fungal tissue used in the skin filler. Furthermore, the type of decellularized plant or fungal tissue used in the skin filler may affect the ratio of enzymes from different sources and / or different types of enzymes used for its degradation. For example, in certain embodiments where two enzymes from different sources and / or different types of enzymes are selected, the enzymes may be used in a ratio of approximately 25:75 to approximately 50:50.

[0163] In certain embodiments, one or more enzymes may be provided in solution, for example, in a buffer. The buffer may be PBS buffer, sodium acetate buffer, sodium citrate buffer, or any other suitable buffer. One or more enzymes may be provided in the buffer such that the enzyme:buffer ratio is about 25:75 to about 75:25.

[0164] The dermal filler may be broken down by administering one or more enzymes using any preferred method. For example, a solution of one or more enzymes may be injected into a dermal filler previously administered to the subject.

[0165] In another embodiment, a method for preparing a non-absorbable skin filler is provided. A step of providing plant or fungal tissue; A step of decellularizing and reducing the size of plant or fungal tissue to provide particles from which the cellular material and nucleic acids of the tissue have been removed; and Optionally includes a step of sterilizing the particles, A method for providing a non-absorbable skin filler is provided herein.

[0166] In certain embodiments, the decellularized plant or fungal tissue may be chitin-based, chitosan-based, lignocellulose-based, or cellulose-based. In other embodiments, the decellularized plant or fungal tissue may be derived from the leaf structure, root, flesh, hypanthium, or pulp structure of a plant. In yet another embodiment, the decellularized plant or fungal tissue may be derived from lettuce, carrot, apple, or pear, or any combination thereof.

[0167] In any other embodiment of the one or two or more methods described above, the size reduction may include the step of providing particles by mechanical size reduction, and the mechanical size reduction may be performed on a dried, freeze-dried, or freeze-dried material.

[0168] In yet another embodiment of any one or more of the above methods, mechanical size reduction may include the step of providing particles by grinding, extruding, crushing, grinding, sonicating, electrospinning, chemical dissolution, enzymatic degradation, or shearing the plant or fungal tissue before or after decellularization.

[0169] In certain embodiments, mechanical size reduction may include shaping and forming particles from a molten material that can be restored / regenerated (e.g., spheroidizing and / or emulsionizing).

[0170] In any further embodiment of one or more of the above methods, the size reduction may include the steps of drying the plant or fungal tissue before or after decellularization; subjecting the dried plant or fungal tissue to mechanical size reduction to provide particles; and optionally restoring, resuspending, or rehydrating the particles. In certain embodiments, the restoration, resuspending, or rehydrating may include introducing or mixing with water, saline solution, hydrogel, or other dispersion medium.

[0171] In any other embodiment of the one or two or more methods described above, size reduction may provide particles the size of a single structural cell or smaller.

[0172] In certain embodiments, size reduction may include providing particles by maceration, for example, chemical maceration, or providing a single structural cell which may be subjected to further processing to provide particles. An example of a maceration approach is described in PCT Patent Application No. PCT / CA2020 / 050655, titled “Composite Biomaterials,” filed on 14 May 2020, which is incorporated herein by reference in its entirety.

[0173] In yet another embodiment of any one or more of the above methods, the method may further include the step of formulating the particles together with a hydrogel, matrix, or dispersion medium. In certain embodiments, the hydrogel, matrix, or dispersion medium may include PBS, saline solution, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, prulonic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof.

[0174] In any other embodiment of the one or more methods described above, the skin filler may be provided in a dried or hydrated form. In yet another embodiment of the one or more methods described above, the method may further include the step of formulating with lidocaine or another anesthetic.

[0175] In yet another embodiment of any one of the one or two or more methods described above, size reduction may provide particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure. In yet another embodiment, the flake-like structure may have a thickness of about 0.01 to about 100 μm, for example, about 0.1 μm.

[0176] In yet another embodiment of any one or more of the above methods, size reduction may further include the step of obtaining particles having a target size, particles within a target size range, or particles having a target size distribution by extrusion, filtration, centrifugation, or other size separation. For example, in some embodiments, size reduction may provide particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 1000 μm.

[0177] In any further embodiment of the one or two or more methods described above, size reduction may provide particles that are large enough not to be phagocytosed by one or more cells (preferably, size reduction may provide particles having a size, diameter, or minimum ferret diameter of at least about 20 μm); particles having a size, diameter, or maximum ferret diameter of less than about 200 μm; particles having a size, diameter, or ferret diameter distribution in the range of about 20 μm to about 200 μm; particles having a particle size, diameter, or ferret diameter distribution with a peak between about 30 μm and about 100 μm; particles having an average particle size, diameter, or ferret diameter in the range of about 30 μm to about 100 μm; or any combination thereof.

[0178] In any further embodiment of one or more of the above methods, size reduction may provide particles having a size, diameter, or maximum ferret diameter of less than approximately 300 μm; particles having a size, diameter, or ferret diameter distribution in the range of approximately 100 μm to approximately 300 μm; particles having a particle size, diameter, or ferret diameter distribution with a peak within approximately 100 μm to approximately 300 μm; particles having an average particle size, diameter, or ferret diameter in the range of approximately 100 μm to approximately 300 μm; or any combination thereof.

[0179] In yet another embodiment of any one or more of the above methods, the size reduction is approximately 200 to approximately 3000 μm. 2 Within that range, or approximately 200 to 300 μm 2 Particles having an average projected particle area within the range of 0.1 to 100 μm² may be provided; decellularized plant or fungal tissues having a surface area-to-volume ratio of 0.1 to 100 μm². -1 It is broken down into particles; the decellularized plant or fungal tissue consists of particles approximately 4 × 10 5 pieces / mL~particles approx. 7×10 9 It is broken down into particles having a packing density of 1 / mL; or any combination thereof.

[0180] In any further embodiment of the one or more methods described above, the size reduction may include the step of grinding and simultaneously passing the resulting particles through a filter to obtain particles smaller than the upper threshold size.

[0181] In any other embodiment of the one or more methods described above, the method may further include the step of removing particles below a lower threshold size by filtration, fractionation centrifugation, equilibrium centrifugation, or sieving to obtain particles above a lower threshold size.

[0182] In yet another embodiment of any one or more of the above methods, filtration or sieving may be performed using an automated wet sieve.

[0183] In any further embodiment of the one or two or more methods described above, the size reduction may include the step of obtaining particles having a target size, particles within a target size range, or particles having a target size distribution by fractionation centrifugation or equilibrium centrifugation.

[0184] In any other embodiment of the one or more methods described above, the method comprises the steps of: loading particles in a fluid, such as water or a buffer (e.g., physiological saline), into a first syringe or vessel; and loading a hydrogel, matrix, or dispersion medium into a second syringe or vessel, thereby compounding the particles together with the hydrogel, matrix, or dispersion medium, wherein the first and second syringes or vessels are under fluid connection; and further comprising the steps of mixing the contents of the syringes or vessels by passing them back and forth between the first and second syringes or vessels.

[0185] In another embodiment, formulation of particles with a hydrogel, matrix, or dispersion medium may involve mixing the particles with the hydrogel, matrix, or dispersion medium using a planetary mixer, dispenser, high-shear mixer, kneader, multi-axis mixer, ribbon paddle blender, static mixer, roll mill, homogenizer, agglomeration, or any combination thereof.

[0186] In some embodiments, it may be useful to remove agglomerated material before, during, or after mixing with the hydrogel, matrix, or dispersion medium. For example, in one embodiment, a size exclusion mixer, such as a static crosshatch mixer or mesh, may be used to mix the particles with the hydrogel, matrix, or dispersion medium. In such embodiments, it may be possible to mix the particles with the hydrogel, matrix, or dispersion medium while removing, excluding, or decomposing agglomerated material (e.g., agglomerated particles).

[0187] In yet another embodiment of any one or more of the above methods, the method may further include sterilizing the plant or fungal tissue before or after decellularization. In yet another embodiment, the method may include sterilizing the skin filler. In a particular embodiment, sterilization may be performed by gamma ray sterilization. In other embodiments, sterilization may be performed by autoclaving.

[0188] In some embodiments, multiple sterilization steps may be performed. For example, sterilization may include a first sterilization and a second sterilization. The first sterilization may be heat treatment (e.g., autoclaving), and the second sterilization may be sterilization by gamma irradiation, autoclaving, etc. Multiple sterilization steps may be useful to reduce the level of biocontamination of the material. Similarly, the hydration plateau level of the material may be adjusted by employing a first sterilization step, which is heat treatment. It will be understood that adjusting the hydration plateau level may allow for adjustment and / or stabilization of the amount of solvent retained by the particles of the skin filler of this disclosure.

[0189] In yet another embodiment of any one or more of the methods described above, the method may further include mercing a plant or fungal tissue. As described herein, mercing a plant or fungal tissue (preferably decellularized plant or fungal tissue) breaks down the plant or fungal tissue into tissue / cellular components (including a single structural cell, a group of structural cells, or both). In certain embodiments, an alkaline / basic solution and a peroxide may be used for mercing. In certain embodiments, two or more treatments or solutions may be used simultaneously or sequentially. In certain embodiments, mercing may be performed on a plant or fungal tissue followed by decellularization, or mercing conditions may be selected so that mercing is performed on a plant or fungal tissue and decellularization is provided simultaneously. However, as described herein, mercing is preferably performed on a plant or fungal tissue that has already been decellularized.

[0190] In certain embodiments, the mercerization process may include at least one treatment with a base solution. It will be understood that the base solution may generally contain any suitable base, e.g., any suitable base capable of performing osmotic shock and / or disruption of hydrogen bonds and / or polymer crystal structures to extract intact tissue structures. It will be understood that, particularly in skin filler applications, the base may be selected as needed, e.g., physiologically occurring, easily washable, harmless, or any combination thereof. In certain embodiments, the base may include NaOH, KOH, or a combination thereof. In one embodiment, the base may be dissolved / mixed in a suitable solvent to form a base solution. Typically, the solvent may include water, but other solvents or combinations of solvents (e.g., a mixture of water and ethanol) are also conceivable. Typically, the base solution may include base concentrations of about 0.1 to 10 M, or any concentration in between (which may be rounded to the nearest 0.1 unit), or any subrange spanning any two of these concentrations. In certain embodiments, the base concentration may be approximately 0.5 M to 3 M, or any value in between (which may be rounded to the nearest 0.1 unit), or any partial range spanning any two of these concentrations. For example, in certain embodiments, the base solution may contain an aqueous NaOH solution at a concentration of approximately 0.5 M to 3 M. As will be understood, the base solution may be adjusted as desired to suit the desired structure to be extracted, the plant or fungal tissue used, as well as the processing conditions (i.e., heating, stirring).

[0191] In certain embodiments, the base may include a base selected from the group consisting of: carbonates; nitrates; phosphates; sulfates; ammonia; sodium hydroxide; calcium hydroxide; magnesium hydroxide; potassium hydroxide; lithium hydroxide; zinc hydroxide; sodium carbonate; sodium bicarbonate; butyllithium; sodium azide; sodium amide; sodium hydride; sodium borohydride; or lithium diisopropylamine. Depending on the base, neutralization or washing may be performed to remove residual base and other reagents, for example, to prevent undesirable contamination.

[0192] In a preferred embodiment, the mercerization process may include the treatment of plant or fungal tissue (preferably decellularized plant or fungal tissue) using sodium hydroxide and hydrogen peroxide along with heating.

[0193] In certain embodiments of the above method, the mercerization process may involve treating the decellularized plant or fungal tissue with a base and a peroxide, preferably sodium hydroxide or another hydroxylated base as the base and hydrogen peroxide as the peroxide. The mercerization process may chemically decompose the decellularized plant or fungal tissue into single structural cells, groups of structural cells, or both, without destroying its lignocellulose structure.

[0194] In yet another embodiment of any one or more of the above methods, the mercerization process may include treatment of decellularized plant or fungal tissue with an aqueous sodium hydroxide solution and hydrogen peroxide while heating.

[0195] In yet another embodiment of any one or more of the above methods, the mercerization may be carried out with heating to about 80°C. In certain embodiments, such heating may allow for a reduction in reaction time, particularly when sodium hydroxide is used, for example.

[0196] In any further embodiment of one or more of the above methods, the decellularized plant or fungal tissue may be treated with an aqueous sodium hydroxide solution for a first period of time before adding hydrogen peroxide to the reactants. In certain embodiments, the first period may be from about 1 minute to about 24 hours, or any point in time therein, or any partial range between any two such points in time.

[0197] In any other embodiment of the one or two or more methods described above, hydrogen peroxide may be added as a pre-prepared solution of a 30% to 50% aqueous hydrogen peroxide solution.

[0198] In yet another embodiment of any one or more of the above methods, hydrogen peroxide for mercerization may be used in the following ratio: Approximately 20 mL to 5 mL of 30% hydrogen peroxide solution; approximately 100 g of decellularized plant or fungal tissue; approximately 500 mL of 1 M NaOH solution; for example: Approximately 20 mL of 30% hydrogen peroxide solution; approximately 100 g of decellularized plant or fungal tissue; approximately 500 mL of 1 M NaOH solution; Approximately 10 mL of 30% hydrogen peroxide solution: approximately 100 g of decellularized plant or fungal tissue: approximately 500 mL of 1 M NaOH solution; or Approximately 5 mL of 30% hydrogen peroxide solution: Approximately 100 g of decellularized plant or fungal tissue: Approximately 500 mL of 1 M NaOH solution.

[0199] It will be appreciated that these ratios may be scaled up or down as appropriate for particular components, as desired, and the recited amounts are provided to indicate relative ratios, not absolute quantities. For example, in certain embodiments, the 30% aqueous hydrogen peroxide solution is used in an amount of at least about 75 mL per 500 g of decellularized plant or fungal tissue. In certain embodiments, the 1M sodium hydroxide solution is used in an amount of about 2500 mL per 500 g of decellularized plant or fungal tissue. In general, the aqueous hydrogen peroxide solution may be added to result in a final hydrogen peroxide concentration of from about 1% to about 5% of the total volume of the mixture of the decellularized plant or fungal tissue, the sodium hydroxide solution, and the aqueous hydrogen peroxide solution.

[0200] In still another embodiment of any one of the one or more methods described above, the method may further comprise the step of neutralizing the pH by one or more neutralization treatments. In another embodiment of any one of the one or more methods described above, the neutralization treatment may comprise treatment with an acid solution, preferably an aqueous HCl solution.

[0201] In still another embodiment of any one of the one or more methods described above, the mercerization may be performed using a ratio of decellularized plant or fungal tissue: aqueous sodium hydroxide solution (m:v, in units of g:L) of about 1:5 for 1M aqueous sodium hydroxide solution, or an equivalent ratio for another aqueous sodium hydroxide solution concentration. It will be appreciated that these ratios may be scaled up or down as appropriate for particular components, as desired, and the recited amounts are provided to indicate relative ratios, not absolute quantities.

[0202] In yet another embodiment of any one of the one or more methods described above, the mercerization may be performed for at least about 30 minutes, preferably for about 1 hour.

[0203] In a further alternative embodiment of any one of the one or more methods described above, the method may further comprise formulating the dermal filler for intradermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof.

[0204] In another embodiment, provided herein is a dermal filler prepared by any one of the one or more methods described herein.

[0205] In another embodiment of any one of the one or more dermal fillers described herein, from about 0.1% to no more than about 5% or less of the particles of the dermal filler may have a Feret diameter or a minimum Feret diameter of less than about 20 μm. In yet another embodiment of any one of the one or more dermal fillers described herein, less than about 0.5% of the particles of the dermal filler may have a Feret diameter, or a minimum Feret diameter, of less than 20 μm.

[0206] In yet another embodiment of any one of the one or more dermal fillers described above, less than about 0.1% to less than about 5% (e.g., less than about 0.5%), or less of the particles of the dermal filler may have a size small enough to be phagocytosed by one or more cells of a subject.

[0207] In another embodiment, provided herein is a kit comprising any one or more of the following: any one of the one or more dermal fillers described herein; a hydrogel, a matrix, or a dispersion medium; PBS, physiological saline, hyaluronic acid (crosslinkable or non-crosslinkable), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof; lidocaine or other anesthetic; one or more syringes, or another injection device; Luer lock fittings or connectors for two or more syringes; Instructions for performing any of the one or more uses or one or more methods described herein; One or more decellularizing reagents; One or more containers, packages, or vessels; One or more buffer solutions, water, or saline solution for injection; Reagents or enzymes (e.g., cellulase) for dissolving skin fillers in undesirable areas or locations; Or any combination thereof.

[0208] In certain embodiments, the skin fillers described herein may be used for cosmetic purposes to improve wrinkles, acne scars, or for reconstructive surgery.

[0209] In certain embodiments, the skin fillers described herein may, as desired, be molded (mechanically or chemically, to be spherical), functionalized, and / or combined with a delivery vehicle, such as a cellulose-derived gel formulation or a cellulose-based hydrogel (which may be a temporary delivery vehicle).

[0210] In certain embodiments, skin filler particles may be prepared from dissolved material restored to a spherical or specific size / shape. For example, in certain embodiments, cellulosic biomaterials, such as decellularized plant or fungal tissue, may be dissolved with DMAc and LiCl, or cellulase (and / or similar enzymes, e.g., endoglucanase (EG, endo-1,4-D-glucanohydrolase, or EC 3.2.1.4.), exoglucanase, or cellobiohydrolase (CBH, 1,4-β-D-glucancellobiohydrolase, or EC 3.2.1.91.), and subsequently sphericalized, for example, during cellulose regeneration.

[0211] In certain embodiments, the skin fillers described herein may be adapted for use, for example, as bone graft paste for bone reconstruction, or as fillers in food applications (e.g., for food engineering to provide a scaffold for texture and / or mouthfeel) or as foams (e.g., for bone, cartilage, soft tissue reconstruction, food, insulation, packaging, etc.).

[0212] In certain embodiments, it is conceivable that cellulose may be provided or used, for example, to break down undesirable materials, such as substances inadvertently injected into undesirable locations or blood vessels, or for dissolving particles after injection.

[0213] In the following embodiments, non-absorbent, naturally derived plant polymers are developed and tested as attractive alternatives to synthetic particles, such as PMMA microspheres. [Examples] [Examples]

[0214] Apple-based skin filler paste In this example, to develop a cellulose-based skin filler, apple hypanthium tissue was first decellularized using the decellularization protocol described in International Publication No. 2017 / 136950, entitled "Decellularised Cell Wall Structures from Plants and Fungus and Use Thereof as Scaffold Materials," which is incorporated herein by reference in its entirety. Briefly, apple tissue was sliced ​​into 1.2 mm thick sections on a mandolin slicer. Cylindrical discs of apple tissue were prepared using a 10 mm biopsy punch. These discs were decellularized in 0.1% SDS (as described in International Publication No. 2017 / 136950).

[0215] After obtaining decellularized 10 mm apple discs, an injection paste was prepared. Several discs were placed in a 50 mL Falcon tube and centrifuged to remove all remaining liquid. Under sterile conditions, the discs were then crushed using a plunger in a 1 mL syringe and homogenized to a high-viscosity paste. The paste was then aspirated into a new 1 mL syringe (without a needle). It was found that the paste could be extruded after attaching a sterile 18 G needle to the syringe. Attempting to extrude the paste through higher gauge needles proved difficult, and 18 G was the smallest inner diameter needle used. While 18 G may be acceptable for certain dermal filler applications, sizes of 26-27 G are often preferred for certain applications, for example, in the cosmetic field.

[0216] Figure 1 shows the extruded, decellularized cellulose paste described in this embodiment (left panel), and also shows a 1 mL syringe after loading the paste with an 18 G needle (right panel).

[0217] To test biocompatibility, a pilot animal study was conducted. Briefly, 1 mL of dermal filler paste was subcutaneously injected into three sites (3 × 1 mL) in the back of female Sprague-Dawley rats (400–700 g) using an 18G syringe. Cellulose was subcutaneously injected into three different sites (see Figure 2 for lateral view (A) and magnified view (B)). At 4 weeks, neovascularization was present around the implant (see Figure 2(C)), and the implant maintained its shape after excision (see Figure 2(D)).

[0218] The injected material appears to integrate with the surrounding tissue, which indicates cell infiltration and matrix deposition around the injected material. The injection site was easily visible and was measured weekly with calipers (height, x and y widths) to obtain measurements of how well the implant retained its shape over time. Animals were monitored and sacrificed at the 4th and 8th week time points after injection. Figure 3 shows that cell infiltration and matrix deposition were observed after 8 weeks in the animal's body. The cellulose filler appeared to be biocompatible and remained generally spherical over time. Shown are Masson's trichrome staining (shown in Figures 3(A)(C)) and hematoxylin and eosin staining (shown in Figures 3(B)(D)) at 8 weeks after subcutaneous injection ((A, B) scale bar = 2 mm; (C, D) scale bar = 200 μm). Figure 4 shows the results of manual measurement of the implant site from outside the animal using calipers. A decrease in implant area was observed throughout the 8-week test period. However, the aspect ratio (the ratio of the width in the x and y directions) did not change significantly. Figure 5 shows that when measured on the outside of the animal using calipers, the height of the implant decreased significantly by about 75% over the 8-week test period. This correlates with the decrease in the area of the injection site observed above.

[0219] This study revealed promising data (generation of injectable biocompatible cellulose). However, in this example, due to the nature of its preparation, the cellulose filler was amorphous and most likely consisted of an aggregate of variable, ill-defined particles and a disrupted cellulose structure. This can lead to difficulties in attempting to extrude through a 26~27G needle, which is particularly desirable for certain cosmetic applications. Most commercially available dermal filler products are composed of the material in a carrier hydrogel (HA or collagen are the most common), which was not used in this example. The production of further fine particles of pulverized cellulose with controllable size characteristics, and the ability to be controllably mixed with a carrier hydrogel, are described in further detail below. [Examples]

[0220] Controlled-size skin fillers Based on the results of Example 1 described above, this example developed a more controlled method for producing cellulose particles for use as a skin filler. Several methods of crushing or grinding biomaterials using a decellularization approach were tested to develop a skin filler suitable for injection through smaller gauge needles, and to develop a method for producing the skin filler in a controllable and reproducible manner.

[0221] In this example, a protocol for preparing a dried powder was developed and described according to the following method. The apple cellulose biomaterial was first decellularized as previously described (see International Publication No. 2017 / 136950, titled "Decellularised Cell Wall Structures from Plants and Fungus and Use Thereof as Scaffold Materials," which is incorporated herein by reference in its entirety). After obtaining the decellularized apple biomaterial, it was dried in the air on a drying rack for 24 hours. Once dried, the material was broken down into fine particles using an adjustable bar mill, and these particles were repeatedly milled to create aggregates of particles, which were then sieved to the desired size and shape (see Figure 6, showing the milled dried biomaterial (left panel) and the rehydrated extruded skin filler (right panel)). Once the dried powder was obtained, the particles were then resuspended in DPBS in a volume 10 to 15 times the weight of the dried biomaterial to prepare a paste or filler material (see Figure 6).

[0222] A good method for reducing (and minimizing) the size of the pulverized particles was found to be to over-dilute it and pass it through multiple times with a gradually decreasing needle size. Using this method, the smallest gauge needle that could be used to extrude the filler was a 22.5G needle in this study. This is still larger than desired for certain applications, for example, in certain applications where dermal fillers are preferably injected with needles of gauge 26-31.

[0223] Microscopic observation revealed that the method used to produce this powder yielded not only large clumps of material but also single, intact structural cells. These cells typically exceed 200 μm in diameter, which limits the passage of the filler material through fine gauge needles. Notably, the grinding method used also produced extremely fine particles appearing to be in the 1–20 μm range. Particles of this size may, in certain applications, have adverse effects after transplantation, potentially leading to inflammation, granulomas, and / or chronic / persistent foreign body reactions.

[0224] Figure 7 shows that the biomaterial was sufficiently sheared by the needle method described above to obtain at least some single, intact structural cells (e.g., isolated cell wall pockets) that appear to be perfectly shaped and undisintegrated.

[0225] Because the powder size prepared in this example was relatively small, three skin filler formulations were prepared. In each case, the skin filler contained 4% cellulose particles (w / v) and 0.3% lidocaine (w / v) in a dispersion medium of physiological saline, hyaluronic acid, or bovine collagen. The formulations were prepared as follows: Cellulose suspended in PBS dermal filler: 0.2943 mg of cellulose powder was dissolved in the following: 6.54 mL of dH2O • 0.73 mL of 10x PBS • 0.145 mL of 15% lidocaine (w / v, dissolved in dH2O) Cellulose suspended in hyaluronic acid dermal filler: 0.2031 mg of cellulose powder was dissolved in the following: • 5.078 mL of 0.2% non-crosslinked hyaluronic acid (m / v, dissolved in PBS) • 0.102 mL of 15% lidocaine (w / v, dissolved in dH2O) Cellulose suspended in collagen dermal filler: 0.1835 mg of cellulose powder was dissolved in the following: 3.6 mL of 0.3% (m / v) Corning® Collagen I, bovine 0.45 mL of 10x PBS 0.36 mL of 0.1N NaOH 0.09 mL of 15% lidocaine (w / v, dissolved in dH2O)

[0226] As described above, small-scale animal experiments were conducted to investigate biocompatibility. Briefly, female Sprague-Dawley rats (300-700g) were subcutaneously injected into three sites (3 x 0.4mL) via a 22.5G syringe through the back. In all cases, the animals were sacrificed four weeks after implantation, and tissue sections were collected.

[0227] During the 4-week trial period, the injection site was easily visible and measured weekly with calipers (height, x, and y width) (see Figure 8) to obtain measurements of how well the implant maintained its shape over time.

[0228] Figure 8 shows the implant height as a function of time. No statistically significant differences were observed among the various formulations. However, there was an approximately 10-fold difference in HA and collagen concentrations compared to commercially available products. Consistent with low w / v concentration collagen / HA hydrogels, this result appears to behave similarly to saline-based fillers, which reduce height by approximately 50%.

[0229] Figure 9 shows the calculated volume of the implant mass measured externally from the animal using calipers, as a function of time. The implant volume was calculated using height, x-width, and y-width, assuming a semi-ellipsoid shape. No statistically significant differences were observed among the various formulations, showing a trend consistent with a decrease in height.

[0230] Similar to Example 1, this approach involved preparing a cellulose powder that could be subcutaneously injected into a rat animal model. However, without fine control over particle size, a wide size distribution could result, which may include undesirable small particles (less than 20 μm) that could have undesirable effects, and / or large clumps of particles (greater than 200 μm) that could lead to needle clogging. Therefore, further testing and development were carried out to enhance particle size control, as described below. [Examples]

[0231] Skin fillers with highly controlled particle size The development and testing described in this embodiment were intended to provide the following: 1. To produce cellulose powder from decellularized plants having a controllable average diameter, e.g., an average diameter of less than 100 μm; 2. Determine whether the resulting particles can be sterilized by gamma irradiation at a level of 15 kGy; Three types of dermal filler formulations will be prepared, each consisting of 3.20% particles (v / v), 0.3% lidocaine (v / v), and 79.3% dispersion medium (physiological saline, 3.5% bovine collagen (w / v), or 1% cross-linked hyaluronic acid (w / v)), and compared with other dermal filler formulations; 4. Conduct animal biocompatibility tests on multiple animals; and 5. Perform an in vitro cell culture test.

[0232] Particle size PMMA particles have become the gold standard for permanent skin fillers. They are easy to produce and their size can be precisely controlled. However, given that these spheres are rigid and impermeable, the resulting tissue after implantation in the body remains largely composed of synthetic microspheres, unlike human tissue. Figure 10 shows 30-50 μm PMMA microspheres (white circles) three months after implantation. Although natural tissue proliferates around the implant, the volume ratio of PMMA in the tissue is very high. This indicates that the tissue is composed primarily of synthetic materials, rather than natural cells and proteins.

[0233] Considering a sphere with a diameter of 30 μm, in this case, the surface area of ​​the sphere is 2827 μm². 2 The volume is 14137 μm³. 3 This volume represents the total excluded volume of native tissue that can grow in the injected area. The surface area-to-volume ratio (SA:V) is 0.2. This means that while cells and matrix proteins can be deposited on the surface of the sphere, the amount is very small compared to the total volume excluded by the hard particles themselves.

[0234] On the other hand, consider a nearly circular, thin particle or flake (approximately 0.1 μm) with a diameter of 60 μm or a radius of 30 μm. In this case, the surface area is 2846 μm². 2 (Approximately the same size as a 30 μm sphere), excluded volume 283 μm 3 Therefore, SA:V is approximately 10. This means that the available surface area increases 50-fold relative to the volume excluded. In other words, a 60 μm diameter section provides a similar amount of surface area to support cell proliferation and matrix deposition, but with far less exclusion relative to the volume of the proliferating native tissue.

[0235] As the inventors have observed in numerous tests, the thin walls (approximately 0.1 μm) of plant tissue provide an excellent support structure upon which cells and tissues can proliferate and infiltrate, while also leaving sufficient space for blood vessels, matrix deposition, and tissue accumulation.

[0236] Therefore, this embodiment aimed to produce a permanent dermal filler with a superior SA:V ratio of natural tissue to permanent filler particles compared to other dermal filler products. For this reason, the efforts described below aimed to develop plant-derived natural flakes rather than spherical particles. Furthermore, flakes with a diameter of less than 100 μm can be injected through a 26-27 G syringe, unlike the previous formulations described above. This could result in the benefits of being a natural product, having a non-absorbable, permanent structure, high biocompatibility, and a significant increase in natural tissue. In dermal filler procedures, it is desirable that the patient's own body replaces the defect with as much natural tissue as possible. This strategy is designed with these goals in mind.

[0237] Preparation of cellulose sections In this embodiment, the first step in preparing a substitute for natural particles was to decellularize the plant material. This process was achieved using an established protocol outlined in Hickey, R. et al., Customizing the Shape and Microenvironment Biochemistry of Biocompatible Macroscopic Plant-Derived Cellulose Scaffolds. ACS Biomater. Sci. Eng., 4, 3726 (2018), which is incorporated herein by reference in its entirety. Since the final product was intended to be usable by patients, it was important to establish standardized GLP and GMP methods. In this case, the material was produced in a GLP-compliant manner. Figure 11 shows the sterile sample handling, in which the GLP version of the decellularization process was performed using sterile materials and sterile techniques.

[0238] To process the soft material and produce cellulose flakes, the scaffold was freeze-dried in a freeze-dryer (48 hours, -46°C, 0.05 mbar). Once the material was dry, it was immediately placed in a Retsch grinder. Bulk grinding was performed at 18,000 rpm, 12,000 rpm, and 6,000 rpm. Higher speeds reduced processing time. An 80 μm filter was used to limit the powder size to less than 80 μm. With the filter in place, the inventors observed no dependence of the final particle size, dimensions, or yield on the grinding speed. Therefore, high-speed grinding was used to reduce processing time.

[0239] Figure 12 shows the freeze-drying process of a decellularized cellulose scaffold derived from apples as described. Figure 12(A) shows the collection of the decellularized material and its placement in a Falcon tube, with the channel pressurized to allow water vapor to escape via evaporation / sublimation. Figure 12(B) shows the material being placed in a freeze-dryer, and Figure 12(C) shows freeze-drying performed at -46C, 0.05 mbar for 48 hours. Figure 12(D) shows the final freeze-dried product. Figure 13 shows the dried cellulose biomaterial being ground into a powder at 18000, 12000, and 6000 rpm as described, while simultaneously passing through an 80 μm filter. The collection tray after processing is shown. The fastest RPM setting was used to minimize processing time. No effect of grinding rate on particle size distribution was observed (data shown below).

[0240] Figure 14 shows the filtration process in more detail. Figure 14(A) shows that the powder obtained by grinding the material with an 80 μm filter was subjected to wet sieving by passing it through 45 μm and 25 μm sieves (B) to limit the size range of the powder (C). The narrow size range of particles was concentrated by centrifugation (see Figure 14(D)). The automated wet sieving dramatically improved processing time and efficiency, and was subsequently used as a standard practice.

[0241] The process was first carried out as follows: 5 mL of loosely packed powder was resuspended in dH2O to a final volume of 45 mL and poured into a sieve. The particles were washed continuously for 3 minutes. After 3 minutes, the top sieve (45 μm) was removed, and a second sieve (25 μm) was stirred and washed for another 3 minutes. This material was collected in a Falcon tube and centrifuged: the yield was approximately 20% (5 mL of wet powder was isolated from 25 mL of dry powder).

[0242] Automated wet sieving was performed using a Gilson SS 23 wet / dry sieve vibrator equipped with ISO 565 BS 410 ISO 3310-1 25 and 50 μm stainless steel 8-inch sieves and a notched collection bucket. 5 mL of dry powder was diluted in 45 mL of dH2O. The sieve was placed on the vibrator with a larger mesh on top. The vibrator was operated and the particles were poured over the 50 μm mesh. The particles were rinsed three times with 150 mL of dH2O for 3 minutes each. The vibrator was then stopped and the upper sieve was removed. The vibrator was operated again and the lower sieve was washed three times with dH2O in 50 mL aliquots for 3 minutes each. The surface of the mesh was then washed with dH2O at an angle to collect the filtered material. The sieved material was concentrated by centrifugation. The yield was approximately 20% (5 mL of wet powder was isolated from 25 mL of dry powder).

[0243] To evaluate the powder yield, mass was recorded at key stages in the process. The initial mass was recorded before any processing was performed on the apples. Since the mass varied from apple to apple, the number of apples was not a sufficient measure of the starting material content. By combining the number of apples with the total mass of a set of apples, a baseline for yield determination was obtained. After decellularization, the material was freeze-dried to obtain the dried and decellularized mass outlined above. The dried material was then ground into particulate form. Some loss of the sample occurred during processing; therefore, the ground mass was calculated to evaluate the loss during the grinding process. The next step involved filtering the particles using an automated sieve with 50 μm and 25 μm sieves to limit the size distribution. To quantify the final yield, the sieved particles were freeze-dried to remove moisture.

[0244] [Table 1]

[0245] The transfer of powder from the Retsch tray to the tubes was easily performed in a fume hood using a spatula to avoid electrostatic charging of gloves, tubes, and air. Certain existing commercially available products have been shown that particle sizes smaller than 20 μm may lead to increased phagocytosis and / or immune responses. Therefore, we aimed to limit particle size. The particles were passed through two sieves (45 and 25 μm) using a wet filtration process.

[0246] Characterization of particle size Particle size was characterized using fluorescence microscopy and scanning electron microscopy (SEM). For fluorescence microscopy, particles were stained with 0.1% Congo red dye filtered through a 0.22 μm layer. Imaging was performed at 2.5x and 10x magnification. SEM samples were imaged as dry specimens using lyophilization. To enable conductivity, particles were coated with a 5–10 nm layer of gold by gold sputtering. Figure 15 shows particles stained with Congo red. Particles were stained with 0.1% Congo red and imaged at 2.5x (A, B) and 10x (C, D). (A, C) Unfiltered particles. (B, D) Filtered particles. The images were collected to quantify the particle size distribution. Typically, about 1000 particles are obtained from 10 images at 2.5x magnification, which is a statistically significant sample size.

[0247] Microscope images were used to analyze the particle size distribution. Fiji (ImageJ) was used for image processing, and Origin 2020 was used for result analysis. For batch processing of images, the raw images were assembled into a stack using Fiji (ImageJ). The images were first converted to grayscale, and then thresholded using the automatic thresholding function. The thresholding was visually verified to ensure that appropriate limits were applied. Next, a particle function for analysis was applied to calculate the area, shape descriptor, centroid, fitted ellipse, and ferret diameter. No size or shape constraints were imposed on the particle analysis. To avoid bias in the distribution, all particles were analyzed except for those at the edges of the field of view. The output image files of the analyzed particle contours were compared with the original images to ensure that the segmentation was correct.

[0248] Figure 16 shows the particle size analysis as described. The particles were thresholded and segmented using Fiji (ImageJ). Figures 16(A, B) show filtered particles, and Figures 16(C, D) show unfiltered particles. Figures 16(A, C) show the thresholded images, and Figures 16(B, D) show the particle contours obtained by size analysis.

[0249] Optical and fluorescence microscopy revealed that the ground cellulose powder appeared to form flaky layers rather than spherical particles. Many quantitative descriptors can be calculated to study irregularly shaped objects, including roundness, circularity, aspect ratio, and minimum and maximum ferret diameters. Given that the material is an aggregate of irregular flaky layers, the most useful shape descriptors were determined to be the maximum and minimum ferret diameters, thickness, and projected 2D area to describe the particle morphology.

[0250] Applying these analytical techniques to powders revealed that while the sample exhibits a very large size distribution before sieving, it shows a narrower size distribution after sieving. In particular, smaller particles are removed by filtration. The wide size distribution of unfiltered particles is also evident in the projected particle area. The average projected particle area of ​​the unfiltered sample was 2036.42 ± 242.53 μm². 2 However, the average area of ​​the filtered particles was 236.92 ± 38.18 μm². 2 There was a significant difference in the average maximum ferret diameter (P=7.4×10). -55 (Unfiltered = 47.34 ± 1.04 μm, filtered = 68.84 ± 0.63 μm). When using the maximum ferret diameter, the percentage of particles smaller than 20 μm was 1.6% with filtration and 29.5% without filtration. Similarly, there was a significant difference in the average minimum ferret diameter (P = 6.67 × 10⁻¹⁰). -56 The mean minimum ferret diameter of unfiltered particles was 31.73 ± 0.72 μm, and the size of filtered particles was 46.51 ± 0.37 μm. All values ​​are mean and standard error of the mean. Unfiltered N=2292, filtered N=1595.

[0251] Figure 17 shows the particle size analysis of filtered and unfiltered decellularized apple particles. Ferret diameter was used to quantify particle size. Images of N=15 particles under each condition were analyzed from fluorescence microscopy images of particles stained with Congo red. N=2292 for unfiltered particles, N=1595 for filtered particles. There was a statistically significant difference in the mean values ​​(P=7.4×10⁻⁶). -55 ).

[0252] To confirm the results of optical microscopy and to better understand the morphology of particles in the cellulose powder, scanning electron microscopy (SEM) was used. Despite being a powerful imaging technique, the preparation of the powder for SEM required further drying, grinding, and gold coating. This could lead to the orientation of the thin sections at various angles relative to the imaging direction, changes in size, and the introduction of artifacts.

[0253] Figure 18 shows SEM micrographs of decellularized apple powder, increasing in magnification (A-D). Figure 19 shows manual image processing to determine the diameter of the thin sections. The thin sections have irregular shapes, and a single length descriptor cannot capture this complexity (Source: Decellularized Apples). Figure 20 shows the SEM particle size distribution of decellularized apples. From the distribution, a peak at 47.11 ± 1.11 μm (N=133 thin sections) was identified. The distribution obtained from SEM image analysis was much narrower than that obtained by optical methods. However, this method has drawbacks, including a small N value due to the manual approach of measuring particles one at a time, the influence of particle angle orientation, and the inability to reliably detect edges. Due to these problems, this method was undesirable for particle size characterization.

[0254] Effect of grinding rate on various particle formulations The grinding rate was an important variable in the preparation of cellulose flakes. In this study, data is presented below showing that the rate did not affect the particle size characteristics (determined by automated optical analysis) and did not vary depending on the plant species (comparing apples and pears).

[0255] Figure 21 shows the particle size distribution after crushing decellularized apples at various rates, measured before automated wet sieving filtration. Particles were generated by crushing at 6000 RPM (black) and 18000 RPM (gray) prior to sieving. The two distributions were similar. The average particle size was 73.07 ± 0.58 μm at 6000 RPM and 73.50 ± 0.56 μm at 18000 RPM. Values ​​are the mean and standard error of the mean. N=2579 for 6000 RPM and N=2354 for 18000 RPM. There was no significant difference in average particle size (P=0.58).

[0256] [Table 2]

[0257] [Table 3]

[0258] Gamma ray sterilization Gamma irradiation is a crucial step in sterilizing biomaterials for clinical use. It has been shown that 15 kGy of gamma irradiation is sufficient to produce sterile plant-based biomaterials. The results shown below demonstrate no significant difference in particle size between gamma-irradiated and unirradiated samples.

[0259] As described above, McIntosh apples from Canada Fancy were purchased from a local supermarket and used the following day. The decellularized raw material was prepared according to the SOP. Briefly, the apples were peeled and sliced ​​into 1 mm thick pieces on a mandolin slicer. The slices were then transferred to a 0.1% SDS solution and placed in a 120 RPM shaker for 3 days. The solution was changed once daily. Next, the slices were washed three times with sterile dH2O, transferred to a 100 mM CaCl2 solution, and returned to the shaker for 24 hours. The biomaterial was then washed three times with sterile dH2O and sterilized with 70% ethanol for 30 minutes. The sample was then washed three times with sterile dH2O and stored in sterile dH2O until the next day. The water was then removed and the sample was freeze-dried at -46°C and 0.050 mbar for 2 days. Once dried, the decellularized material was ground using a Retsch pulverizer equipped with an 80 μm filter and set to a speed of 18,000 RPM.

[0260] The cellulose powder was further restricted in size using wet sieving with 45 μm and 25 μm sieves. The powder was concentrated by centrifugation at 1000 RPM for 3 minutes. The particles were then stored in Nalgene bottles at a concentration of 1 mL of particles per 10 mL of sterile dH2O. Three samples were prepared from separate batches of starting material under each condition.

[0261] Figure 22 shows a sample of a particle suspension in a sealed Nalgene bottle for gamma irradiation, with a label attached.

[0262] The Nalgene bottles were sealed in shrink wrap to ensure an environment free from tampering. The bottles were labeled with a gamma-ray irradiation color indicator; this indicator changes color from orange to red after exposure to gamma rays. The samples were irradiated with at least 15 kGy. The samples were then stored at 4°C until testing.

[0263] Irradiated and unirradiated samples were analyzed. Keyence electron microscopy was used to evaluate particle size. The recorded parameters were particle area, maximum area, minimum area, and perimeter. Particles were stained with Congo red to enable visualization. Using an automated micropipette, 500 μL of sample and 150 μL of triple-filtered (0.22 μm) 0.2% Congo red were added to a 1 mL vial. The vials were mixed and stored overnight in a refrigerator. Small aliquots of the stained suspension were placed between a glass slide and a coverslip. Each specimen was prepared immediately before imaging to avoid interference due to evaporation. The specimens prepared as described above were examined using a Keyence VHX-5000 digital microscopy system equipped with a Z20T lens, according to SGS PSI Method ID 27940 Revision 3. Imaging was performed at the original magnification of 200x using polarized transmitted light. Specimens prepared from each sample suspension were imaged using two-dimensional stitch features. The sample area was selected to avoid concentrated sections or air bubbles, ensuring a more random distribution of particles. The "grain size" in each image was measured using the auto-area function of Keyence software. After selecting the preferred dye binding to the particles, a list of objects to measure was considered, focusing on the approximate maximum diameter at the transition from clumps of contacting or overlapping particles to individual particles. Exclusions were then applied to larger grains and those interrupted at the edges of the image. The analysis was repeated until at least 1,000 particles were measured per sample. Figure 23 shows sample images obtained from Keyence electron microscopy. The bright red overlay indicates the particles used in the analysis.

[0264] There was no significant difference in the average particle area between gamma-ray-irradiated and unirradiated particles (P=0.91, Sample N=3). The average particle area was 1885.3 ± 1144.6 μm². 2 and 1705.4±984.9μm 2The area histogram is shown in Figure 24. The total number of particles analyzed was 3800 for the irradiated sample and 4692 for the unirradiated sample. Figure 24 shows the particle area for particles irradiated with gamma rays (N=3800) and unirradiated particles (N=4692).

[0265] Since the particles were not perfectly spherical, the maximum ferret diameter (or maximum diameter) was a useful quantity for evaluating the size of irregularly shaped particles. This measurement is commonly performed in the analysis of powders and particles. There was no significant difference in the maximum particle diameter between gamma-irradiated and unirradiated particles (P=0.97, sample N=3). The average particle sizes were 62.0±20.1 μm and 61.0±18.4 μm, respectively. The diameter histogram is shown in Figure 25. Figure 25 shows the histogram of the maximum particle diameter for gamma-irradiated particles (N=3800) and unirradiated particles (N=4692).

[0266] In contrast to the maximum diameter, it is also important to evaluate the minimum particle size. There was no significant difference in minimum diameter between gamma-ray-irradiated and unirradiated particles (P=0.90, sample N=3). The average minimum particle sizes were 46.5±15.0 μm and 44.4±13.2 μm, respectively. The diameter histogram is shown in Figure 26. The total number of particles analyzed was 3800 for the irradiated sample and 4692 for the unirradiated sample. Figure 26 shows the minimum particle diameter histograms for gamma-ray-irradiated particles (N=3800) and unirradiated particles (N=4692).

[0267] In summary, these results indicate that particle size does not change significantly with gamma irradiation. Further examination of the data showed that in the current manufacturing method using wet sieving, less than 0.32% of the particles had a maximum diameter of less than 20 μm. This result is particularly interesting for in vivo use, as particles smaller than 20 μm may be phagocytosed and / or induce an immune response. In contrast, commercially available BellaFill dermal filler particles report that less than 1% of their material has a diameter of less than 20 μm.

[0268] The particles are not inherently spherical; therefore, their shape may be described using some shape descriptors, such as those presented above. Importantly, none of these properties changed after 15 kGy of gamma-ray irradiation.

[0269] Alternative approaches to size limitations In addition to wet sieving, fractional centrifugation may be used to separate particles. Furthermore, fractional centrifugation can be a closed-loop production process that can reduce processing time and water usage. Fractional centrifugation is a technique that can be used to separate particles based on particle size. Centrifugation is used to accelerate the sedimentation process. The rate of separation depends on effective gravity, fluid viscosity, path length, and time. The following equations summarize the relationships between the aforementioned variables. These equations assume that the particles are uniform and spherical, which is not the case for the particles in this case. Nevertheless, these considerations serve as a starting point for constructing the variables.

[0270]

number

[0271] Figure 27 shows the particle size distribution of apple-derived particles obtained via fractional centrifugation. (A) shows the size distribution of unfiltered particles after initial removal of larger particle sizes by manual sieving (45 μm), and (B) shows the distribution after five centrifugation cycles of 1 minute each at 1000 rpm. To collect all the material, centrifugation at 5000 rpm for 7 minutes was used.

[0272] In vitro biocompatibility To evaluate the effect of the powder on cell viability, an in vitro biocompatibility test was performed. This test was conducted to compare the effects of filtered and unfiltered particles on NIH3T3 mouse cells, a model strain often used. Sterile powder was used in the assay. Six plates containing 3T3 cells in DMEM medium were used under the following conditions: • Control: No particles or dyes were used; only cells were used. • Filtered particles pre-stained with CR; • Filtered particles - no dyes; • Unfiltered particles pre-stained with CR; • Unfiltered particles - no dyes; • Pigment control - Cells containing only pigment.

[0273] To prepare samples containing filtered particles, filtered biomaterial (apple particles prepared as described above via grinding and subsequent wet sieving) was used. A 20 mL volume (containing 2 mL of particles) was divided into two tubes and centrifuged at 5000 RPM for 7 minutes. The pellet was resuspended in distilled water to a final volume of 3.5 mL. 175 μL of 0.2% CR was added to one of the samples (CR concentration in the tube was 0.01%). The particles were stained for 10 minutes. The contents of the tubes were pipetted into corresponding plates (each plate contained an amount equivalent to 1 mL of wet particles).

[0274] To prepare a sample containing unfiltered particles, unfiltered biomaterial (apple particles prepared as described above via grinding and subsequent wet sieving) was used. 2 mL of powder was resuspended in distilled water to a final volume of 7 mL. This solution was divided into two tubes, and 175 μL of 0.2% CR was added to one of the samples (CR concentration in the tube was 0.01%). The contents of the tubes were pipetted into corresponding plates (each plate contained an amount equivalent to 1 mL of wet particles).

[0275] To prepare a dye control, 175 μL of 0.2% CR was added to a plate containing particle-free 3T3 cells.

[0276] All plates were incubated at 37°C and 5% CO2 for 48 hours, after which they were observed.

[0277] Figure 28 shows an in vitro cell culture test using AA (apple) particles. Blue = 3T3 cell nuclei. In some cases, thin flakes of larger particles may also be visible as a result of Hoechst 33342 staining. Red = particles stained with 0.01% Congo Red, remaining after washing away free particles. Figure 28(A, B) shows the control. Figure 28(C, D) = control and staining. Figure 28(E, F) = filtration: 25-45 μm. Figure 28(G, H) = filtration: 25-45 μm and staining. Figure 28(I, J) = no filtration. Figure 28(K, L) = no filtration and staining. Scale = 250 μm.

[0278] These results indicate that unfiltered powder has a detrimental effect on cell viability. After 48 hours, a significant number of cells had died, appearing necrotic and / or suspended in the culture plate. In contrast, plates with filtered particles had a higher cell density, comparable to the control. The cells appeared normal and viable. While the exact mechanism of powder-induced cell death has not been studied in much detail, these results are consistent with the cytotoxicity of particles smaller than 20 μm in diameter. In this case, the unfiltered solution contains a large number of particles below the 20 μm threshold, which may contribute to the increased cell death. The cause of cell death has not been investigated in much detail, but both osmotic effects and apoptosis due to phagocytosis of small particles have been hypothesized. Results from lowering the concentration of the particle suspension to alter the severity of the osmotic shock suggest that this was the primary cause of the observed cell death. In preliminary tests, cells cultured with both unfiltered particles and 50-fold diluted filtered particles were viable.

[0279] Superior results were obtained with filtered particles, demonstrating that cell density was higher and comparable to the control group when filtered particles were present. The cells appeared normal and viable.

[0280] Formulation and manufacturing of skin fillers Since the particles may be used in dermal fillers and dermal filler applications, their applicability to delivery via syringe and needle was tested. Alginate was used for viscous mixing of the particles.

[0281] The formulation contained 0.5% alginate and 20% particles by volume. In the initial attempt to prepare the formulation, a liquid component was prepared by mixing 5 mL of 1% alginate with 5 mL of water. This solution was somewhat viscous; however, it could be easily mixed by conventional pipetting techniques. Next, 2 mL of unfiltered powder was added to the liquid component (prepared as described above). Conventional pipetting and stirring did not yield a homogeneous solution of particles. Similarly, vortexing did not produce a homogeneous suspension.

[0282] In an alternative approach, 2 mL of unfiltered powder was first combined with 5 mL of water. This mixture was then gradually introduced as a 500 μL aliquot into 5 mL of 1% alginate. This approach made mixing the solutions much easier and resulted in a more homogeneous final composition.

[0283] Next, a needle occlusion test was performed using these two formulations. A 27G needle was used. Both formulations blocked and clogged the needle; in the first method, it clogged immediately.

[0284] The third formulation prepared was identical to the second prototype, except that it used 25-45 μm particles instead of unfiltered particles. When the same needle occlusion test was applied, the particle mixture did not occlude the needle.

[0285] Figure 29 shows an injectable skin filler containing alginate. The particles accounted for 20% of the volume. Two mixing methods were tested. (A) shows mixing the powder in water and alginate solution. (B) shows mixing the powder first in the water component, followed by the slow addition of alginate. The first method did not mix well and the needle clogged. The second method mixed well, but unfiltered particles clogged the needle. When the unfiltered particles were replaced with filtered particles, the mixture could be easily pushed out.

[0286] These results suggest that the mixing process used in the prototype can be further optimized. Slowly adding one component to another is time-consuming, and the complexity of material migration increases the risk of contamination and even error propagation.

[0287] Therefore, the components of the filler were mixed using a Luer-lock (F / F) syringe connector. One syringe was loaded with particles mixed with 0.9% saline and 0.1% Congo red dye to visualize the mixing process. The second syringe was loaded with 1% alginate. The two syringes were connected with a Luer-lock (F / F) connector. These solutions were mixed by passing the material back and forth 60 times from one syringe to the other. After mixing was complete, the material was transferred to one of the syringes. The empty syringe was removed and replaced with a 1cc syringe. The desired volume (400 μL in this case) was loaded into the syringe. The 1cc syringe was removed and a needle of the appropriate size was attached.

[0288] Figure 30 shows the mixing of skin filler components using a syringe Luer lock connector. (A) shows the two components loaded into individual syringes. The clear liquid is 1% alginate, and the red liquid is particles suspended in 0.9% saline and lidocaine (final concentration = 0.3%). Congo Red was added for visualization (final concentration = 0.1%). (B) shows the Luer lock connector. (C) shows the mixing of the components (a total of 60 back-and-forth movements). (D) shows the Luer lock being removed and replaced with an extrusion needle. Note that the solution does not clog the 27G needle.

[0289] Further examples of skin filler formulations used in this embodiment and approaches / procedures for their preparation are as follows:

[0290] Skin filler formulation containing a physiological saline dispersion medium Important equipment 1. Safety Cabinet 2. Centrifuge (capable of handling both 50mL Falcon tubes and microcentrifuges) 3. Pipette gun 4. Micropipette solution 1.70% ethanol 2. Sterile water 3. Sterile physiological saline (0.9%) 4. Lidocaine 2% procedure Arrangement 1. Turn on the power to the safety cabinet (BSC). 2. Clean the BSC with an Accel wipe. 3. Spray 50 mL of 70% ethanol into a Falcon tube and rack and place them in the BSC. One Falcon tube was used to collect particles; the other was used as a waste container. 4. Clean the pipette gun using an Accel wipe and transfer the contents to the BSC. 5. Take a photograph of gamma-ray irradiated particles in an unopened, shrink-wrapped bottle, ensuring that the radiation warning sticker is visible. 6. Wipe the particle bottle with an Accel wipe and place it in the BSC. 7. Shake the container to resuspend the particles. 8. Wipe a new, sterile bottle of 0.9% saline solution and transfer it to the BSC. Particle preparation 1. All material transfer steps were performed within the BSC using aseptic methods. Sterile gloves were used. Pour the entire contents (20 mL) of the gamma-ray irradiation bottle into a 2.50 mL Falcon tube. 3. Centrifuge the particles at 1000 rpm for 3 minutes at room temperature. 4. Clean the Falcon tube with an Accel wipe and return it to the BSC. 5. Discard the supernatant using a pipette gun. Do not tilt or vigorously move the vial, as some particles may resuspend in the solution. Resuspend the pellet in 6.6.8 mL of sterile 0.9% physiological saline. Mix thoroughly. Add 7.1.2 mL of 2% lidocaine. Mix thoroughly. 8. Transfer a 500 μL aliquot of the solution to an autoclaved microcentrifuge tube. Note: The autoclaved microcentrifuge tube packaging was opened inside the hood. The outer packaging was not allowed to touch the surface of the hood, nor was it passed over the opened container. Syringe loading 1. Create a sterile area within the BSC by placing a sterile hack towel on one side of the BSC. 2.1 researchers used the open method to put on sterile gloves. These researchers are identified as sterile researchers. 3. A non-sterile researcher brought a sterile 1cc syringe into the BSC. The package was not touched on any surface. The package was opened and dropped into the sterile field, or placed there by a sterile researcher. 4. Repeat step 3 for the needle. The needle gauge was set to 26G. 5. A non-sterile researcher holds a microcentrifuge tube containing the skin filler at a 45-degree angle, while a sterile researcher draws 400 μL into a syringe. 6. Loosely recapped the loaded syringe. Note: Place the cap over a sterile field and insert the needle into the cap with one hand. Avoid using both hands in case the needle touches or penetrates the plastic cap. 7. Transfer the loaded syringe to a sterile field adjacent to the rat's surgical site. Skin filler formulation containing hyaluronic acid carrier hydrogel Important equipment 1. Safety Cabinet 2. Centrifuge (capable of handling both 50mL Falcon tubes and microcentrifuges) 3. Pipette gun 4. Micropipette Hyaluronic acid kit 1. HyStem Kit - Advanced BioMatrix - Cat GS311 solution 1.70% ethanol 2. Sterile water 3. Sterile physiological saline (0.9%) 4. Lidocaine 2% procedure Arrangement 1. Turn on the power to the safety cabinet (BSC). 2. Clean the BSC with an Accel wipe. 3. Remove the HyStem package from the freezer / ice pack. Open the HyStem package and warm the vial to room temperature. 4. Spray 50 mL of 70% ethanol into a Falcon tube and rack and place them in the BSC. One Falcon tube was used to collect particles; the other was used as a waste container. 5. Clean the pipette gun with an Accel wipe and transfer the contents to the BSC. 6. Take a photograph of gamma-ray irradiated particles in an unopened, shrink-wrapped bottle, ensuring that the radiation warning sticker is visible. 7. Wipe the particle bottle with an Accel wipe and place it in the BSC. 8. Shake the container to resuspend the particles. 9. Wipe a new, sterile bottle of 0.9% saline solution and transfer it to the BSC. Particle preparation 1. All material transfer steps must be performed within the BSC using aseptic methods. Sterile gloves were used. Pour the entire contents (20 mL) of the gamma-irradiated bottle's particle solution into a 2.50 mL Falcon tube. 3. Centrifuge the particles at 1000 rpm for 3 minutes at room temperature. 4. Clean the Falcon tube with an Accel wipe and return it to the BSC. 5. Discard the supernatant using a pipette gun. Do not tilt or vigorously move the vial, as some particles may resuspend in the solution. Resuspend the pellet in 6.10 mL of sterile 0.9% physiological saline. Mix thoroughly. 7. Transfer a 500 μL aliquot of the solution to an autoclaved microcentrifuge tube. Note: The packaging of the autoclaved microcentrifuge tube was opened inside the hood. The outer packaging was not allowed to touch the surface of the hood, nor was it passed over the opened container. 8. Centrifuge the microcentrifuge tube at 1000 rpm for 3 minutes at room temperature. 9. Wipe the vial with an Accel wipe and return it to the BSC. 10. Discard the supernatant using a micropipette. Hyaluronic acid preparations 1. Wipe all vials with Accel wipes. Aseptic methods were used throughout the preparation process. 2. Using a syringe and needle, add 1 mL of degassed (DG) water to the Glycosil vial. Note: Glycosil crosslinks in the presence of oxygen; do not remove the cap. 3. Turn the vial on its side and shake until the solid is completely dissolved. 4. Using a syringe and needle, add 0.5 mL of DG water to the Extralink-Lite vial. Invert the vial several times to dissolve. 5. Once the Glycosil has dissolved, resuspend the particle pellet in 260 μL of Glycosil solution using a syringe and needle. 6. Add 65 μL of Extralink-Lite solution to the particle-glycosil mixture. 7. Add 75 μL of 2% lidocaine solution to this mixture and mix thoroughly using a sterile 1 mL pipette. Syringe loading 1. Create a sterile area within the BSC by placing a sterile hack towel on one side of the BSC. 2.1 researchers used the open method to put on sterile gloves. These researchers were identified as sterile researchers. 3. A non-sterile researcher carried a sterile 1cc syringe into the BSC. The package was not touched on any surface. The package was opened and dropped into the sterile field, or placed there by a sterile researcher. 4. Repeat step 3 for the needle. The needle gauge was set to 26G. 5. A non-sterile researcher holds a microcentrifuge tube containing the skin filler at a 45-degree angle, while a sterile researcher draws 400 μL into a syringe. 6. Loosely recapped the loaded syringe. Note: Place the cap over a sterile field and insert the needle into the cap with one hand. Avoid using both hands in case the needle touches or penetrates the plastic cap. 7. Transfer the loaded syringe to a sterile field adjacent to the rat's surgical site. 8. The injection was administered within 30 minutes of adding the Extralink-Lite solution. It was possible to prepare Glycosil and leave it in a microcentrifuge tube for up to 4 hours before adding Extralink-Lite. Skin filler formulations containing collagen carrier hydrogel Important equipment 1. Safety Cabinet 2. Centrifuge (capable of handling both 50mL Falcon tubes and microcentrifuges) 3. Pipette gun 4. Micropipette 5. Luer lock syringe connector collagen 1.65 mg / mL of fibrous atelocollagen solution 1.70% ethanol 2. Sterile water 3. Sterile physiological saline (0.9%) 4. Lidocaine 2%-CDMV Cat:123683 procedure Arrangement 1. Turn on the power to the safety cabinet (BSC). 2. Clean the BSC with an Accel wipe. 3. Remove the HyStem package from the freezer / ice pack. Open the HyStem package and warm the vial to room temperature. 4. Spray 50 mL of 70% ethanol into a Falcon tube and rack and place them in the BSC. One Falcon tube was used to collect particles; the other was used as a waste container. 5. Clean the pipette gun with an Accel wipe and transfer the contents to the BSC. 6. Take a photograph of gamma-ray irradiated particles in an unopened, shrink-wrapped bottle, ensuring that the radiation warning sticker is visible. 7. Wipe the particle bottle with an Accel wipe and place it in the BSC. 8. Shake the container to resuspend the particles. 9. Wipe a new, sterile bottle of 0.9% saline solution and transfer it to the BSC. Particle preparation 1. All material transfer steps were performed within the BSC using aseptic methods. Sterile gloves were used. 2. Pour the entire contents (20 mL) from the two gamma-ray irradiation bottles into two 50 mL Falcon tubes. 3. Centrifuge the particles at 1000 rpm for 3 minutes at room temperature. 4. Clean the Falcon tube with an Accel wipe and return it to the BSC. 5. Discard the supernatant using a pipette gun. Do not tilt or vigorously move the vial, as some particles may resuspend in the solution. Resuspend the pellet in 6.8.5 mL of sterile 0.9% physiological saline. Mix thoroughly. 7. Transfer 1000 μL aliquots of the solution to autoclaved microcentrifuge tubes. Note: The autoclaved microcentrifuge tube package was opened inside the hood. The outer packaging was not allowed to touch the surface of the hood, nor was it passed over the opened container. 8. Centrifuge the microcentrifuge tube at 1000 rpm for 3 minutes at room temperature. 9. Wipe the vial with an Accel wipe and return it to the BSC. 10. Discard the supernatant using a micropipette. A mixture of particles and collagen 1. Create a sterile area within the BSC by placing a sterile hack towel on one side of the BSC. 2.1 researchers used the open method to put on sterile gloves. These researchers are identified as sterile researchers. 3. A non-sterile researcher carried a sterile 3cc syringe into the BSC. The package was not touched on any surface. The package was opened and dropped into the sterile field, or placed there by a sterile researcher. 4. A non-sterile researcher brought a sterile Luer-lock F / F syringe connector into the BSC. The package was handled carefully to avoid touching any surface. The package was opened and dropped into the sterile field, or placed there by a sterile researcher. 5. A non-sterile researcher removed the collagen syringe from the refrigerator and wiped it with an Accel wipe. The collagen syringe was then transferred to a sterile field. 6. Using a sterile syringe and needle, add 0.58 mL of physiological saline to the microcentrifuge tube containing the particles. 7. Using a sterile syringe and needle, add 0.28 mL of 2% lidocaine. 8. A sterile researcher draws the particle solution into a 3cc syringe and needle. 9. Connect the particle solution syringe to a 3cc collagen syringe containing 1mL of 65mg / mL collagen. Ensure no air bubbles are generated. Remove as much air as possible before connecting to the Luer lock. This was done by a sterile researcher. 10. Inject the contents of one syringe into the other syringe, mixing the contents 40 times. Begin by adding the particles to the collagen syringe. Syringe loading 1. A non-sterile researcher brought sterile 1cc syringes into the BSC. The packaging was kept from touching any surface. The packaging was opened and dropped into the sterile field, or placed there by a sterile researcher. These syringes were for the final injection. 2. Repeat step 1 for the needle. The needle gauge was set to 21G. 3. At this point, all materials were handled exclusively by sterile researchers. 4. Transfer all 2.33 mL of the dermal filler into one syringe of the mixing system. Remove the empty syringe from the Luer lock. Attach the 5.1cc syringe to the Luer lock. Load 400 μL of dermal filler into a 6.1 cc syringe. Note: This 1 cc syringe does not lock the Luer lock; maintaining pressure against the Luer lock during loading will prevent the 1 cc syringe from being ejected due to the loading pressure. 7. Loosely recapped the loaded syringe. Note: Place the cap over a sterile field and insert the needle into the cap with one hand. Avoid using both hands in case the needle touches or penetrates the plastic cap. 8. Transfer the loaded syringe to a sterile field adjacent to the rat's surgical site.

[0291] [Table 4]

[0292] For comparison, commercially available BellaFill was purchased and used to evaluate the particle size distribution compared to the cellulose particles currently under development suspended in collagen as described above. The measured particle size distribution of the PMMA beads confirms the starting mean particle size in BellaFill. The PMMA spheres are easily identifiable in microscopic images and appear spherical. To visualize the cellulose particles currently under development, they were stained with Congo Red (0.1%) before mixing with collagen, as previously described (it was confirmed that there was no nonspecific staining of collagen by Congo Red). In the formulation currently under development, the cellulose particles are well distributed throughout the collagen gel.

[0293] Figure 31 shows the collagen fillers described. Figure 31(A) shows the particle size distribution of PMMA beads in BellaFill. Figure 31(B) shows Congo red-stained collagen to be used in a dermal filler currently under development, with only minimal secondary nonspecific staining. Figure 31(C) shows the PMMA beads in BellaFill. Figure 31(D) shows cellulose particles to be used in a collagen dermal filler currently under development, stained with Congo red. Note: Background staining of collagen is weaker compared to the signal from cellulose particles. Scale = 250 μm.

[0294] In vivo biocompatibility The key performance characteristics of the dermal filler formulations currently under development can be evaluated in a subcutaneous animal model. Each formulation (AAS, AAHA, AAC, produced as described above) can be injected into four locations on the back of N=9 animals. The implant sites can be measured weekly (height, x, and y width), and at 4 weeks, N=3 animals can be sacrificed to excise the implants. At 12 weeks, only 2 of the 3 animals in the formulation cohort can be sacrificed, and the remaining 1 can be maintained for a longitudinal study (e.g., 6–12 months). This means that data can be obtained for each formulation (AAS, AAHA, AAC) at longer time points, and data can be obtained for one animal per formulation from each of the four types of implants. Commercially available BellaFill may be used in an adjunct study. Data can be collected in a study of 3 animals (400uL each, injected twice). These studies can provide GLP data that can be used, for example, to inform studies using similar formulations in a larger number of animals. The anticipated surgical procedures are described below.

[0295] implantation surgery Pre-operative check 1. Before commencing treatment, ensure that all materials and supplies are available. Check the following: a. Oxygen tank level b. Isoflurane level c. Sterilized pack d. Suture material e. Sterile physiological saline f. Sterile water g. Tear Gel H. buprenorphine i. Heater for the anesthesia station 2. Always weigh the animal and administer the corresponding amount of buprenorphine: 0.05 mg / kg. 3. Calculate the amount of saline solution to administer: 5 mL / kg. 4. Start oxygen supply. Set to level 2. 5. Initiate isoflurane administration. Connect the supply line to the anesthesia box. Set to level 3. Animal preparation 1. Transfer the rat to the anesthesia box. 2. Once the rat loses consciousness, move it to the preparation station. Connect isoflurane to the preparation station. 3. Lower the isoflurane level to 2. 4. Apply Teargel to the rat's eye. 5. Shave one side of the rat's back. 6. Remove by suction from the hair. 7. Cleanse the skin with a cotton swab dipped in water to remove all loose hair. 8. Use a dry cotton swab to remove moisture from the skin and brush away any remaining hair. 9. Inject saline solution to maintain hydration in the non-shaved side of the rat. 10. Move the rat to the surgical site. 11. Sterilize the skin by dipping a cotton swab in chlorhexidine (4%). Wipe in one direction. Ensure that all of the skin is wiped clean. injection 1. One researcher wears a gown and sterile gloves. Depending on whether the researcher is wearing a new gown, the appropriate glove method (closed / open) is used. Transport 400 μL of 2.4 doses into a sterile area adjacent to the animal. 3. A non-sterile researcher photographs the injection site before the injection. 4. A sterile researcher injects the contents of the syringe into four separate locations on the sterile, shaved back of the rat. 5. A non-sterile researcher photographs the injection site. 6. Transfer the rat to the measurement station. 7. Next, move the rat to the recovery station and place the animal ID card on top of the recovery cage.

[0296] Weekly size measurements To assess the size of the implant, begin the following procedure on the day of injection and then apply it weekly to all animals thereafter.

[0297] Animal anesthesia 1. Open the oxygen tank. 2. Connect the isoflurane line to the anesthesia box. 3. Increase the isoflurane dose to 3. 4. Transfer the animal to the anesthesia box. 5. When the animal loses consciousness and begins to breathe deeply (once every 3 seconds), move the rat to the measurement station. Set the isoflurane level on the measurement station to 2.

[0298] measurement 1. To maximize the reliability of the measurements, hair may be shaved from the implant site. 2. Use a Vernier caliper to measure the size of the subcutaneous bump caused by the injection of the skin filler. Before starting each measurement in a series of measurements, the caliper must be zeroed out. 3. Collect and record the size measurements (e.g., diameter X, diameter Y, height). 4. Once finished, draw a circle around the implant site. 5. The order of the parts should be from head to tail; for example, part 1 is closest to the rat's head. 6. The X direction is inward-outward, while the Y direction is caudal-cephalic. 7. The measurements of diameter X and diameter Y may be obtained using the front end of a caliper. 8. Measure the height using the projection at the bottom of the caliper. 9. Once the measurements have been taken and recorded, the animals may be returned to their cages and animal rooms. 10. Ensure all water bottles are returned in the correct orientation.

[0299] Slaughter and tissue collection 1. Transfer the animal to the euthanasia box. 2. If performing this procedure on two rats at once (by connecting two boxes), set the initial CO2 flow rate to 6, and then increase it to 12 when the rats lose consciousness. 3. Observe the animal's breathing pattern. Wait at least 5 minutes. 4. Confirm that breathing has stopped for one minute. 5. Stop CO2. 6. Remove the rat from the euthanasia box and place it on its back. 7. Locate the xiphoid process and make an incision in the skin. 8. Make a hole in the diaphragm to expose the heart. 9. The heart is cut open and it is confirmed that blood begins to accumulate. 10. Place the animal in a prone position, exposing its back. 11. Make an incision in the skin from the waist down to the shoulder, along the center of the spine. Separate the skin and excise the connective tissue. The flap should contain the implant / injected material. 12. Take a photograph of the skin flap along with a ruler for measuring. 13. Cut out each implant individually. Ensure that the skin is beneath the material. This helps in oriented the sample during histological examination and allows for direct comparison with native tissue. 14. Quickly transfer the sample to formalin (4%). 15. Depending on the size of the implant and the staining procedure, transfer the sample to 70% ethanol after 48 or 72 hours of formalin fixation.

[0300] Histological examination The specimens are sent for histological examination and sectioned after embedding in paraffin blocks. To observe the cross-section of the implant, the blocks may be sectioned perpendicular to the skin surface. The implant is sectioned at one level approximately 500 μm from the edge, and then further sectioned at a second level approximately 1.5 mm into the tissue. This allows examination of both the outer edge and approximately the center of the implant. Order H&E and Masson tricolor staining, and order a few slides unstained.

[0301] The following in vivo biocompatibility results have been obtained.

[0302] Collected results of in vivo biocompatibility The dermal fillers examined were saline (AAS), hyaluronic acid (AAHA), and collagen (AAC) based fillers, including the filtered gamma-sterilized cellulose particles described herein. All three types of dermal fillers were injected into rat models.

[0303] Figure 32 shows the results of dermal filler injection. Figure 32(A) shows the contour of the elevation boundary before injection, and (B) shows the contour after injection. Figure 33 shows the excision of fillers based on saline, hyaluronic acid (HA), and collagen, combined with 20% decellularized apple-derived filtered particles and 0.3% lidocaine.

[0304] As described above, the implant site was measured weekly for all animals and all formulations. The size characteristics of the implants were as shown in Figures 34 and 35. Figure 34 shows the implant sizes: height of AAS (blue), AAHA (red), AAC (black), and BellaFill (purple) implants. All implants shrank over time due to reabsorption of the dispersion medium / hydrogel. The AAS formulation was absorbed rapidly. Figure 35 shows the implant volumes: volumes of AAS (blue), AAHA (red), AAC (black), and BellaFill (purple) implants. All implants shrank over time due to reabsorption of the dispersion medium / hydrogel. The AAS formulation was absorbed rapidly.

[0305] This data supports the rapid shrinkage of AAS fillers due to the reabsorption of saline into the animal's body. In the case of collagen, HA, and BellaFill, the implants shrink more slowly but remain visible several months after the initial injection. Although the number of animals is small, qualitatively, the implant size characteristics of BellaFill and the dermal fillers currently under development are nearly identical. Potentially, the fillers currently under development may not shrink as rapidly as the BellaFill product, but they appear to reach a similar baseline size.

[0306] Suitable animals were slaughtered at 4, 8, and 12 weeks, and implant tissue was collected. In the case of AAS, only the filler particles were visible beneath the skin (consistent with the measured size data) because the saline solution was rapidly absorbed into the animal's body. Therefore, the skin filler was indeed non-absorbable, but the dispersion medium used in the skin filler formulation was absorbed. [Examples]

[0307] Modified skin fillers This embodiment considers modified skin fillers. To provide greater control over the shape and size distribution of the material, it is envisioned that cellulosic materials be dissolved and crosslinked into specific shapes and / or sizes. Several crosslinking methods are envisioned in certain embodiments, including, for example, chemical crosslinking with succinic acid, treatment with sodium hydroxide and urea, and composite materials with alginate and calcium chloride. An outline of the envisioned sample dissolution protocols is given below: Ratio: 50g of decellularized apple = 1.568g of cellulose material

[0308] Preparation of solvent: • DMAC: 115°C for 15 minutes • LiCl: 48 hours at 180℃ Protocol: Weigh 50g of decellularized material. • Immerse in acetone (in an ultrasonic bath for 15 minutes) • Remove acetone by centrifugation. Repeat the previous two steps twice. • Immerse in DMAc (15 minutes in an ultrasonic bath). • Remove acetone by centrifugation. Repeat the previous two steps twice. Add LiCl at a ratio of 6g per 50mL of DMAC. Maintain at 100°C for 1 hour. • Reduce the temperature to 50°C over 72 hours (while stirring). • Regenerate cellulose through water exchange. [Examples]

[0309] Efficiency of cellulose particle production The tests described in this embodiment aimed to gain insights into the potential yield of cellulosic particle production using apples as a starting material.

[0310] Decellularization of apple samples Canada Fancy's Macintosh apples were divided into three separate batches, and each of the three batches was weighed. The weights of each batch are shown in Table 5 below.

[0311] [Table 5]

[0312] Apples from each batch were washed with 70% ethanol and Accel TB disinfectant, and then peeled. After peeling, the samples from each batch were sectioned to a thickness of 1 mm. The apple cores were removed, and the sections were divided into four equal parts.

[0313] To decellularize the samples, they were then placed in 0.1% SDS for 72 hours, with the solution changed once daily. Each batch of samples was then washed three times with distilled water and subsequently immersed in 100M CaCl2 solution for 24 hours. During the decellularization process, the samples were shaken at 120 RPM.

[0314] Next, each batch of samples was washed three more times with distilled water and sterilized in 70% ethanol for 30 minutes. The samples were then stored in distilled water at 4°C until further use.

[0315] Freeze-drying of decellularized samples The decellularized samples were drained to remove as much distilled water as possible, and then placed in 50 mL Falcon test tubes. The samples were then frozen at -20°C, placed in glass containers, and loaded into Labconco freeze-dryers with 3-4 test tubes per container. The samples were freeze-dried at 55 mbar and -47°C for 48 hours. After drying, the samples were weighed, and the results are shown in Table 6 below.

[0316] Grinding of dried samples The decellularized, lyophilized samples from each batch were ground at 18,000 RPM using a Retsch Mill ZM-200 equipped with an 80 μm sieve. The particles were collected in 50 mL tubes and weighed as shown in Table 6 below. The samples were then stored at 4°C until further use.

[0317] Sieving of the crushed sample The ground samples from each batch were sieved using a Gilson vibrating sieve shaker (SS-23) system, which allows for continuous sieving. The upper sieve had a 50 μm mesh, and the lower sieve had a 25 μm mesh. The 50 μm sieve held particles larger than 50 μm. Particles smaller than 25 μm passed through the 25 μm sieve. Filtered particles (size 25 μm to 50 μm) were collected from the 25 μm sieve and weighed.

[0318] After grinding, 5 mL of the ground sample from each batch was resuspended in distilled water to a final volume of 45 mL. The resuspension was poured into a 50 μm sieve, and 150 mL of distilled water was added after 2 minutes. After 1 minute, another 150 mL of water was added to the upper sieve (this step was repeated twice). The 50 μm sieve was then removed, and 50 mL of distilled water was added to a 25 μm sieve. After 1 minute, another 50 mL of water was added to the sieve (this step was repeated twice). The wet particles of the ground sample on the 25 μm sieve were collected and placed in a centrifuge tube. This process was repeated until all the ground samples had been filtered. The filtered samples were then centrifuged at 5000 RPM for 7 minutes to pelletize the particles, and stored at 4°C.

[0319] The filtered and pelletized samples were then freeze-dried under the same conditions as described above, and subsequently weighed as shown in Table 6 below.

[0320] [Table 6]

[0321] Please note that the second freeze-drying process was performed solely for the purpose of measuring the dry mass of the sample and was not necessary for the production of the skin filler sample.

[0322] Determination of particle yield Using the data collected using the procedure described above, three different particle yields were calculated: from the initial batch mass (whole apples), the freeze-dried batch mass, and the ground batch mass. The results are shown in Table 7.

[0323] [Table 7]

[0324] The average yield was calculated and is shown in Table 8.

[0325] [Table 8]

[0326] result The yield from the batch starting mass was calculated using the mass of dried 25-50 μm particles and the batch starting mass. The yield from the batch starting mass was 0.119% ± 0.018%, which means that 0.119 g of dried particles were obtained from 100 g of starting material, or that 83,843.38 g of apples were needed to produce 100 g of dried particles.

[0327] The yield from the lyophilized batch mass was calculated using the mass of dried 25-50 μm particles and the lyophilized batch mass. The yield from the lyophilized batch mass was 13.9% ± 1.6%, which means that 13.9 g of dried particles were obtained from 100 g of lyophilized sample, or that 721.7 g of lyophilized batch sample was required to produce 100 g of dried particles.

[0328] The yield from the grinding batch mass was calculated using the mass of the dried 25-50 μm particles and the grinding batch mass. The yield from the grinding batch mass was 15.2% ± 1.5%, which means that 15.2 g of dry particles were obtained from 100 g of the grinding sample, or that 658.0 g of the grinding sample was required to produce 100 g of dry particles.

[0329] Variations in yield from batches may be partly due to sample preparation. While not bound by any specific theory, it is assumed that variations in apple size, the amount of pulp remaining in the apple core, powder loss during grinding, and the degree of separation during sieving affect the yield, either individually or collectively.

[0330] Nevertheless, these tests provide insights into the materials that may be required when scaling up the methods of this disclosure. [Examples]

[0331] Density of cellulose particles The tests described in this embodiment aimed to determine the number density (number of particles per volume) of the cellulose particles of the present disclosure. Generally, standard industry practice states the particle concentration of dermal fillers as mass / volume concentration. However, in some cases, it may be convenient to state the particle concentration of a filler as number density.

[0332] Density determination As described in Example 5 above, the produced decellularized, sterile (unfiltered) apple particles were filtered using a Gilson vibrating screen shaker, also as described in Example 5. The filtered particles were collected in a 15 mL Falcon tube and pelletized by centrifuging at 5000 RPM for 7 minutes. This process was repeated until 2.5 mL of wet 25–50 μm particles were obtained.

[0333] The particles were resuspended in 15 mL of water and then equally divided into three tubes (0.833 mL of particles in each tube). For particle count analysis using Multisizer 4, 33 μL of the particle equivalent (16.7% v / v resuspension) suspended in 198 μL of water was taken from each tube.

[0334] The remaining 0.800 mL of filtered particles in each tube were pelletized, frozen, and freeze-dried in a Labconco freeze-dryer at 55 mbar and -46°C for 4 days. The particles were then weighed, and the particle mass density was calculated as shown in Table 8.

[0335] [Table 9]

[0336] Next, the average density of dry particles per unit of wet volume was calculated, which is shown in Table 9.

[0337] [Table 10]

[0338] The density of the dry particles is 0.118 g / mL ± 0.00168 g / mL, which means that there are 0.118 g of dry particles per 1 mL of wet particles, or that 8.47 mL of wet particles will weigh 1 g when dried.

[0339] In a standard injection volume of 400 μL of skin filler, particles occupy 20% of the volume, resulting in 80 μL of particles per injection. Therefore, based on the above concentration and density results, the dry mass of particles per 400 μL injection was 9.4 mg.

[0340] Particle number analysis Two samples were prepared from each of the three samples: (4) 10 μL of 16.7% v / v particle suspension mixed with 10 mL of ISOTON, and (5) 20 μL of 16.7% v / v particle suspension mixed with 10 mL of ISOTON. For each sample, particle count analysis was performed using a Multisizer 4 Coulter Counter with a 100 μm opening and a 200 μL analysis volume. This means that 0.0336 μL of particles were analyzed for sample (4) and 0.0673 μL of particles were analyzed for sample (5). In the first run, particles from 2 to 60 μm were analyzed, and in the second run, particles from 10 to 60 μm were analyzed.

[0341] Between each run, an ISOTON (blank) sample was analyzed using the same settings to quantify the number of bubbles counted by the Coulter Counter. These values ​​were used to adjust the values ​​obtained for samples (4) and (5). The blank values ​​are shown in Table 10.

[0342] [Table 11]

[0343] Table 11 shows the results of particle number analysis for each sample (4) and sample (5).

[0344] [Table 12]

[0345] For illustrative purposes, the particle size distribution of sample (4) is shown in Figure 36. Table 12 shows the average number of particles in sample (4) and sample (5) from each of samples 1 to 3.

[0346] [Table 13]

[0347] As discussed above, the opening used was 100 μm. This opening can count particles with diameters from 2 μm to 60 μm. Analysis of 2-60 μm particles yielded 123,834,101 ± 2,919,049 particles per 1 mL of wet material, while analysis of 10-60 μm particles yielded 76,302,909 ± 1,279,872 particles per 1 mL of wet material.

[0348] This means that there were 9,906,728 particles (2–60 μm analysis) or 6,104,233 particles (10–60 μm analysis) per 400 μL injection of skin filler.

[0349] The following is a simplified theoretical estimate of the particle number concentration based on the assumption of a cylindrical particle shape with a radius of 15 μm and a thickness of 1 μm. If the thickness is assumed to be 0.1 μm, the number of particles is thought to increase tenfold. V 薄片 =π(15μm) 2 (1 μm) V 薄片 = 706.5um 3 Number of particles = V 粒子 / V 薄片 Number of particles = (80 μL (1 × 10) 9 μm 3 / μL)) / (706.5um 3 ) Number of particles = 1.13 × 10 8

[0350] The discrepancy between theoretical and observed values ​​can be attributed to several factors, including inaccuracies in Coulter Counter analysis (e.g., bubbles, particles settling from suspension), variations in particle size, and packing parameters (void volume is not considered in the calculation).

[0351] Despite these discrepancies, the particles are approximately 1 × 10⁻⁶ 7 The number density is 1 / 400μL injection, the mass density of the dry particles is 9.4mg / 400μL injection, and 706.5μm 3Combining these volume estimates for a single particle (or flake), the single particle density is 1.33 g / cm³. 3 This is the literature value for cellulose density (1.5 g / cm³). 3 It is almost the same as ). [Examples]

[0352] Cellular response to cellulose particles in vitro This study aimed to evaluate in vitro cellular responses to filtered and unfiltered cellulose particles of the present disclosure.

[0353] Particle preparation To prepare filtered particles, sterile, unfiltered, decellularized, ground apple particles were sieved using sterile water with a Gilson vibrating screen shaker (SS-23) system using the following procedure.

[0354] 5 mL of particles were resuspended in sterile distilled water to a final volume of 45 mL. This resuspension was poured into a 50 μm sieve, and 150 mL of distilled water was added after 2 minutes. After 1 minute, another 150 mL of water was added to the upper sieve (this step was repeated twice). The 50 μm sieve was removed, and 50 mL of distilled water was added to a 25 μm sieve. After 1 minute, another 50 mL of water was added to the sieve (this step was repeated twice). The wet particles on top of the 25 μm sieve were collected and placed in a 50 mL Falcon tube. This sieving process was repeated until a sufficient amount of filtered particles was collected.

[0355] Both filtered and unfiltered particles were centrifuged at 5000 RPM for 7 minutes to form pellets. The volumes of the pelletized filtered and unfiltered particles were used to calculate the volume added to the plate between different trials.

[0356] Assay Before adding to the plate, the particles were resuspended in preheated DMEM to a final volume of 2.5 mL. 50,000 C2C12 cells were placed in a 6-well plate (9.6 cm²) 24 hours before the experiment.2 The cells were plated into each well of the ) . The cells were incubated with the particle solution at 37°C and 5% CO2 for 48 hours. Then, 2.5 mL of the particle solution was added to each well.

[0357] The conditions used in the test were particle volume relative to cell medium: volume percentage. The percentages used were 1%, 2%, 3%, and 20%. In other words, at a 1% concentration, there were 25 μL of particles in a total volume of 2.5 mL of culture medium.

[0358] The 20% concentration was chosen to replicate the in vivo concentration previously used herein. However, as will be understood, in vitro and in vivo conditions differ significantly, and it was necessary to select a concentration that would not disrupt cell morphology. For example, in vitro systems lack the ability to regulate gas exchange and maintain isotonic conditions, and as a result, a reduction in concentration, e.g., by about 1%, may be necessary to avoid affecting cell morphology. Therefore, in vitro results may not directly reflect in vivo toxicity results.

[0359] Cell culture, fixation, staining, and imaging The culture medium and the particles it contained were removed from the plate for imaging. Because the particle density was relatively high and the layer beneath the cells was difficult to observe, the cells were fixed after particle removal.

[0360] The cells were washed three times with 5 mL of PBS, and 3 mL of 3.5% PFA was added to each plate. After incubation for 10 minutes, the cells were washed again with 5 mL of PBS. Then, 5 mL of PBS was added to the cells, the plates were sealed with Parafilm, and stored at 4°C. 5 μL of Hoechst 33342 was added to each plate containing 5 mL of PBS. The plates were incubated in the dark at room temperature for 30 minutes, then sealed with Parafilm and stored at 4°C.

[0361] Next, the plate was imaged using an Olympus SZX16 microscope.

[0362] result The addition of 20% v / v particles to C2C12 cells had a clear effect on cell density in plates after incubation at 37°C and 5% CO2 for 48 hours. Both filtered and unfiltered particles showed altered cell morphology, appearing atrophied, although some cells remained attached to the plates. Plates containing particles had significantly fewer cells than the control, which exhibited normal myoblast morphology. Plates with filtered particles had a higher cell density than plates with unfiltered particles. While not bound by any specific theory, it is hypothesized that in an in vitro environment, small particles may induce osmotic cell death, necrosis due to chemical leaching, and / or phagocytosis and apoptosis.

[0363] In the 20% sample, the high concentration of particles in the dish made it difficult to observe cells attached to the plate, resulting in the observation of only suspended cells. By imaging cells without particles, it became possible to quantify cell density more accurately because there were no particles blocking the signal during imaging.

[0364] Figure 37 shows a microscopic image of a 20% sample, Figure 37A shows a control microscopic image, Figure 37B shows a microscopic image of cells from a 20% filtered particle sample, and Figure 37C shows a microscopic image of cells from a 20% unfiltered particle sample. The magnification is 10x, and the scale bar is 500 μm.

[0365] Figure 38 shows the cell concentration (cells / mm³) of 20% filtered and unfiltered particle samples. 2 This indicates that...

[0366] As described above, it was anticipated that the 20% sample could affect cell morphology under in vitro conditions. However, as discussed above, in vitro and in vivo conditions are significantly different. Consequently, it is anticipated that a 20% particle concentration will not cause changes in cell morphology in vivo.

[0367] High particle concentrations in the culture medium alter the osmotic pressure of the solution, potentially leading to water being drawn out of cells due to entropy factors. Furthermore, the presence of a layer of particles above the cells can hinder efficient gas exchange, potentially leading to cell death. Under in vivo conditions, natural systems exist to regulate gas exchange and compensate for changes in solute concentration and osmotic pressure gradients or pressures.

[0368] Therefore, to evaluate the effect of particle concentration when normal cell morphology is observed, we selected lower concentrations than those discussed below. For both filtered and unfiltered samples, particle suspensions at low particle concentrations of 1%, 2%, and 3% were used.

[0369] Figure 39 shows the surface area coverage of cells in the control sample and in filtered and unfiltered low-concentration samples. As shown, at a concentration of 2%, there was a significant difference between filtered and unfiltered particles.

[0370] These results suggest that particle concentration can affect cell viability, with increased particle content in the culture medium potentially leading to a higher rate of cell death. Furthermore, filtration appeared to affect the amount of adherent cells. Unfiltered particles generally showed lower cell proliferation / coverage and higher cell death rates.

[0371] Here again, as discussed above, due to processes such as osmotic pressure regulation, gas exchange, and immune cells, the exact particle concentration is not directly reflected from the in vitro system to the in vivo system.

[0372] For example, there are significant differences in oxygen diffusion between in vitro and in vivo systems. More specifically, in vitro systems rely on oxygen diffusion through the cell medium. The distance over which oxygen must diffuse is generally much greater than the distance typically required in mammalian tissues. Furthermore, the rate of oxygen consumption under standard cell culture conditions often exceeds the rate of oxygen diffusion through the cell medium, and the presence of cellulose particles can further reduce the diffusion rate.

[0373] Another variable that differs between in vitro and in vivo systems is the maintenance of osmotic pressure, particularly turgor pressure, for the cell. Physiological values ​​of hydrostatic pressure (HP) vary considerably depending on the tissue (e.g., approximately 0.5 kPa to approximately 6 MPa). The number of solutes in a solution can affect osmotic pressure and, consequently, cell volume. Therefore, in an in vitro system, the addition of cellulose particles can affect osmotic pressure and potentially lead to cell death.

[0374] Furthermore, the cell types in cell culture systems differ from those in vivo. In immunocompetent animals, immune cells are induced to respond to foreign substances. However, in vitro, the processes that can occur are limited (e.g., phagocytosis).

[0375] Nevertheless, the above tests may collectively illustrate the effects of increased particle concentration on cells. [Examples]

[0376] Use of UV-VIS spectroscopy to evaluate cellulose particle concentration This study aimed to determine whether UV-VIS spectroscopy is a viable alternative to graduated cylinders, graduated Falcon tubes, and microcentrifuge tubes for measuring the concentration of cellulose particles.

[0377] More specifically, this study aimed to determine whether the absorbance or transmittance of light passing through a sample is suitable for more accurately measuring the concentration of cellulose particles within it.

[0378] While not bound by any particular theory, the principle behind this experiment is that cellulose particles scatter incident light, and the amount of scattering may indicate the concentration of particles in the sample. Absorbance is the negative logarithm of transmittance, or in other words, the logarithm of the ratio of incident radiant flux to transmitted radiant flux, as shown below. A = -log10T A = log(Φi / Φt) where A=absorbance, T=transmittance, Φi=incident radiant flux, Φt=transmitted radiant flux.

[0379] Sample preparation Particles derived from crushed and decellularized pears were suspended in a 2M sucrose solution. Sucrose solution was used because the particles would not remain suspended in water alone. Table 12 shows an overview of the prepared solution.

[0380] [Table 14]

[0381] spectroscopy UV-Vis spectrophotometers of the Cary 1E and Synergy models were used. For the Carey model, the wavelength was set to 500 nm, the averaging time to 0.1 s, and the SBW to 1.5 nm. A standard 1 cm cuvette was used. The Carey model is a dual-beam model; therefore, two 2 M sucrose solutions were used as blanks. The instrument was zeroed, and then the cuvette closest to the user was changed for sample reading.

[0382] As shown in Figure 40, absorbance-concentration standard curves were constructed using the samples. However, as shown, the intercept for high-concentration regimens (5-20%) is not close to zero, which suggests that the measurements are incorrect or that the portion of the analyzed curve was due to nonlinearity occurring at low concentrations.

[0383] Lower concentration ranges were tested using a Synergy model UV-VIS spectrometer. The 20% pre-mixture was serially diluted, and absorbance was measured at 450 nm, 475 nm, 500 nm, and 525 nm. The results are shown in Figure 41.

[0384] Wavelength sweeps were also performed on the 20% pre-prepared solution and the 2M sucrose control solution using a Synergy model UV-VIS spectrometer. The results are shown in Figure 42, where the black line represents sucrose and the red line represents pear-derived particles. As shown, no peak absorption was found in the tested range, and both particles and sucrose showed higher absorption at smaller wavelengths.

[0385] Due to the high absorbance at 320 nm, the absorbance of the above continuous dilutions was analyzed using 320 nm light. The results are shown in Figure 43. As shown, a gentler nonlinear deviation occurred. Linear fitting down to a powder concentration of 5% yielded an R² of 0.99, a slope of 0.2, and a y-intercept of 0.05.

[0386] conclusion These preliminary results indicate that a standard curve can be created for determining the concentration of cellulose particles in a sample using particle concentrations up to 5%. [Examples]

[0387] Extrusion force of various carriers containing cellulose particles This study aimed to investigate the effects of the carrier and other variables on the extrusion force of the dermal filler described herein.

[0388] Four formulations were prepared for testing, and their details are shown in Table 13 below. The lyophilized, decellularized apple particles used in the formulations were pulverized into flakes using a Retsch pulverizer and an 80 μm filter. The flakes were then wet-sieved using Gilson sieves and a Gilson Test Vibrator, soldered to 45 μm and 25 μm specifications. The filtered particles were concentrated by centrifugation at 5000 rpm for 7 minutes.

[0389] [Table 15]

[0390] Please note that the gelatin and alginate preparations were melted by heating them to 37°C in a water bath before use.

[0391] For the test, an extrusion distance of 5 mm was selected. The initial load volume of the syringe used was 0.3 mL, which corresponds to a plunger crosshead displacement of 5 mm. Since the formulation is a viscoelastic fluid, the compression rate or extrusion rate affects the measured extrusion force. The effects of extrusion rates of 1 mm / s, 2.5 mm / s, and 5 mm / s (also called crosshead rates) were investigated along with the effects of different needle sizes, namely 27G and 30G needles.

[0392] result The extrusion force of the HAAA formulation was measured at a crosshead speed of 1 mm / s. The force-displacement curve for N=14 extrusions is shown in Figure 44. The needle size was 27G.

[0393] Since the extrusion rate affects the apparent force, defining the extrusion rate is considered useful to facilitate comparison between the dermal fillers described herein and conventional dermal fillers. The extrusion characteristics of BellaFill are shown in Table 14 below.

[0394] [Table 16]

[0395] Figure 45 shows a complementary force-displacement plot of the BellaFill extrusion force when passing through 26G at 0.48 mm / s.

[0396] Similar results were observed for the HAAA formulation. Another run using HAAA is shown in Figure 46. In this run, the HAAA differed from the above because the HA concentration was 4.8% and the particle concentration was 28% due to the addition of a crosslinking agent and particles. The crosshead speeds were set to 1 mm / s (solid line), 2.5 mm / s (dashed line), and 5 mm / s (dotted line). As shown, the force increased with speed, and no plateau was observed at the highest speed. Furthermore, the initial force peak observed at medium speeds was absent in the extrusion at low speeds. While not bound by any particular theory, the absence of the peak may be due to the velocity-responding fluid during shearing of the syringe and needle.

[0397] The extrusion force of GE samples was measured at a crosshead speed of 1 mm / s and compared using a 27G needle and a 30G needle. The results are shown in Figure 47, where Figure 47A shows the GE extrusion force through the 27G needle and Figure 47B shows the GE extrusion force through the 30G needle. The measured maximum extrusion forces are shown in Table 15.

[0398] [Table 17]

[0399] The smaller the needle, the significantly higher the maximum extrusion force.

[0400] For the GEAA sample, the extrusion force was measured at an extrusion rate of 1 mm / s using a 27G needle. The results are shown in Figure 48. The maximum extrusion force measured is shown in Table 16 below. As shown, the extrusion force of the GE formulation significantly increased with the inclusion of particles. It should also be noted that the results for the GEAA formulation were not significantly different from those for HAAA.

[0401] To directly compare the results of the GE and GEAA formulations, the GE formulation was diluted to 20% (m / v). The diluted GE formulation was kept warm before extrusion by maintaining the formulation in a 37°C water bath. The temperature at extrusion was approximately 24.5°C, and the results of the diluted GE extrusion are shown in Figure 49A. As shown, the diluted GE exhibited a “classic” extrusion force curve, with an initial peak followed by a plateau.

[0402] Since gelatin gelation is temperature-dependent, the extrusion force of the diluted GE formulation was also measured at room temperature (approximately 21°C) using the same operating parameters. The results are shown in Figure 49B. As shown, the diluted GE formulation at room temperature, which did not contain particles, had a higher extrusion force than both the heated diluted GE formulation and the GEAA formulation. A comparison of the maximum extrusion forces is shown in Table 16.

[0403] [Table 18]

[0404] The extrusion force of the AL formulation was measured using a 27G needle and an extrusion speed of 1 mm / s. The results are shown in Figure 50.

[0405] Therefore, the extrusion force of the skin fillers described herein may be affected by the carrier used, the concentration of the carrier, and the extrusion rate. [Examples]

[0406] Comparison of wet and dry masses of decellularized tissue processed by Marcel. Decellularized apples were added to 1M NaOH in a ratio of 1:5 (m / v) to produce marcel-processed apples (AA). Marcel processing was carried out at 80°C for 1 hour with stirring, and hydrogen peroxide (30% pre-prepared solution) was added to lighten the color. After the reaction was complete, the beaker was removed from the heat source and neutralized with HCl. This material was concentrated by centrifugation using a Sorvall ST 16 R centrifuge or an Avanti J-26XPI high-performance centrifuge. The supernatant was then removed, and the pellet of marcel-processed AA material was resuspended in water. The neutralization and centrifugation process was repeated in a continuous cycle until the pH was maintained between 6.8 and 7.2. After neutralization, final centrifugation was performed, and the material was collected in a 50 mL Falcon tube and then stored in a refrigerator.

[0407] Comparison of wet mass and dry mass Approximately 1 g of three different batches of mercerized AA material was weighed. The weighed samples were frozen at -20°C and then freeze-dried in a LabConco freeze-dryer at 55 mbar and -46°C for 24 hours. The samples were weighed again after drying. The results are summarized in Table 17 below.

[0408] [Table 19]

[0409] Despite having the same wet mass, the final dry masses differed for the Marcel-processed AA materials. The average dry mass was 0.052 ± 0.005 g (mean ± standard error of the mean). The variability in dry mass yield may be due to variations in the wetness of the starting materials, the use of different centrifuges, and / or the location where the sample material was taken on the pellet. [Examples]

[0410] The effect of centrifugal processing on the density of mercerized apples Two batches of mercerized AA were prepared using the same process outlined in Example 10, except that 0.75 L volumes of both batches were placed in 1 L Avanti centrifuge bottles and centrifuged using an Avanti centrifuge (8000 rpm, 15 minutes). During centrifugation, the volume was kept constant to normalize the packing force as much as possible. Subsequently, the total volume of 50 mL was placed in a 50 mL tube and one batch was centrifuged using a Sorvall Benchtop Centrifuge (5000 rpm, 15 minutes).

[0411] After preparation, batch 1, which underwent further centrifugation, produced approximately 3.5 50mL tubes worth of material, while batch 2, which did not undergo further centrifugation, produced approximately 2.5 50mL tubes worth. Therefore, the densities differed.

[0412] To quantify the change in density, a 0.5 mL sample volume, measured with a 1 cc syringe, was extruded into a pre-weighed 15 mL Falcon tube. The mass was then recorded (wet mass). Next, the tube was placed in a -20°C freezer. Once frozen, the sample was loaded into a Buchi freeze-dryer and left overnight at 0.1 mbar and -55°C. The next day, the mass of the tube containing the dried material was recorded. The recorded mass and calculated mass are shown in Table 18 below.

[0413] [Table 20]

[0414] Therefore, changing the centrifuge parameters can affect the density of the mercerized AA material produced. Such changes can affect the mixing ability, rheological properties, and extrusion force of the mercerized AA material. [Examples]

[0415] Mass density and dry mass percentage of mercerized apples under set centrifugal processing conditions. Marcel-processed AA samples were prepared according to the procedure outlined in Example 10. Note that the marcel-processed AA material was concentrated (pelletized) for 15 minutes at 8000 RPM using only an Avanti centrifuge.

[0416] The wet mass of the mercerized AA material was recorded for each sample. The material was then transferred to a 15 mL Falcon tube. The weight of the tube, cap, and mercerized AA material was recorded.

[0417] Next, the sample was frozen at -20°C and loaded into a Buchi freeze-dryer at 0.1 mbar and -55°C. The sample was removed after 24 hours. The masses of the tube, lid, and sample were recorded as having subtractible masses, making it possible to calculate the amount of mercerized dried AA material in case of material loss when the dried AA material was removed from the tube.

[0418] Finally, the mercerized dried AA material was removed and weighed. The mass measurements are shown in Table 19 below.

[0419] [Table 21]

[0420] The dry mass was used to calculate the percentage of the wet mass relative to the dry mass. The results are shown in Table 20.

[0421] [Table 22]

[0422] Therefore, the mean dry mass percentage was 3.78, the standard deviation was 1.20, and the standard error was 0.54.

[0423] In addition to the dry mass percentage, the mass density of the samples was also calculated. To calculate the mass density, 1 mL of mercerized wet AA material was loaded into a syringe and extruded from each sample. The results are shown in Table 21.

[0424] [Table 23]

[0425] Therefore, the mean density was 0.92, the standard deviation was 0.03, and the standard error was 0.02.

[0426] The calculated density was consistent with semi-quantitative observations made during the preparation of the mercerized AA material, with a 50 mL Falcon tube containing approximately 50 g of material. This means that the mass density of the mercerized wet AA material is similar to that of water. Therefore, measuring the wet density alone may be insufficient to determine the concentration of the mercerized AA material. The freeze-dried dry mass can be used instead of the wet mass, or in combination with the wet mass.

[0427] conclusion The results of this embodiment can be used for quality assurance when upscaling the method of this disclosure. This data can be used to standardize, for example, the amount of mercerized material contained in a particular product.

[0428] Similarly, these results may affect future standard operating procedures (SOPs) when upscaling the methods described herein. For example, SOPs may be implemented to reduce mass variations throughout the procedure caused by "dead" head space in the syringe or by mass transfer to, from, or between tubes. [Examples]

[0429] Mass density and dilution of mercerized apples This study aimed to determine whether the dry mass content of mercerized AA could be adjusted by calculating the mass density of the stock material and diluting it accordingly.

[0430] Wet and dry AA samples were prepared according to the procedures outlined in Examples 10 and 12. The samples were then diluted. The masses of the samples during preparation and before and after dilution are shown in Table 22 below.

[0431] [Table 24]

[0432] Next, as shown in Table 22, the density of the sample was calculated as the dry mass % of the original wet mass. Thus, it is clear that the density of the mercel-processed cellulose materials described herein can be adjusted through dilution.

[0433] Furthermore, as shown above, dilution by increasing washing with water and centrifugation in distilled water resulted in the production of mercel-processed AA material with lower density after centrifugation. However, it was also found that incubation of the sample with PBS before the final centrifugation could restore the initially observed density of the sample. The effect of PBS on the density of the mercel-processed AA sample is shown in Figure 51.

[0434] Qualitatively, densities of approximately 4% to 5% or higher appeared to be suitable for use in skin fillers. [Examples]

[0435] The relationship between NaOH and apples during the mercerization process. This study aimed to investigate the appropriate mass / volume ratio of AA material to NaOH solution for AA merceleration. More specifically, the merceleration procedure generally uses a ratio of 1:5 for decellularized AA to 1M NaOH. This study aimed to determine the minimum ratio of AA material to NaOH solution that yields merceleration AA with a sufficiently small particle size suitable for use in skin fillers.

[0436] The experimental protocol is as follows: 1. Decellularized AA was divided into three portions and weighed: 20g, 50g, and 100g. All AA material was pressurized to remove excess moisture. 2. Three 1L beakers were filled with 100mL of 1M NaOH and placed on a magnetic stirring plate. 3. All solutions were heated to 80°C; then a stirring bar and a portion of the decellularized AA were added to each, and the solutions were appropriately labeled according to the weight of the AA added. 4. 5 mL of 30% hydrogen peroxide (H2O2) was added to each beaker. 5. All three solutions were stirred at 80°C for 1 hour. 6. After mercerization, each beaker was removed from the hot plate and allowed to cool completely to room temperature. 7. Once cooled, all three solutions were neutralized and centrifuged separately until a stable, neutral pH was obtained (pH range: 6.8–7.2). 8. The three tested conditions (i.e., 20g of AA in 100mL of NaOH, 50g of AA in 100mL of NaOH, and 100g of AA in 100mL of NaOH) were stored separately in 50mL Falcon tubes in the refrigerator for subsequent microscopic examination. 9. For particle analysis, each of the three conditions involving AA and NaOH was resuspended in distilled water, stained with Congo Red for 10 minutes, and mounted on microscopic slides. 10. Using an SZX 16 Olympus microscope, slides were imaged at 2.5x magnification using fluorescence microscopy (BV light filter).

[0437] Microscopic images are shown in Figure 52, where Figure 52A represents an AA:NaOH ratio of 1:5, Figure 52B represents an AA:NaOH ratio of 1:2, and Figure 52C represents an AA:NaOH ratio of 1:1. As shown, a 1:1 ratio of AA to NaOH is sufficient to achieve mercel processing. Similarly, while some larger particles were present in the cases of AA:NaOH ratios of 1:1 and 1:2, these were generally rare throughout the images.

[0438] Microscope images were thresholded and segmented using Fiji ImageJ. After conversion to binary, a watershed filter was applied to the images. Ferret diameter was calculated using the Analyze Particles plugin. The results are shown in Figure 53. As shown, the particle size histograms were similar across three different AA:NaOH ratios.

[0439] Furthermore, ANOVA analysis was also performed using Tukey post-hoc analysis at a significance level of 0.05. The results are shown in Tables 23 and 24.

[0440] [Table 25]

[0441] [Table 26]

[0442] Thus, although the size distributions were qualitatively similar, the mean values ​​of the three distributions differed statistically from each other. The variance test did not show a significant difference, suggesting that the difference in means may be due to actual differences, limited sample size, high concentration aggregation of AA samples, or variability in the starting apple material.

[0443] From the above perspective, for mercel processing, ratios of AA:NaOH of 1:1 and 1:2 may be used, but a ratio of 1:5 may be optimal, at least in some cases, because the viscosity of the solution is lowest. Similar results may be obtained with higher concentrations of AA, but it should be noted that mixing may be more difficult. [Examples]

[0444] Removal of small particles from mercerized apples This study aimed to investigate the removal of smaller particles (e.g., less than 20 μm) during particle filtration of mercerized materials.

[0445] In this study, unfiltered, crushed, decellularized pear particles were mixed with mercerized, decellularized AA material because pear particles generally contain more particles smaller than 20 μm than apple particles.

[0446] 10 mL of mercerized AA was mixed with 10 mL of unfiltered, decellularized pear powder. The sample was diluted with distilled water to a final volume of 750 mL.

[0447] The test was conducted according to the following procedure. 1. Prepare the mixture. 2. Collect aliquots for staining and imaging. 3. Centrifuge the material in an Avanti centrifuge (at 8000 RPM for 15 minutes) to form pellets. 4. Collect aliquots from the supernatant for staining and imaging. 5. Remove the supernatant. 6. Collect aliquots from the pellet for staining and imaging. 7. The pellets are sieved using an autoclavable 45 μm Gilson sieve and a vibrator, filtered, and washed three times with 150 mL of dH2O. 8. Collect aliquots of the sieved material for staining and imaging. 9. The material is concentrated again by centrifugation. 10. Discard the supernatant. 11. Collect samples from the final material for staining and imaging.

[0448] Staining was completed by adding an equal volume of 0.2% Congo Red (0.5 mL) to the sample. Due to variations in concentration, the sample was diluted as needed. Stained particles were imaged at 2.5x and 10x magnification using an SZX16 stereomicroscope through a BV filter. The images were analyzed using Fiji ImageJ.

[0449] Images with N=20 per condition were stacked. The stacks were converted to binary, and the brightness and contrast settings were appropriately adjusted. A Gaussian filter was applied to segment the images without introducing pseudo-noise (2px for 2.5x and 5px for 10x). The Analyze Particles plugin was used. For the 2.5x images, the particle size limit was not applied due to the small size of the pixels. For the 10x images, the lower limit was set to single-pixel noise (0.8μm). 2 The setting was changed to ). Ferret diameter was used as the particle size scale.

[0450] result Figure 54 shows microscopic images of the mixture of AA and pear powder (before centrifugation) that had been initially processed by Marcel and stained with Congo red. Figure 54A shows a microscopic image at the 500 μm scale, and Figure 54B shows a microscopic image at the 100 μm scale. As shown, particles with a size of less than 20 μm were observed. As discussed above, this was expected from the addition of pear powder.

[0451] Figure 55 shows microscopic images of the Congo red-stained supernatant collected after the initial centrifugation of the mixture, with Figure 55A showing a 500 μm scale microscopic image and Figure 55B showing a 100 μm scale microscopic image. As shown, the supernatant contained small particles that were not concentrated in the pellet.

[0452] Figure 56 shows microscopic images stained with Congo red of the pellets formed after the initial centrifugation of the mixture, with Figure 56A showing a microscopic image at the 500 μm scale and Figure 56B showing a microscopic image at the 100 μm scale. As shown, particles with a size of less than 20 μm were observed, similar to the initial mixture.

[0453] Figure 57 shows microscopic images of the pellets after sieving the sample, stained with Congo red. Figure 57A shows a microscopic image at a 500 μm scale, and Figure 57B shows a microscopic image at a 100 μm scale. As shown, only a few particles with a size of less than 20 μm were observed.

[0454] Figure 58 shows microscopic images of the pellet sample after final centrifugation, stained with Congo red. Figure 58A shows a microscopic image at a 500 μm scale, and Figure 58B shows a microscopic image at a 100 μm scale. As shown, only a few particles smaller than 20 μm were observed. Note the large particle size distribution due to the presence of two different materials in the mixture.

[0455] Figure 59 shows the particle distribution of each microscopic image acquired at 2.5x magnification, presented as the relative frequency of ferret diameter of the particles. Figure 60 shows the particle size distribution of each microscopic image acquired at 2.5x magnification, with Figure 60A showing the particle size distribution of the pellet after the final centrifugation, Figure 60B showing the particle size distribution of the sieved pellet, Figure 60C showing the particle size distribution of the particles after the initial centrifugation, Figure 60D showing the particle size distribution of the supernatant, and Figure 60E showing the particle size distribution of the initial mixture.

[0456] Figure 61 shows the particle distribution of each microscopic image acquired at 10x magnification, presented as the relative frequency of ferret diameter of the particles. Figure 62 shows the particle distribution of each microscopic image acquired at 10x magnification, with Figure 62A showing the particle size distribution of the pellet after the final centrifugation, Figure 62B showing the particle size distribution of the sieved pellet, Figure 62C showing the particle size distribution of the pellet after the initial centrifugation, Figure 62D showing the particle size distribution of the supernatant, and Figure 62E showing the particle size distribution of the initial mixture.

[0457] As shown, the presence of particles smaller than 20 μm was significantly reduced after sieving. It appears that post-sieving centrifugation does not generate many small particles. Furthermore, the supernatant sample contained small particles. Therefore, centrifugation may be useful in removing small particles by fractional centrifugation. This conclusion is supported, at least in part, by the 10x magnification image. The 2.5x magnification image has a larger N-value; however, the single pixel size of the 2.5x magnification image is 12.25 μm. 2 Therefore, image interpolation with 10x magnification is useful.

[0458] Furthermore, it should be noted that this distribution does not coincide with the distribution of the pure material. Since this experiment included a mixture of two components, a bimodal distribution was expected.

[0459] The percentage of particles with a size of less than 20 μm was also calculated and is shown in Table 24.

[0460] [Table 27]

[0461] Thus, it is clear that the method of this disclosure may be effective in removing smaller particles that may be unsuitable for use in dermal fillers. [Examples]

[0462] Particle size after extrusion of mercerized material This study aimed to examine the particle size of mercerized, decellularized plant tissue before and after extrusion through a syringe.

[0463] Undiluted, mercerized AA material, prepared using the procedure outlined in Example 10, was loaded into a syringe by backfilling the material after removing the plunger shaft. Once the material had moved, the plunger was inserted and the 27G needle was secured to the syringe. Next, the plunger was removed from the second syringe, and the material was pushed out through the 27G needle using the first syringe. This step was performed to remove any large pieces of material that could clog the needle.

[0464] The AA material was stained with Congo Red to a final concentration of 0.1%. To perform the staining, 1 mL of AA material was combined with 1 mL of 0.22 μm filtered 0.2% Congo Red using an F / F Luer lock coupler. The solutions were mixed by passing the bottle back and forth 30 times. The stained solution was left to stand and incubated at room temperature for 10 minutes. The resulting solution was too concentrated for imaging for particle analysis, so a 1 / 64 dilution with sterile water for washing was used. For the control sample, the AA material was not extruded at all through a 27G needle.

[0465] Using an SZX16 stereomicroscope, samples were imaged at 2.5x magnification through a 2-pixel Gaussian blur filter. Ten individual images of representative regions were collected for both the control (pre-extrusion) and post-extrusion samples.

[0466] For particle analysis, images were imported into Fiji ImageJ and stacked. Preliminary brightness and contrast settings were adjusted. Images were converted to 8-bit files, and then thresholds were set to ensure particle capture. Images were converted to binary, and the watershed plugin was applied. The resulting stacks were analyzed using the Analyze plugin. Ferret diameter was used as the particle size parameter.

[0467] Figure 63 shows the particle size distribution of the AA material before and after extrusion. Table 26 shows the descriptive statistics of the particle size distribution.

[0468] [Table 28]

[0469] Thus, it is clear that extrusion through a 27G needle does not result in an increase in particles with a size of less than 20 μm.

[0470] Furthermore, the percentage of particles smaller than 20 μm was found to be 1% and 0.85% in the pre-extrusion and post-extrusion populations, respectively, which is consistent with conventional skin filler formulations. [Examples]

[0471] The effect of mercerized particle concentration on extrusion force. This study aimed to investigate the effect of the concentration of mercerized particles on the extrusion force of skin fillers.

[0472] Three formulations were tested. Each formulation was prepared in a 5 ml syringe, and 0.3 ml was transferred to a 1 cc syringe. The formulations were thoroughly mixed between the syringes using an interlock connector. The formulations were mixed by transferring them back and forth between the syringes 30 times. A summary of the tested formulations is shown in Table 27.

[0473] [Table 29]

[0474] The extrusion force of the formulations was tested using a Cell Scale Univert device. One 1cc syringe containing one of the formulations was placed inside the device using two clamps fixed to two adjacent retort stands.

[0475] The effects of needle size, syringe type, and extrusion speed were also investigated. For needle size, 27G and 30G needles were fitted to 1cc syringes for comparison. For syringe type comparison, standard 1cc syringes and BellaFill syringes were used to complete the tests. For extrusion speed, the formulation was extruded from a 1cc syringe fitted with a 27G needle at extrusion speeds of 1 mm / s, 2.5 mm / s, and 5 mm / s. These tests were completed using only the Mer100 formulation.

[0476] result Figure 64 shows the results of the extrusion force test. Figure 64A shows the force-displacement curve for extrusion of water from a 1cc syringe N=10, Figure 64B shows the force-displacement curve for extrusion of Mer20Sal80 formulation from a 1cc syringe N=10, and Figure 64C shows the force-displacement curve for extrusion of Mer100 formulation from a 1cc syringe N=10.

[0477] Figure 65 shows the maximum extrusion force recorded for each formulation. Table 28 shows the statistics for the maximum extrusion force.

[0478] [Table 30]

[0479] An ANOVA analysis was performed on the recorded maximum extrusion force, and the results are shown in Table 29.

[0480] [Table 31]

[0481] The plateau extrusion force of the formulation was also analyzed. The plateau extrusion force represents the average extrusion of the formulation, thus excluding the rise in extrusion force as well as the slack in extrusion force after extrusion is complete. For the recorded force-displacement curves, the plateau extrusion force corresponds to a displacement range of approximately 1 mm to approximately 8 mm.

[0482] A comparison of plateau extrusion forces is shown in Figure 66. Descriptive statistics of plateau extrusion forces are shown in Table 29, and their ANOVA analysis is shown in Table 30.

[0483] [Table 32]

[0484] [Table 33]

[0485] Therefore, considering the above, the undiluted mercerized material (i.e., Mer100) has a significantly greater extrusion force than the Mer20Sal80 formulation and the water formulation. Furthermore, there is no significant difference in the extrusion force of the Mer20Sal80 formulation and the water formulation. This means that although the viscosities of the Mer20Sal80 formulation and the water formulation differ slightly, this difference could not be identified by the experiments outlined in this embodiment.

[0486] Figure 67 shows the force-displacement curves of the Mer100 formulation extruded through a 27G needle (blue line) and a 30G needle (red line) at a crosshead speed of 1 mm / s.

[0487] Figure 68 shows the force-displacement curves of the Mer100 formulation extruded through a 27G needle at a crosshead speed of 1 mm / s from a standard 1 cc syringe (blue line) and a BellaFill syringe (black line).

[0488] The maximum extrusion force for the tests performed in Figures 67 and 68 is shown in Figure 69, where "BD syringe" refers to a standard 1cc syringe and "BF syringe" refers to a BellaFill syringe. Descriptive statistics for the maximum extrusion force are shown in Table 31, and their ANOVA analysis is shown in Table 32.

[0489] [Table 34]

[0490] [Table 35]

[0491] One-way ANOVA showed no significant difference in maximum extrusion force between the two syringe types. However, the extrusion force of the 30G needle was significantly higher than that of the 27G needle.

[0492] Figure 70 shows the force-extrusion curves of the Mer100 formulation extruded through a 27G needle at crosshead speeds of 1 mm / s (black line), 2.5 mm / s (blue line), and 5.0 mm / s (red line). The maximum extrusion force for each crosshead speed is shown in Figure 71. Descriptive statistics for the maximum extrusion force for each crosshead speed are shown in Table 33, and their ANOVA analysis is shown in Table 34.

[0493] [Table 36]

[0494] [Table 37]

[0495] As shown, at a crosshead speed of 5 mm / s, the extrusion force was significantly higher than at 1 mm / s and 2.5 mm / s. [Examples]

[0496] Effect of carrier on extrusion force of dermal filler formulations This study aimed to investigate the effect of gelatin on the extrusion force of skin filler formulations.

[0497] Marcel-processed AA was prepared using the procedure outlined in Example 10. The marcel-processed AA material was then loaded into a 3 mL HSW syringe and transferred to a 1 cc syringe using an F / F Luer lock connector. The marcel-processed AA material was then extruded through a 30 G needle into a clean 3 mL syringe, and then through a 27 G needle.

[0498] A 40% (m / v) pre-prepared solution was prepared by adding 1 g of crystalline gelatin (GE) powder to 1.25 mL of non-sterile water. Another 1.25 mL of water was added to the pre-prepared solution. This solution was allowed to swell at room temperature for 1 hour. After swelling, the temperature was raised to 60°C, and the gelatin dissolved within a few minutes. The resulting gelatin remained fluid at 4°C, whereas standard Knox gelatin produced a viscous solution that gelled at temperatures below approximately 30°C.

[0499] Various formulations were prepared using mercerized AA and gelatin. A summary of the formulations is shown in Table 34 below. The formulations were prepared using a gelatin solution loaded into a 3 mL syringe (prepared via pipette). Mercerized AA material was transferred to a 3 mL syringe via a Luer lock connector. Once the mercerized AA material had been transferred, the syringe was discarded, and a new 3 mL syringe was connected to the Luer lock connector. The solution was then passed through the 3 mL syringe 30 times to produce the formulation.

[0500] [Table 38]

[0501] The extrusion force of the formulation was tested using a CellScale UniVert device at a crosshead speed of 1 mm / s. The setup was the same as described in Example 17, except that a support bar was fixed between two stands. Five runs were completed using a compression of 12 mm. The sixth run was completed using a compression of 15 mm.

[0502] BellaFill dermal fillers were also tested as a control. The control was visually and texturally compared to the test gelatin formulations. In general, both BellaFill and the formulations of the present disclosure can be manipulated to form small spheres that retain their shape. Furthermore, the formulations of the present disclosure had a more hydrated feel and were more translucent.

[0503] result Figure 72 shows the force-displacement curves of formulations extruded through a 27G needle at a crosshead speed of 1 mm / s. Figure 72A shows the force-displacement curve for the 5% GE formulation, Figure 72B shows the force-displacement curve for the 2.5% GE formulation, Figure 72C shows the force-displacement curve for the 1% GE formulation, Figure 72D shows the force-displacement curve for the 0.5% GE formulation, and Figure 72E shows the force-displacement curve for the 0.25% GE formulation. The maximum extrusion force for each formulation is shown in Figure 73. Note that the 2.5% GE formulation was used only four times.

[0504] The BellaFill dermal filler tested outperformed the 10N load cell of the UniVert device.

[0505] conclusion As shown, the gelatin concentration did not have a significant effect on the extrusion force of the formulation. Furthermore, the formulation exhibited a lower maximum extrusion force than the BellaFill dermal filler used as a control.

[0506] The observed force-displacement curves were noisier overall than in previous tests. While not bound by any specific theory, we hypothesize that the more rigidly fixed equipment configuration (due to the use of support bars) may be the cause of the noise, as the support bars hindered the bending or flexing of the equipment configuration that would smooth or dampen the curves. [Examples]

[0507] Rheology of dermal fillers as disclosed herein This study aimed to investigate the rheological properties of the dermal filler described herein.

[0508] The mercerized AA material was prepared according to the procedure outlined in Example 10. After preparation, a portion of the mercerized AA material was diluted with water by 50%.

[0509] Vibrational mechanical testing was performed using a CellScale UniVert device equipped with a 1N load cell. The sample was placed in a beaker inside the UniVert device using a clamp.

[0510] A sinusoidal strain (5%) was applied to a Marcel-processed AA sample using periodic compression. The phase angle between stress and strain could be calculated through the vibrational motion. Since strain is a vibrational function, the dynamic modulus was measured. Young's modulus, along with the phase difference, was used to calculate the material's storage modulus and loss modulus.

[0511] result Figure 74 shows stress and strain versus time charts for Marcel-processed AA samples. Figure 74A shows stress and strain versus time charts for undiluted Marcel-processed AA samples, and Figure 74B shows stress and strain versus time charts for diluted Marcel-processed AA samples. The black curves represent measured strain values, and the red curves represent measured stress values.

[0512] As shown, the peak offsets of stress and strain were greater in the diluted samples. Furthermore, the stress amplitude was greater in the undiluted, Marcel-processed AA samples.

[0513] The phase angle was calculated by dividing the time difference between peaks by the period of each cycle, which corresponds to 2π radians. The real component (storage modulus or modulus) and the imaginary component (loss modulus) were obtained by multiplying the value of the complex dynamic modulus (stress amplitude for each frequency) by cos(δ) or sin(δ), respectively. The loss coefficient was also calculated as tan(δ) from the phase shift.

[0514] Figure 75 shows the storage modulus, loss modulus, and loss coefficient curves for each sample. Figure 75A shows the storage modulus (E'; black line) and loss modulus (E''; gray line) of the undiluted Marcel-processed AA sample, Figure 75B shows the loss coefficient curve of the undiluted Marcel-processed AA sample, Figure 75C shows the storage modulus (E'; black line) and loss modulus (E''; gray line) of the diluted Marcel-processed AA sample, and Figure 75D shows the loss coefficient curve of the diluted Marcel-processed AA sample.

[0515] As shown, the storage modulus and loss modulus are linear in the low-frequency range for the undiluted sample, which suggests that the measurements were performed in the linear viscoelastic region (LVR), and the material may be characterized as primarily an elastic solid. For the diluted sample, a slight increase in storage modulus and loss modulus was observed with increasing low-frequency range.

[0516] Furthermore, both the undiluted and diluted Marcel-processed AA samples exhibited primarily elasticity at the tested frequencies and strains, while the diluted samples showed a greater fluid contribution.

[0517] In addition, the viscosity of the samples was tested using a helical path t-bar spindle viscometer. Each sample was found to have a viscosity ranging from approximately 100,000 cp to approximately 200,000 cp. [Examples]

[0518] Stability of mercerized tissue materials This study aimed to investigate the time-dependent stability of mercerized microstructure materials.

[0519] Marcel-processed, decellularized AA was prepared according to the procedure outlined in Example 10 above, except that after extruding the material through a 27G needle, it was sieved using a Gilson SS 23 Test Sieve Vibrator with an autoclavable, soldered 45 μm sieve and washed three times with 150 mL of distilled water. 0.5 mL of mercel-processed AA material and 0.5 mL of 0.2% Congo Red were mixed by passing them back and forth 30 times between two 3 mL syringes connected via an F / F Luer lock connector. The resulting mixture was diluted with 7 mL of water and further mixed 30 times between interconnected 20 mL syringes.

[0520] Next, the contents of the mixture were divided equally into two 15 mL Falcon tubes. One tube was stored in a refrigerator at 4°C (control), while the other tube was placed in a Thermo Scientific shaking incubator at 40°C and 120 RPM to accelerate sample aging. The two tubes were kept untouched for 5 days.

[0521] Aliquotes of the sample contained in each tube were taken and used for imaging with an SZX16 stereomicroscope at 2.5x and 10x magnification. The images were then analyzed with Fiji ImageJ. The 2.5x images were stacked and converted to 8-bit. The initial brightness and contrast settings of the images were adjusted, and a 2px Gaussian blur was applied to the images. A threshold was then set on the images, and a watershed effect was applied. Particles in the images were analyzed using the Analyze Particles plugin without size limitations.

[0522] result Figure 76 shows microscopic images of the analyzed samples; Figure 76A shows a microscopic image of a sample stored at 4°C, and Figure 76B shows a microscopic image of a sample maintained in a shaking incubator. The particle size distribution of the samples was determined and is shown in Figure 77, where the gray bars represent the particle size distribution of the sample stored at 4°C, and the black bars represent the particle size distribution of the sample maintained in the shaking incubator.

[0523] As shown, the distributions were similar. Samples maintained in a shaking incubator showed small shoulder peaks for 30–50 μm particles, but the percentage of particles smaller than 20 μm remained low (1.62%).

[0524] The circularity of the particles was also analyzed. The circularity parameter C is given by C = 4πA / P 2 It is defined as follows, where A is the area and P is the perimeter. A value of C of 1 represents a perfect circle, and a value close to 0 represents an increase in shape elongation. Also, the roundness of the particle R = 4A / (πR m 2 ) also evaluates, and here R m is the principal axis of the fitted ellipse. Similar to the roundness ratio, the value ranges from 0 to 1, with a value of 1 being a perfect circle. The results are shown in Figure 78, where Figure 78A shows the roundness ratio distribution of particles from samples stored at 4°C (gray bars) and samples maintained in a shaking incubator (black bars), and Figure 78B shows the roundness distribution of particles from samples stored at 4°C (gray bars) and samples maintained in a shaking incubator (black bars).

[0525] As shown, the particles in both samples are fairly round and quite spherical.

[0526] Therefore, the particles in both samples have a similar distribution of particle size and shape, which means that the particles do not expand or change shape over time. [Examples]

[0527] Microbiological testing of the dermal fillers disclosed herein This study aimed to investigate the sterilization cycle of the method for producing the skin filler described herein.

[0528] Marcel-processed, decellularized AA material was prepared according to the procedure outlined in Example 10. A portion of the marcel-processed AA material was mixed with lidocaine and gelatin as previously described herein to form a skin filler, which was degassed for 15 minutes and then loaded from the front into a commercially available 1 cc syringe using a Luer lock connector. The syringe was autoclaved for 3 minutes in a wet cycle at 130°C or 135°C.

[0529] Two agar media, Sabouraud Dextrose Agar (SDA) and Tryptic Soy Agar (TSA), were used. Five plates of each medium were prepared by calculating and adjusting the required volume (final volume 200 ml) of the medium in a 100 mm × 16 mm dish. The composition of each medium is shown in Table 35.

[0530] [Table 39]

[0531] After autoclaving the culture medium at 121°C for 1 hour, it was cooled in a 60°C water bath, and approximately 15 mL to 30 mL of the medium was poured into a plate in a safety cabinet. The plate filled with the medium was left in the cabinet with the lid half-open until it solidified. Once the medium had solidified, the plate was sealed with paraffin and placed in a sterile refrigerator at 4°C.

[0532] Next, agar plates were prepared under five conditions: an unopened control plate, a plate streaked with skin filler autoclaved at 130°C, a plate streaked with skin filler autoclaved at 135°C, a plate streaked with mercerized AA material (unautoclaved), and a streaked control. The streaking pattern used was the standard four-quadrant method.

[0533] After preparation, the TSA plates were incubated at 32.5°C for 5 days, and the SDA plates were incubated at 22.5°C for 7 days.

[0534] result Colonies and growth were observed only on plates streaked with mercerized AA material that had not been autoclaved.

[0535] Therefore, autoclaving cycles of 3 minutes at 130°C and 135°C were sufficient to sterilize the syringes. In unopened controls, the pouring technique was confirmed to be sterile. Streak controls verified that any contamination that occurred was likely due to the mercerized AA material or skin filler, rather than the environment or the pouring technique.

[0536] Furthermore, autoclave sterilization of mercerized AA material was observed to cause slight yellowing of the material. While not bound by any specific theory, it is hypothesized that the yellowing may be a result of caramelization of reducing sugars present in the mercerized AA material. [Examples]

[0537] SDS Quantification in Skin Fillers of the Disclosure This study aimed to determine the amount of residual SDS in the dermal filler of this disclosure.

[0538] The residual SDS content was determined using the Bio Basic Residual SDS Detection Kit. This kit has an operating range of 0.002% to 0.014% SDS. The analysis was performed using spectrophotometric methods.

[0539] The experimental protocol is outlined below.

[0540] standard curve The experimental values ​​for SDS refer to a standard curve created from SDS of known concentrations: 1. Weigh 0.1 g of SDS powder and add it to 10 mL of dH2O to prepare a 0.1% solution for standard preparation. 2. For SDS estimation, calibration plots are created with known SDS concentrations in the range of 0.002% to 0.014%, as shown in Table 36.

[0541] [Table 40]

[0542] 3. Transfer 50 μL from each of the SDS solutions into eight new 2 mL microcentrifuge tubes. 4. Add 50 μL of Solution A (from the kit) to the tube from step 3. Mix thoroughly. 5. Add 1.5 mL of Solution B (from the kit) to each tube from step 3, and let stand for 30 seconds. -1 Mix vigorously by vortexing for several minutes. 6. Let stand at room temperature for 5 minutes. Centrifuge at 5000 rpm (2000 × g) for 5 minutes. 7. Transfer 150 μL of the supernatant to a 96-well plate. 8. Blank the microplate reader, then measure the optical density at OD 499 nm. 9. Draw a standard curve with the x-axis representing the % SDS concentration and the y-axis representing the OD 499nm reading.

[0543] Detection of SDS in the sample 1. Dilute the sample appropriately so that the SDS estimate falls within the range of the standard curve. Prepare three 2.2 mL microcentrifuge tubes. Add 50 μL of diluted sample to tubes 1 and 2. Add 50 μL of dH2O to the third tube as a blank control. 3. Add 50 μL of solution A to the tube from step 2. Mix thoroughly. 4. Add 1.5 mL of Solution B (from the kit) to each tube and let stand for 30 seconds. -1 Mix vigorously using a vortexing method for several minutes. 5. Let stand at room temperature for 5 minutes. Centrifuge at 5000 rpm (2000 × g) for 5 minutes. 6. Transfer 150 μL of the supernatant to a 96-well plate. 7. Blank the microplate reader, then measure the optical density at OD 499 nm. 8. Use the standard curve to obtain the percentage of SDS in the diluted sample. The SDS concentration in the sample is obtained using the following formula: % of SDS in the sample = (percentage of diluted sample) (dilution factor)

[0544] Preparation of decellularized materials While not bound by any particular theory, it is assumed that SDS quantification is best suited for decellularized materials, rather than mercel-processed decellularized materials.

[0545] Decellularized AA material was prepared according to the procedure outlined in Example 5. The SDS content was analyzed at various time points throughout the procedure.

[0546] result The standard curve was created using the following data obtained from known SDS solutions.

[0547] [Table 41]

[0548] The linear fit of the standard curve was R² = 0.997. The linear fit equation was y = 23.952x - 0.0067.

[0549] This curve was used to detect the SDS content in decellularized AA samples. • Repeated tests of 3 samples using a 1:10 dilution of SDS solution for decellularization (0.10 ± 0.01), with N=3. • 1:10 dilution from the liquid phase of decellularized AA material after CaCl2 incubation, subsequent washing, and 72-hour incubation = undetectable. • Undiluted liquid phase of decellularized material after CaCl2 incubation, subsequent washing, and 72-hour incubation = 0.008% or 80 ppm.

[0550] Thus, the SDS content of the decellularized samples was sufficiently low. Furthermore, the SDS content is expected to decrease further during the mercerization process due to the multiple centrifugation and washing steps involved. [Examples]

[0551] Quantitative determination of peroxides in the skin filler of this disclosure This study aimed to determine the amount of peroxide remaining in the skin filler of this disclosure.

[0552] To test the peroxide content, Bartovation test strips (0–100 ppm) were immersed in mercerized apple material produced according to the procedure outlined in Example 10. Typically, the test strip was immersed in the material for 1 second, and any excess material was shaken off. After 10 seconds, the color of the strip was compared to calibrated test pads, which were calibrated color indicators for 0 ppm, 1 ppm, 3 ppm, 10 ppm, 50 ppm, and 100 ppm.

[0553] Four batches of mercerized AA were produced and tested. The peroxide content of the first batch was 1 ppm to 3 ppm, the peroxide content of the second batch was approximately 3 ppm, the peroxide content of the third batch was approximately 0 ppm, and the peroxide content of the fourth batch was approximately 0 ppm. Overall, it was found that the peroxide content decreased with each washing and centrifugation cycle.

[0554] To verify the above results, a spike test was also conducted. The spike test involved spike-dosing one batch of mercerized AA with approximately 10 ppm of hydrogen peroxide. The peroxide content of the spike-doped sample was approximately 10 ppm, indicating that the test was successful and the results were valid. [Examples]

[0555] Peroxide concentration suitable for bleaching This study aimed to determine the range of peroxide concentrations suitable for bleaching decellularized materials.

[0556] Decellularized AA material was mercerized using the procedure outlined in Example 10 above. In this experiment, the volume of hydrogen peroxide was changed to 25 mL.

[0557] In the first trial, 50 mL of hydrogen peroxide was used for bleaching when producing mercerized AA. The color of the AA material became lighter, but it was not completely bleached.

[0558] In the second trial, when 75 mL of hydrogen peroxide was used for bleaching during the production of mercerized AA, the AA material was sufficiently bleached.

[0559] In the third trial, 150 mL of hydrogen peroxide was used for bleaching when producing mercerized AA. Although the AA material was sufficiently bleached, further centrifugal cycles were required to reduce the peroxide content of the AA material to less than 10 ppm. [Examples]

[0560] pH of components of skin fillers This study aimed to determine the pH of each component of the dermal filler of this disclosure in order to evaluate its effect on the overall pH of the dermal filler.

[0561] Table 38 shows the pH levels of the components of the dermal filler of this disclosure:

[0562] [Table 42]

[0563] In some embodiments, the target pH range for dermal fillers is approximately 6.5 to 7.5. While not bound by any particular theory, it is hypothesized that PBS may maintain the pH of mercerized AA within that range. [Examples]

[0564] Enzymatic degradation of the dermal filler of this disclosure This study aimed to investigate enzymes capable of degrading the dermal fillers of this disclosure. As described above, the dermal fillers of this disclosure are considered permanent in that the human body does not naturally produce enzymes capable of degrading them. However, it may be recognized that in some cases it is desirable to remove permanent dermal fillers. One method for removing permanent dermal fillers is thought to be enzymatic degradation using enzymes that are not produced in the human body.

[0565] Chemicals and Equipment 3,5-Dinitrosalicylic acid (DNSA) and D-(+)-glucose were obtained from Alfa Aesar (Canada). Sodium sulfite was obtained from ANKOM Technologies (USA). Acetic acid, Congo Red, sodium acetate trihydrate, sodium hydroxide, and phosphate-buffered saline (PBS) were obtained from Fisher Scientific (Canada). Sodium potassium tartrate tetrahydrate was obtained from Acros Organics (Canada). The enzymes used were cellulase and pectinase derived from Aspergillus niger from TCI America (USA), cellulase derived from Trichoderma sp. from Sigma (Canada), and Macerozyme R-10 derived from Rhizopus sp. from Plantmedia (USA). The investigation was conducted using a benchtop pH meter (Sartorius), a Synergy Mx spectrometer (BioTek), a MaxQ stirring incubator (Thermo Scientific), and an SZX16 stereomicroscope with a fluorescence filter (Olympus).

[0566] Preparation of reagents and solutions Dinitrosalicylic acid reagent 1% (DNSA reagent) was prepared by dissolving 10 g of DNSA, 500 mg of sodium sulfite, and 10 g of sodium hydroxide (NaOH) in 1 L of distilled water and stored at room temperature. 40% potassium sodium tartrate solution (Rochelle salt) was prepared by dissolving 40 g of potassium sodium tartrate tetrahydrate in 100 mL of distilled water and stored at room temperature. Sodium citrate buffer (50 mM) was prepared by diluting 50 mL of 100 mM sodium citrate with distilled water to a final volume of 100 mL, adjusting the pH to 6, and storing at room temperature. Sodium acetate buffer (100 mM) was prepared by dissolving 1.3 g of sodium acetate and 5 mg of acetic acid in 100 mL of distilled water, adjusting the pH to 6, and storing at room temperature. PBS buffer 1X was prepared by diluting 10 mL of 10× PBS with distilled water to a final volume of 100 mL and stored at room temperature. Enzyme pre-preparations were prepared in various buffer solutions at the same enzyme concentration of 1 mg / mL and stored at 4°C. The 0.1% Congo red staining solution was prepared by dissolving it in distilled water; the solution was filtered through a 0.45 μm syringe filter to remove precipitate and stored at 4°C.

[0567] Glucose standard curve The DNSA method quantifies the amount of glucose produced in a solution by colorimetric analysis. This method is used to confirm the presence of free carboxyl groups (C=0) caused by reducing sugars such as glucose. When the aldehyde functional group present in glucose is oxidized, it reacts with DNSA and is reduced to 3-amino-S-nitrosalicylic acid (ANSA), causing the solution to turn reddish-brown. Using a 10 mg / ml pre-prepared solution of D-glucose in distilled water, standard curves were created for concentrations of 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 mg / ml. Using the DNSA reagent method and the HIMEDIA protocol, a standard curve for glucose production by the degradation of cellulose-based skin fillers can be established. The D-glucose pre-prepared solution was diluted to concentrations from 0.1 mg / mL to 10 mg / mL, and 200 μL of the standard was dispensed. 0.5 mL of DNSA reagent was added to the standard, and the sample was boiled (95°C) for 15 minutes. After completion, 0.5 mL of potassium sodium tartrate (40%) was added to the sample and mixed by vortexing. 150 μL of each standard was added to a 96-well plate, and the absorbance at 540 nm was obtained using a Synergy Mx spectrometer.

[0568] Dilution enzyme assays in various buffers This assay was used to determine the optimal buffer and enzyme for the degradation of smaller-scale cellulosic dermal fillers. Enzyme pre-formulations (1 mg / mL) were prepared in different buffers (PBS, sodium acetate, sodium citrate), and 50 μL of the pre-formulation was diluted with 950 μL of the same buffer. 1 mL of cellulosic dermal filler was added to the wells of a 24-well plate, followed by the addition of the diluted enzyme solution to the wells. The plates were placed in a 37°C incubator without agitation for three different timeframes: 1 hour, 24 hours, and 48 hours. 200 μL aliquots were collected from each timeframe and stored at 4°C to inhibit enzyme activity until DNSA analysis. Glucose production was estimated by the DNSA method.

[0569] Dilution pectinase / cellulase ratio assays in various buffers This assay was used to determine the optimal buffers for the degradation of cellulose-based skin fillers by pectinase and cellulase in different ratios. Using pre-prepared pectinase (1 mg / mL) and cellulase (1 mg / mL) solutions in different buffers (PBS, sodium acetate, sodium citrate), pectinase:cellulase ratios of 100:0, 75:25, 50:50, and 25:75 were achieved in a final volume of 50 μL. These solutions were then diluted with 950 μL of the corresponding buffer. 1 mL of cellulose-based skin filler was added to each well of a 24-well plate, followed by the addition of the diluted pectinase and cellulase mixtures to the wells. The plates were incubated at 37°C for 1 hour, 24 hours, and 48 hours without agitation. 200 μL aliquots were collected for each time frame, stored at 4°C, and glucose production was estimated by DNSA.

[0570] Various enzyme concentration assays This assay was used to determine the optimal concentration for complete degradation of cellulose-based dermal fillers in the optimal buffer tested above. Using enzyme pre-preparation (1 mg / mL) in sodium acetate or sodium citrate, the ratios of 100:0, 75:25, 50:50, 25:75, and 0:100 (enzyme:buffer) were determined by diluting to a final volume of 1.2 mL with the corresponding buffer. 0.5 mL of cellulose-based dermal filler was added to a 24-well plate, and solutions of different enzyme concentrations were added to the appropriate wells. The plates were placed in a 37°C incubator for 1 hour, 24 hours, and 48 hours without agitation. After the specified incubation time, 200 μL aliquots were collected from each well and stored at 4°C to inhibit enzyme activity until DNSA analysis. Glucose production was estimated by DNSA, and the degradation of dermal filler particles was visualized by Congo red staining using 2.5x fluorescence microscopy imaging with a SZX16 stereomicroscope using a Blue-Violet filter.

[0571] Concentration assays of various pectinase and cellulase ratios This assay was used to determine the optimal ratio of pectinase and cellulase mixture for complete degradation of cellulose-based skin fillers and to visualize whether the addition of pectinase caused any changes. The selection of buffers used in this assay was based on experimental results using the method in Section 2.4. Using pre-prepared pectinase solution (1 mg / mL) and pre-prepared cellulase solution (1 mg / mL) of sodium acetate or sodium citrate, the required amounts of each solution were combined to a final volume of 1.2 mL, with ratios of 100:0, 75:25, 50:50, 25:75, and 0:100 (pectinase:cellulase). 0.5 mL of cellulose-based skin filler was added to the wells of a 24-well plate, and the pectinase-cellulase solution was added to the appropriate wells. The plates were placed in a 37°C incubator for 1 hour, 24 hours, and 48 hours without agitation. After the specified incubation period, 200 μL aliquots were collected from each well and stored at 4°C to inhibit enzyme activity until DNSA analysis. Glucose production was estimated using the DNSA method, and the degradation of skin filler particles was visualized with Congo red staining using 2.5x fluorescence microscopy imaging with a Blue-Violet filtered SZX16 stereomicroscope.

[0572] Effectiveness of enzymatic degradation at various time points and concentrations. This assay was used to determine whether the efficiency of enzyme solutions prepared in advance and stored at different temperatures changed compared to fresh enzymes. High concentrations of enzyme at 1, 1.5, 2, 2.5, and 3 mg / mL were also tested. In the above assay, solutions were prepared over a period of 2 hours and placed in an ice bath to keep the enzyme solutions fresh. Conversely, the experiment was repeated with solutions kept at 4°C for one week. The enzymes used were cellulase from Trichoderma and a mixture of cellulase from Trichoderma and pectinase from Aspergillus niger in a 25:75 (pectinase:cellulase) ratio in sodium acetate buffer. 1 mL of cellulose-based skin filler was added to each well of a 24-well plate, and the enzyme solution was added to the appropriate wells. The plates were placed in a 37°C incubator for 1 hour, 24 hours, and 48 hours without agitation. After the specified incubation time, 200 μL aliquots were collected from each well and stored at 4°C to inhibit enzyme activity until DNSA analysis. Glucose production was estimated using the DNSA method, and the degradation of skin filler particles was visualized using Congo red staining with 2.5x magnification fluorescence microscopy imaging with a SZX16 stereomicroscope equipped with a blue-violet filter.

[0573] Imaging of microscopic examinations The remaining sample after enzymatic digestion was stained with 0.1% Congo Red solution, and this was used to evaluate whether the particles had been degraded. For image analysis, a 1 / 64 dilution was performed to visualize individual particles. 1 mL of each sample was added to a 24-well plate and imaged at 2.5x magnification using an SZX16 stereomicroscope with a Blue-Violet filter.

[0574] statistical analysis Statistical analysis of the obtained values ​​was performed using two-way ANOVA with Origin 2021 software. All values ​​presented are mean ± standard error (SE). Values ​​considered statistically significant were defined as p < 0.05.

[0575] result Cellulose is a linear polysaccharide in which multiple D-glucose subunits are linked by β-1,4-glycosidic bonds. Cellulase enzymes cleave these bonds, releasing D-glucose subunits. Therefore, a standard curve of D-glucose produced from the enzymatic activity of cellulosic skin fillers was obtained using the DNSA method. The decomposition of cellulosic particles to D-glucose was quantified using the standard curve shown in Figure 79. The concentration of the produced D-glucose can be calculated from the equation obtained from the linear curve: for a wavelength of 540 nm, [D-glucose] = (absorbance + 0.05185) / 0.36664; and for a wavelength of 575 nm, [D-glucose] = (absorbance + 0.01969) / 0.11256.

[0576] Referring to Figure 80, it can be seen that cellulase (T) derived from the genus Trichoderma was the most efficient at converting cellulose to glucose at an incubation temperature of 37°C compared to cellulase (A) derived from Aspergillus niger and macerozyme R-10 (M). This can be explained by the optimal temperature of the enzymes, with the optimal temperature for macerozyme R-10 being between 40°C and 50°C; the optimal temperature for cellulase derived from Aspergillus niger being 30°C, which may significantly reduce its enzymatic activity; and the optimal temperature for cellulase derived from the genus Trichoderma being 40°C, which may explain why Trichoderma was the only enzyme that produced a large amount of glucose. Cellulase T performed better in sodium acetate (ACE) and sodium citrate (CIT) buffers. The control values ​​shown in Figure 80 indicate that only small amounts of D-glucose were present from the cellulosic skin filler in the buffer. This may be caused by the mercerization process, which can break down components of apple cell walls, such as lignin, cellulose, and hemicellulose, into glucose.

[0577] Next, various ratios of pectinase to cellulase were evaluated. Figure 81 shows the analysis of various pectinase:cellulase ratios in different buffers. As shown, with pectinase alone at a ratio of 100:0, little particle degradation occurred. Adding pectinase to cellulase at a ratio of 25:75 with T ACE yielded optimal degradation compared to other samples. While not bound by any particular theory, it is thought that the addition of pectinase may help degrade hemicellulose polymers bound to cellulose microfibrils, potentially resulting in the release of more cellulose that can be used for hydrolysis by cellulase.

[0578] Referring to Figure 82, cellulase T showed high glucose production even at a 25% concentration, indicating that ACE was the optimal buffer. For the other enzymes (A and M), little glucose was produced when compared at different culture times. Figure 83 shows that cellulose particles were completely degraded by both T CIT and T ACE at concentrations from 100% to 50%, and partially degraded at 25%. This means that 1.2 mL of enzyme solution may be able to completely degrade cellulose particles in 0.5 mL of cellulose-based skin filler from concentrations of 100–50%.

[0579] The results of the analysis of different pectinase:cellulase ratios are shown in Figure 84. As shown, the optimal ratio for cellulase T varied depending on the buffer used. For T ACE, the optimal pectinase:cellulase ratio was 25:75, and for T CIT, it was 75:25. The stained microscopy images shown in Figure 85 show the total degradation of T ACE at pectinase:cellulase ratios of 50:50, 25:75, and 0:100. Images of T CIT, which contains pectinase, were not considered because cellulase enzyme was not added to the mixture.

[0580] As shown in Figure 86, when the concentrations of fresh enzyme solutions differed, both in the presence and absence of pectinase, the concentration of D-glucose produced after 48 hours for all different cellulase concentrations plateaued between 12 mg / mL and 16 mg / mL. This plateau may indicate that there was insufficient enzyme for the amount of substrate available. Total degradation of cellulose particles was observed at concentrations of 2.5 mg / mL and 3 mg / mL, both in the presence and absence of pectinase, as shown in Figure 87. Partial degradation of particles was also observed at concentrations of 1.5 and 2 mg / mL in T ACE with pectinase, and at concentrations of 1, 1.5, and 2 mg / mL in T ACE.

[0581] As shown in Figure 88, the differences in concentration of the pre-prepared enzyme solutions showed a gradual peak as the concentration increased, in contrast to the fresh enzyme solution which showed a plateau. D-glucose production was higher with T ACE alone (12.5 mg / mL to 20 mg / mL) compared to 12.5 mg / mL to 15 mg / mL when pectinase was added. By comparing the results with the fresh enzyme solution, it became clear that storage at 4°C for one week did not affect the enzyme activity. This result was as expected, as cellulase can be stored at 4°C for 7.5 months without a decrease in enzyme activity.

[0582] Therefore, among the enzymes tested and the various combinations evaluated herein, the optimal enzyme for degrading the cellulosic skin fillers of this disclosure, both in the presence and absence of pectinase, is cellulase derived from the genus Trichoderma. [Examples]

[0583] In vivo injection of the dermal filler of this disclosure This study aimed to expand upon the results obtained in Example 3. Furthermore, in vivo injections were performed using the dermal filler of this disclosure.

[0584] Three types of skin fillers were prepared: one using a saline carrier, one using a hyaluronic acid (HA) carrier, and one using a collagen carrier. The formulations were prepared using the procedure outlined in Example 3.

[0585] Each of the three formulations was administered by subcutaneous injection to three rats. The injection procedure outlined in Example 3 was followed. Excisions were performed on each rat at weeks 4 and 8. After 12 weeks, two of the rats from each formulation were euthanized, and tissue was collected from them. After one year, the remaining rat was euthanized, and tissue was collected from it.

[0586] result Figure 89 shows examples of excised tissue samples taken from one rat from each formulation test. Figure 89A is an excised tissue sample taken from a rat injected with a saline solution, Figure 89B is an excised tissue sample taken from a rat injected with an HA solution, and Figure 89C is an excised tissue sample taken from a rat injected with a collagen solution.

[0587] The injected preparations were visually evaluated after excision. Generally, the saline preparations were brown in color. The HA preparations were similar in color to the saline preparations, but the morphology of the HA injections appeared "bumpy" or "fragmented" compared to the saline preparations. The collagen fillers remained in a dense oval shape, were white for the first four weeks, and turned brown at later points in time, which may correspond to the time frame of collagen reabsorption in the rat body.

[0588] Samples were collected at various time points after each injection and stained with Masson's tricolor stain (MT) or hematoxylin and eosin (HE), and imaged under a microscope. Microscopic images of each formulation at 12 weeks are shown in Figures 90 to 92.

[0589] Figure 90 shows microscopic images of injected saline solution at 12 weeks. Figure 90A shows a microscopic image of the injected saline solution stained with MT at 1x magnification, Figure 90B shows a microscopic image of the injected saline solution stained with MT at 10x magnification, Figure 90C shows a microscopic image of the injected saline solution stained with MT at 20x magnification, Figure 90D shows a microscopic image of the injected saline solution stained with HE at 1x magnification, Figure 90E shows a microscopic image of the injected saline solution stained with HE at 10x magnification, and Figure 90F shows a microscopic image of the injected saline solution stained with HE at 20x magnification.

[0590] Figure 91 shows microscopic images of HA preparation injections at 12 weeks. Figure 91A shows a microscopic image of the MT-stained injected HA preparation at 1x magnification, Figure 91B shows a microscopic image of the MT-stained injected HA preparation at 10x magnification, Figure 91C shows a microscopic image of the MT-stained injected HA preparation at 20x magnification, Figure 91D shows a microscopic image of the HE-stained injected HA preparation at 1x magnification, Figure 91E shows a microscopic image of the HE-stained injected HA preparation at 10x magnification, and Figure 91F shows a microscopic image of the HE-stained injected HA preparation at 20x magnification.

[0591] Figure 92 shows microscopic images of collagen injections at 12 weeks. Figure 92A shows a microscopic image of the injected collagen stained with MT at 1x magnification, Figure 92B shows a microscopic image of the injected collagen stained with MR at 10x magnification, Figure 92C shows a microscopic image of the injected collagen stained with MT at 20x magnification, Figure 92D shows a microscopic image of the injected collagen stained with HE at 1x magnification, Figure 92E shows a microscopic image of the injected collagen stained with HE at 10x magnification, and Figure 92F shows a microscopic image of the injected collagen stained with HE at 20x magnification.

[0592] Each sample of the injected formulation was also stained with Congo red and examined under a microscope to determine the extent to which rat cells had invaded the skin filler. Invading rat cells were labeled with Hoechst 33342. The results are shown in Figure 93, where Figure 93A shows the injected saline formulation at 10x magnification, Figure 93B shows the injected HA formulation at 10x magnification, and Figure 93C shows the injected collagen formulation at 10x magnification. As shown, considerable rat cell invading occurred in all three formulations at 12 weeks.

[0593] Blood vessels and red blood cells were found in each of the injected formulations. To investigate the angiogenic interaction between rats and the skin filler formulations, the injected formulations were stained with CD31 at 12 weeks. Similarly, the immune response of the rats was evaluated using CD45 staining, and elastin was identified using Verhoeff van Gienson (Verhoeff) staining. The results of each staining are shown in Figure 94. As shown, CD31 staining confirmed the formation of blood vessel walls (brown loop structures), and CD45 staining showed the expected immune response to the injected foreign body (brown cytoplasm and blue nuclei). Verhoeff staining did not show a large amount of elastin fibers (black), but collagen fibers (red / pink) were present as expected.

[0594] Histological analysis Histological analysis was also performed at 12 weeks for the injected dermal fillers and commercially available Bellafill dermal fillers. The injected preparations were evaluated according to the ISO 10993-6 guidelines, and the results are shown in Table 39 below.

[0595] [Table 43]

[0596] Table 40 details the samples selected for evaluation according to ISO 10993-6.

[0597] [Table 44]

[0598] The results of the ISO 10993-6 evaluation for each of the groups identified in Table 40 are shown in Tables 41 to 43.

[0599] [Table 45]

[0600] [Table 46]

[0601] [Table 47]

[0602] [Table 48]

[0603] Table 45 shows an overview of the average values ​​of various parameters for each sample group.

[0604] [Table 49]

[0605] As shown, no polymorphonuclear cells, necrosis, fat infiltration, fibrous exudate, calcification, granuloma, hemorrhage, or foreign body debris were observed at the implant sites in groups 1, 2, 3, and 4.

[0606] The tissue response to the test implants in Groups 1, 2, and 3 was characterized by heavy infiltration of 6 to 5 lymphocytes and macrophages, 1 to 5 plasma cells, and heavy infiltration of densely packed giant cells, as well as minimal to mild collagen deposition / fibrous connective tissue per high-power field.

[0607] In the test group, absorption / degradation of the test formulation particles was observed within giant cells or surrounded by macrophages, while lymphocytes and plasma cells were mostly found around the implant.

[0608] Minimal fibrous encapsulation, characterized by thin bands of fibrous connective tissue, was observed around the test implant sites in groups 1, 2, and 3.

[0609] The tissue response at the control implant sites in Group 4 was characterized by 6 to severe lymphocyte infiltration, 1–5 plasma cells, 6–10 macrophages, and 3–5 giant cell infiltration per high-power field, as well as minimal to mild collagen deposition / fibrous connective tissue. In the control group, inflammatory cells were observed around the control microspheres.

[0610] In the Group 2 study and Group 4 control implant sites, angiogenesis characterized by groups of 4-7 capillaries with supporting fibroblast structures was observed, while in the Group 1 and 3 study implant sites, broad bands of capillaries with supporting tissue were observed.

[0611] The inflammatory response appeared slightly more severe in the test implants of groups 1 and 3 than in the test implants of group 2 and the control implants of group 4. While the inflammatory response was significant based on ISO 10993-6 scoring, the test implants of group 2 were considered non-irritating compared to the control of group 4, while the test implants of groups 1 and 3 were considered mildly irritating. A summary of the irritancy of the formulations is shown in Table 46.

[0612] [Table 50]

[0613] Overall, inflammatory responses (primarily composed of giant cells, lymphocytes, and macrophages) were observed in all groups, and no necrosis, fat infiltration, fibrous exudate, calcification, granuloma, hemorrhage, or foreign body debris were observed. Based on ISO 10993-6 scoring, the test implants in Group 2 were considered non-irritating compared to the control implants in Group 4, while the test implants in Groups 1 and 3 were considered mildly irritating.

[0614] Measuring the size of the injection The size of the elevation formed by the volume of the injected dermal filler was monitored for each formulation, similar to the study using commercially available BellaFill dermal fillers. The generally elliptical injection was monitored by recording the length and height (perpendicular to the skin) of two vertical diameters using calipers. The measurements were used to calculate the in-plane area and estimate the volume of the ellipsoid.

[0615] The change in the height of each injection site, expressed as a decrease in the normalized percentage of the formulation over time, is shown in Figure 95, where collagen preparations are represented by the black line, HA preparations by the red line, saline preparations by the blue line, and BellaFill preparations by the purple line.

[0616] As shown, the collagen and HA preparations gradually decreased in size and eventually plateaued, while the saline preparation decreased rapidly in height as expected. The height of the BellaFill dermal filler injection gradually decreased and reached a plateau, similar to the collagen and HA preparations.

[0617] It should be noted that a decrease in the size of the injection ridge does not indicate particle degradation. The histological evaluation described above indicates that the particles remain intact. Rather, the decrease in size may be due to carrier reabsorption, material compression, lateral expansion of the formulation, and / or an increase in the rat's mass over time. [Examples]

[0618] Further in vivo testing of the dermal filler of this disclosure Further in vivo studies were conducted using the dermal filler formulations of the present disclosure, which include mercerized apple material.

[0619] Four formulations were tested: the first formulation (Mer100) containing only mercerized apples; the second formulation (20Mer80Sal) containing 20% ​​mercerized apples in 0.9% physiological saline; the third formulation (20Mer80Col) containing 20% ​​mercerized apples in 3.5% collagen solution; and the fourth formulation (20Mer80Reg) containing 20% ​​mercerized apples in dissolved regenerated cellulose. Each formulation also contained 0.3% lidocaine.

[0620] Dissolved regenerated cellulose is produced by dissolving decellularized apple material in a solution of LiCl and dimethylacetamide (DMAc). The dissolved cellulose is then "regenerated" by exchanging the solvent and mixing it with mercerized apples.

[0621] Each formulation was injected four times into two rats. For each formulation, one rat was excised after 12 weeks and the other after 1 year. The injection volume was 600 μL of the formulation in each case. The elevations formed after injection of the formulation were measured weekly for 12 weeks, and then monthly thereafter. Elevation size was measured using calipers as previously described herein.

[0622] result Based on observations, it was noted that the elevations caused by injections of 20Mer80Sal and 20Mer80Col were smaller than those caused by the Mer100 formulations. Furthermore, the elevation caused by injection of 20Mer80Reg was the most rigid among the formulations tested.

[0623] Figure 96 shows the changes in elevation height over time after injection of each formulation. For comparison, the results for the elevation change in Example 27 are included, where DFAAC refers to the collagen formulation of Example 27, DFAAHA refers to the HA formulation of Example 27, DFAAS refers to the saline formulation of Example 27, and DFBF refers to the BellaFill dermal filler.

[0624] As shown, each formulation containing mercerized apples generally showed a decrease in height until it eventually plateaued.

[0625] The injected formulation was also analyzed histologically. The injected formulation was stained with HE, MT, CD45, CD31, and Verhoeff stains as described in Example 27 above, and analyzed under a microscope. The results at a 200 μm scale are shown in Figure 97. Notes from the person who performed the histological analysis are shown in Table 47.

[0626] [Table 51] JPEG0007953902000053.jpg48148

[0627] Overall, histological analysis showed that the formulation using mercerized apples exhibited a reduced inflammatory response compared to the formulation examined in Example 27. Furthermore, the formulation using mercerized apples demonstrated biocompatibility, exhibited angiogenesis, and showed extracellular matrix deposition.

[0628] Furthermore, it is noteworthy that the 20Mer80Reg formulation exhibited localized cellular infiltration in its peripheral region. While not bound by any specific theory, the localization of cellular infiltration in the peripheral region of the 20Mer80Reg formulation may be due to the small pore size of the fused cellulose polymer after dissolution and regeneration. [Examples]

[0629] Further quantification of SDS content in dermal fillers of this disclosure In this study, based on the results of Example 22, we attempted to further characterize the amount of residual SDS in the dermal filler of this disclosure.

[0630] Further samples were analyzed by spectrophotometrics using the standard curve and process outlined in Example 22. The samples used included material from 5 apples (5AA), 10 apples (10AA), or 15 apples (15AA).

[0631] Table 48 shows the results of SDS quantification of beaker solutions (dilution 1:10) from 5AA, 10AA, and 15AA samples after incubation in 0.1% SDS for 72 hours.

[0632] [Table 52]

[0633] Table 49 shows the liquid-phase (undiluted) SDS quantification from 5AA, 10AA, and 15AA samples after the decellularization process.

[0634] [Table 53]

[0635] Therefore, as shown, the SDS content of the sample is sufficiently low, which supports the results of Example 22. Moreover, the SDS content is further reduced due to the multiple centrifugation and washing steps in the mercerization process.

[0636] One or more exemplary embodiments have been described as examples. It will be understood by those skilled in the art that several variations and modifications can be made without departing from the scope of the invention as defined in the claims.

[0637] References 1. Huh, J. B et al. Effects of PMMA and Cross-Linked Dextran Filler for Soft Tissue Augmentation in Rats. Int. J. Mol. Sci. 16, 28523 (2015). 2. Hillel, A. T. et al. Validation of a Small Animal Model for Soft Tissue Filler Characterization. Dermatologic Surg. 38, 471 (2012). 3. Cena, R. B. et al. Effects of Crosslinked Dextran in Hydroxylpropyl Methylcellulose on Soft Tissue Augmentation in Rats. J. Biomed. Mater. Res. - Part B Appl. Biomater. 102, 131 (2014). 4. Lee, Y. B. et al. Histology of a Novel Injectable Filler (Polymethylmethacrylate and Cross-Linked Dextran in Hydroxypropyl Methylcellulose) in a Rat Model. J. Cosmet. Laser Ther. 16, 191 (2014). 5. Lemperle, G.; Morhenn, V. B.; Pestonjamasp, V.; Gallo, R. L. Migration Studies and Histology of Injectable Microspheres of Different Sizes in Mice. Plast. Reconstr. Surg. 113, 1380 (2004). 6. Lemperle et al. ArteFill Permanent Injectable for Soft Tissue Augmentation: I. Mechanism of Action and Injection Techniques. Aesth Plast Surg. 34, 264 (2010). 7. Luebberding et al. Critical Appraisal of the Safety of Dermal Fillers: A Primer for Clinicians. Curr Derm Rep 2, 150 (2013). 8. Frazer, R.Q. et al. PMMA: An essential material in medicine and dentistry. J. Long Term Effect Med. Implants. 15, 629 (2005). 9. Hickey, R. et al. Customizing the Shape and Microenvironment Biochemistry of Biocompatible Macroscopic Plant-Derived Cellulose Scaffolds. ACS Biomater. Sci. Eng. 4, 3726 (2018). 10. WO2017 / 136950, entitled "Decellularised Cell Wall Structures from Plants and Fungus and Use Thereof as Scaffold Materials". 11. Nguyen et al. "Cosmetic Medicine: Facial Resurfacing and Injectables", Plast Reconstr Surg. 129, 142e (2012). 12. Luebberding et al. "Critical Appraisal of the Safety of Dermal Fillers: A Primer for Clinicians", Curr Derm Rep. 2, 150 (2013).

[0638] All references cited herein and elsewhere are incorporated herein by reference in their entirety.

Claims

1. A non-absorbable skin filler comprising decellularized plant tissue, wherein the cellular material and nucleic acids of the tissue are removed, and the decellularized plant tissue is broken down into particles having a size, diameter, or minimum ferret diameter of at least about 20 μm.

2. The skin filler according to claim 1, wherein the decellularized plant tissue is chitin-based, chitosan-based, lignocellulose-based, or cellulose-based; the decellularized plant tissue is derived from the leaf structure, root, pulp, hypanthium, or pulp structure of a plant; or the decellularized plant tissue is derived from lettuce, carrot, apple, or pear, or any combination thereof.

3. The skin filler according to claim 1 or 2, wherein the decellularized plant tissue is homogenized; and / or the decellularized plant tissue is dried, pulverized, and restored or rehydrated; and / or the decellularized plant tissue is broken down into particles the size of a single structural cell or smaller.

4. A skin filler according to any one of claims 1 to 3, further comprising a hydrogel, matrix, or dispersion medium for decellularized plant tissue; wherein the hydrogel, matrix, or dispersion medium comprises PBS, physiological saline, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof.

5. A skin filler according to any one of claims 1 to 4, which is dried or hydrated; and / or comprises lidocaine or another anesthetic.

6. A skin filler according to any one of claims 1 to 5, wherein decellularized plant tissue is broken down into particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure; and the flake-like structure has a thickness of about 0.01 to about 100 μm, for example, about 0.1 μm.

7. The skin filler according to any one of claims 1 to 6, wherein the decellularized plant tissue is broken down into particles that are large enough not to be phagocytosed by one or more cells.

8. A skin filler according to any one of claims 1 to 7, wherein the decellularized plant tissue is broken down into particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 1000 μm, or the decellularized plant tissue is broken down into particles having a size, diameter, or ferret diameter distribution in the range of about 100 μm to about 300 μm.

9. A skin filler according to any one of claims 1 to 8, wherein the decellularized plant tissue is broken down into particles having a size, diameter, or ferret diameter distribution in the range of approximately 20 μm to approximately 200 μm, or the decellularized plant tissue is broken down into particles having a particle size, diameter, or ferret diameter distribution with a peak within approximately 30 μm to approximately 100 μm, or the decellularized plant tissue is broken down into particles having a particle size, diameter, or ferret diameter distribution with a peak within approximately 100 μm to approximately 300 μm.

10. A skin filler according to any one of claims 1 to 9, wherein the decellularized plant tissue is broken down into particles having an average particle size, diameter, or ferret diameter in the range of about 30 μm to about 100 μm; or the decellularized plant tissue is broken down into particles having an average particle size, diameter, or ferret diameter in the range of about 100 μm to about 300 μm.

11. A skin filler according to any one of claims 1 to 10, wherein the decellularized plant tissue is broken down into particles having a size, diameter, or maximum ferret diameter of less than approximately 200 μm, or the decellularized plant tissue is broken down into particles having a size, diameter, or maximum ferret diameter of less than approximately 300 μm.

12. The particles are approximately 200 to 3000 μm in size. 2 Within the range of approximately 200 to 300 μm 2 Does it have an average projected particle area within the range of; decellularized plant tissue is approximately 0.1–100 μm? -1 It is broken down into particles having a surface area-to-volume ratio; decellularized plant tissue is composed of particles approximately 4 × 10 5 pieces / mL ~ particles approximately 7 x 10 9 A skin filler according to any one of claims 1 to 11, which is broken down into particles having a packing density of 1 / mL; or any combination thereof.

13. A skin filler according to any one of claims 1 to 12, wherein the skin filler, decellularized plant tissue is sterilized; the sterilization is by gamma ray sterilization or autoclaving; the sterilization comprises a plurality of sterilization steps; and the first sterilization step comprises heat treatment.

14. A skin filler according to any one of claims 1 to 13, wherein the skin filler has a viscosity of less than about 500,000 cp, or the skin filler has a viscosity in the range of about 100,000 cp to about 200,000 cp, and / or the decellularized plant tissue is treated by heating with sodium hydroxide and hydrogen peroxide.

15. A skin filler according to any one of claims 1 to 14, wherein decellularized plant tissue is mercerized.

16. A skin filler according to any one of claims 1 to 15, formulated for subdermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof; and / or provided in a syringe or injection device.

17. A skin filler according to any one of claims 1 to 16, for use in a method in an object requiring the improvement of cosmetic appearance, for increasing tissue volume, for smoothing wrinkles, or any combination thereof, The skin filler, wherein the method comprises the step of administering or injecting the skin filler into an area where it is needed in order to improve the cosmetic appearance of the object, increase the tissue volume of the object, smooth out wrinkles in the object, or any combination thereof.

18. The skin filler according to claim 17, wherein the native cells of the subject infiltrate the skin filler; or the skin filler is non-absorbent to such an extent that the decellularized plant tissue remains substantially intact within the subject.

19. The skin filler according to claim 17 or 18, wherein the skin filler is degradable by the addition of one or more enzymes thereto.

20. The skin filler according to claim 19, wherein the decellularized plant tissue is cellulosic, and the one or more enzymes comprise a cellulase; and the cellulase is a cellulase derived from the genus Trichoderma sp.

21. A method for preparing a non-absorbable skin filler, Steps to provide plant tissue; and A step of decellularizing and reducing the size of the plant tissue to provide particles from which the cellular material and nucleic acids of the tissue have been removed; The method comprising, thereby providing a non-absorbable skin filler, wherein the decellularized plant tissue is broken down into particles having a size, diameter, or minimum ferret diameter of at least about 20 μm.

22. The method according to claim 21, comprising the step of sterilizing particles.

23. The method according to claim 21 or 22, wherein the decellularized plant tissue is chitin-based, chitosan-based, lignocellulose-based, or cellulosic; the decellularized plant tissue is derived from the leaf structure, root, pulp, hypanthium, or pulp structure of a plant; or the decellularized plant tissue is derived from lettuce, carrot, apple, or pear, or any combination thereof.

24. The method according to any one of claims 21 to 23, wherein the size reduction includes the step of providing particles by mechanical size reduction, wherein the mechanical size reduction is performed on a dried, freeze-dried, or freeze-dried material; and the mechanical size reduction includes the step of providing particles by crushing, extruding, grinding, grinding, sonicating, electrospinning, chemical dissolution, enzymatic degradation, or shearing of plant tissue before or after decellularization.

25. The method according to any one of claims 21 to 24, wherein the size reduction comprises the steps of drying the plant tissue before or after decellularization; subjecting the dried plant tissue to mechanical size reduction to provide the particles; and restoring, resuspending, or rehydrating the particles; the size reduction provides particles of the size of a single structural cell or smaller.

26. The method according to any one of claims 21 to 25, further comprising the step of formulating particles together with a hydrogel, matrix, or dispersion medium; the hydrogel, matrix, or dispersion medium comprising PBS, physiological saline, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, prulonic acid (e.g., prulonic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, regenerated cellulose, or any combination thereof; and / or the dermal filler is provided in a dried or hydrated form; and / or further comprising the step of formulating together with lidocaine or another anesthetic.

27. The method according to any one of claims 21 to 26, wherein the size reduction provides particles having an irregular 3D shape and / or a non-spherical, thin, flake-like structure; the flake-like structure having a thickness of about 0.01 to about 100 μm, for example, about 0.1 μm.

28. The method according to any one of claims 21 to 27, wherein the size reduction further comprises the step of obtaining particles having a target size, particles within a target size range, or particles having a target size distribution by extrusion, filtration, centrifugation, or other size separation; or the size reduction provides particles that are large enough not to be phagocytosed by one or more cells.

29. The method according to any one of claims 21 to 28, wherein the size reduction provides particles having a size, diameter, or minimum ferret diameter of at least about 20 μm, or the decellularized plant tissue is broken down into particles having a size, diameter, or ferret diameter in the range of about 20 μm to about 1000 μm, or the size reduction provides particles having a size, diameter, or ferret diameter distribution in the range of about 100 μm to about 300 μm.

30. The method according to any one of claims 21 to 29, wherein by size reduction, particles having a distribution of size, diameter, or ferret diameter in the range of approximately 20 μm to approximately 200 μm are provided, or by size reduction, particles having a distribution of particle size, diameter, or ferret diameter with a peak within approximately 30 μm to approximately 100 μm are provided, or by size reduction, particles having a distribution of particle size, diameter, or ferret diameter with a peak within approximately 100 μm to approximately 300 μm are provided.

31. The method according to any one of claims 21 to 30, wherein by size reduction, particles having an average particle size, diameter, or ferret diameter in the range of approximately 30 μm to approximately 100 μm are provided, or by size reduction, particles having an average particle size, diameter, or ferret diameter in the range of approximately 100 μm to approximately 300 μm are provided.

32. The method according to any one of claims 21 to 31, wherein the size reduction provides particles having a size, diameter, or maximum ferret diameter of less than approximately 200 μm, or particles having a size, diameter, or maximum ferret diameter of less than approximately 300 μm.

33. The method according to any one of claims 21 to 32, wherein the size reduction provides particles having an average projected particle area in the range of about 200 to about 3000 μm 2 , or in the range of about 200 to about 300 μm 2 ; the decellularized plant tissue is broken down into particles having a surface area to volume ratio in the range of about 0.1 to 100 μm -1 ; the decellularized plant tissue is broken down into particles having a packing density of about 4×10 5 particles / mL to about 7×10 9 particles / mL; or any combination thereof, the aforementioned method.

34. A method according to any one of claims 21 to 33, wherein the size reduction includes the step of grinding and simultaneously passing the resulting particles through a filter to obtain particles below an upper threshold size; the method further includes the step of removing particles below a lower threshold size by filtration, fractionation centrifugation, equilibrium centrifugation, or sieving to obtain particles above the lower threshold size; and the filtration or sieving is performed using an automated wet sieve.

35. The method according to any one of claims 21 to 34, wherein the size reduction includes the step of obtaining particles having a target size, particles within a target size range, or particles having a target size distribution by performing fractional centrifugation or equilibrium centrifugation.

36. The method according to any one of claims 21 to 35, comprising the steps of: loading particles in a fluid, such as water or a buffer (such as physiological saline), into a first syringe or vessel; and loading a hydrogel, matrix, or dispersion medium into a second syringe or vessel, thereby formulating the particles together with the hydrogel, matrix, or dispersion medium, wherein the first and second syringes or vessels are under fluid connection; and further comprising the steps of mixing the contents of the syringes or vessels by passing them back and forth between the first and second syringes or vessels; further comprising the steps of mixing the particles with the hydrogel, matrix, or dispersion medium using a size exclusion mixer; and the size exclusion mixer being a static mixer.

37. The method according to any one of claims 21 to 36, further comprising the step of sterilizing plant tissue before or after decellularization; further comprising the step of sterilizing a skin filler; wherein the sterilization is by gamma ray sterilization or autoclaving; wherein the sterilization comprises a plurality of sterilization steps; and the first sterilization step comprises heat treatment.

38. The method according to any one of claims 21 to 37, further comprising the step of processing plant tissue; wherein the processing step is performed after decellularization.

39. The method according to claim 38, wherein the processing step comprises treating decellularized plant tissue with a base and a peroxide; the base is a hydroxide base; and the peroxide is hydrogen peroxide.

40. The method according to claim 38, wherein the processing step includes treating the decellularized plant tissue with an aqueous sodium hydroxide solution and hydrogen peroxide while heating.

41. The method according to claim 39 or 40, wherein the processing includes the step of mercing the decellularized plant tissue.

42. The method according to any one of claims 39 to 41, wherein decellularized plant tissue is treated with an aqueous sodium hydroxide solution for a first period before hydrogen peroxide is added to the reaction.

43. The method according to any one of claims 39 to 42, wherein the peroxide is a pre-prepared solution of 30% to 50% aqueous hydrogen peroxide solution; the pre-prepared solution of aqueous hydrogen peroxide solution is used in an amount of at least about 75 mL per 500 g of decellularized plant tissue; and after the addition of the pre-prepared solution of aqueous hydrogen peroxide solution, the concentration of the peroxide in the mixture of decellularized plant tissue, base and pre-prepared solution of aqueous hydrogen peroxide solution is about 1% to about 5%.

44. The method according to any one of claims 39 to 43, wherein the base is a 1 M sodium hydroxide solution; the 1 M sodium hydroxide solution is used in an amount of about 2500 mL per 500 g of decellularized plant tissue.

45. The method according to any one of claims 21 to 44, further comprising the step of neutralizing the pH by one or more neutralization treatments; wherein the one or more neutralization treatments include treatment with an aqueous solution of HCl.

46. The method according to any one of claims 21 to 45, wherein the mercerizing process is carried out by heating to about 80°C; and the mercerizing process is carried out for at least about 30 minutes.

47. The method according to any one of claims 21 to 46, further comprising the step of formulating a skin filler for subdermal injection, deep dermal injection, subcutaneous injection (e.g., subcutaneous fat injection), or any combination thereof.

48. A skin filler prepared by the method of any one of claims 21 to 47; a skin filler according to any one of claims 1 to 19; wherein about 0.1% to about 5% or less of the particles of the skin filler have a ferret diameter or minimum ferret diameter of less than about 20 μm; or about 0.5% or less of the particles of the skin filler have a ferret diameter or minimum ferret diameter of less than 20 μm; or about 0.1% to about 5% (e.g., less than about 0.5%) or less of the particles of the skin filler are small enough to be phagocytosed by one or more cells of a subject.

49. A kit comprising a skin filler according to any one of claims 1 to 20 and 48, and one or more of the following: Hydrogels, matrices, or dispersion media; PBS, physiological saline, hyaluronic acid (crosslinked or non-crosslinked), alginate, collagen, pluronic acid (e.g., Pluronic F 127), agar, agarose, fibrin, calcium hydroxyapatite, poly-L-lactic acid, autologous fat, silicone, dextran, methylcellulose, dissolved regenerated cellulose, or any combination thereof; Lidocaine or other anesthetics; One or more syringes, or another injection device; Luer lock fittings or connectors for two or more syringes; One or more decellularizing reagents; One or more containers, packages, or vessels; One or more buffer solutions, water, or saline solution for injection; A reagent or enzyme (e.g., cellulase) for dissolving skin fillers in undesirable areas or locations; or Any combination of them;

Citation Information

Patent Citations

  • Decellularized cell wall structures from plants and fungi and their use as scaffolding materials

    JP2019509723A